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Abstract
Purinergic signalling is an important biological process that utilises extracellular
nucleotides to activate P2X and P2Y purinergic receptors. P2 receptors play a range of
roles in human physiology and pathophysiology. Despite this, little is known about canine
P2 receptors. The overarching aim of this thesis was to expand on the limited knowledge
regarding genetics, expression and function of canine P2 receptors.
Chapters 3 and 4 investigated the distribution of missense variants of the canine P2RX7
and P2RX4 genes, respectively. Amongst 134 dogs, the two most prevalent variants of
the canine P2RX7 gene, rs23314713 (Phe103Leu) and rs23315462 (Pro452Ser), were
associated with brachycephalic and non-brachycephalic breeds, respectively. The less
frequent rs851148233 (Arg270Cys) and rs850760787 (Arg365Gln) variants were
associated with dogs of Cocker Spaniel and Labrador Retriever pedigrees, respectively.
In contrast, the canine P2RX4 gene was highly conserved with no missense variants
reported in a cohort of 101 dogs, representing at least 32 different breeds.
Chapter 5 characterised the expression and function of the canine P2X4 receptor using a
heterologous expression system. The canine P2X4 receptor largely colocalised to
lysosomes and was activated by adenosine-5’-triphosphate (ATP) with similar potency
and efficacy compared to the human P2X4 receptor. Despite activating the human P2X4
receptor, 2’(3’)-O-(4-benzoylbenzoyl)-ATP (BzATP) was not an effective agonist of the
canine P2X4 receptor. Ivermectin potentiated ATP-induced responses, while selective
P2X4 antagonists 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2one (5-BDBD) and 1-(2,6-dibromo-4-isopropyl-phenyl)-3-(3-pyridyl)urea (BX430)
inhibited ATP-induced responses through the canine P2X4 receptor. BX430 was a less
effective antagonist of the canine P2X4 receptor compared to the human receptor.
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Chapter 6 investigated the expression and function of endogenous P2 receptors in the
DH82 canine macrophage cell line. This cell line was sensitive to activation by ATP and
uridine-5’-triphosphate (UTP). Antagonists of P2X4 (5-BDBD) and P2Y2 (AR-C118925)
reduced Ca2+ responses in DH82 cells, which were in part controlled by the phospholipase
C

(PLC)/inositol-1,4,5-trisphosphate

(IP3)

signal

transduction

pathway.

This

demonstrated the potential for using DH82 canine macrophages as an endogenous model
of canine purinergic signalling.
Finally, Chapter 7 directly demonstrated that dog platelets express functional P2Y1 and
P2Y12 receptors, which differ in levels of expression compared to human and cat platelets.
A 384-well plate light transmission aggregometry assay was established to study the
aggregation

of

dog

adenosine-5’-diphosphate

platelets.
(ADP)

P2Y1
and

and

P2Y12

receptor

agonists,

2-methylthio-adenosine-5'-diphosphate

(2MeSADP), induced aggregation of dog, cat and human platelets. Meanwhile, P2Y1 or
P2Y12

receptors

antagonists,

N6-methyl-2′-deoxyadenosine-3′,5′-bisphosphate

(MRS2179) and ticagrelor, respectively, inhibited platelet aggregation in dogs and cats,
with similar potency when directly compared to human platelets. Notably, dog platelets
demonstrated unanticipated amounts of spontaneous platelet aggregation that was not
observed with cat or human platelets.
Overall, this thesis has described and compared the expression of a number of functional
canine P2 receptors. A canine macrophage cell model of purinergic signalling has now
been established and holds potential for studying mechanisms of cell signalling in canine
physiology and pathophysiology. Finally, this thesis implicates canine platelet P2Y
receptors in thrombosis and haemostasis in dogs, but suggests caution utilising dogs as
models of human haemostasis due to differences in platelet physiology.
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Chapter 1: Introduction
1.1.

Canine models of human physiology and pathophysiology

Dogs have long been used experimentally for studying biological phenomena both in vivo
and in vitro due to their size, phenotypic diversity amongst behavioural and
morphological traits, as well as their now well understood genetic similarity (~84%) to
humans (Lindblad-Toh et al., 2005). Dogs and humans also share a unique history, having
maintained a close interdependent relationship with humans since domestication > 15,000
years ago, despite the ~400 breeds recognised today being the result of less than a few
centuries of selective breeding (VonHoldt et al., 2010). Dogs have since provided useful
models of a number of human disorders shared by both species, including arterial
thrombosis (Huang et al., 2000), heart failure (Zhou et al., 2010) and Alzheimer’s disease
(Barone et al., 2012).

1.1.1. Dogs as natural models of human health and ageing
With reported numbers of dogs used for procedures (procedures being those that are likely
to cause harm) worldwide in 2015 reaching 207,724 (Taylor & Alvarez, 2019), research
on canine models should look to move away from laboratory based research on dogs
where possible, rather utilising natural canine models of disease. Although the use of dogs
in pre-clinical trials for novel, highly promising therapeutics will likely remain for the
benefit of both human and veterinary medicine, guidelines suggest moving towards more
sustainable and ethical models which more heavily rely on the 3Rs principle,
Replacement, Reduction and Refinement (Fenwick et al., 2009), with the recent addition
of a fourth R for rehoming (Barthelemy et al., 2019).
Canine natural or ‘spontaneous’ models of disease include those breeds at increased risk
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of certain cancers, such as glioma in Bulldogs and Mastiffs (Truve et al., 2016) and
osteosarcoma in Rottweilers, Greyhounds and Irish Wolfhounds (Karlsson et al., 2013).
Dogs also provide useful models of natural human ageing and thus prove useful in the
long term for clinical or observational studies of diseases common to both canine and
human ageing populations, such as neurodegenerative diseases (e.g. Alzheimer’s
disease), neuromuscular disorders (e.g. Duchenne muscular dystrophy), cardiovascular
diseases and chronic pain (Head, 2013; Sandor & Kubinyi, 2019).
Naturally occurring canine genetic variants also complement dogs as models of natural
disease. One example of this is the SOD1 gene, a well-studied disease gene in humans
and animals that accounts for around 20% of human familial amyotrophic lateral sclerosis
(ALS) cases (Saccon et al., 2013). A missense mutation in the canine SOD1 gene,
resulting in an Glu40Lys substitution, has been reported in canine degenerative
myelopathy (Awano et al., 2009). This spontaneous mutation in dogs results in a fatal
neurodegenerative disease (Awano et al., 2009) that is common in breeds such as the
German Shepherd, Welsh corgi, Boxer and Rhodesian ridgeback (Braund & Vandevelde,
1978; Coates et al., 2007) and has been suggested as a naturally occurring model of human
ALS (Morgan et al., 2013; Nardone et al., 2016). A number of other spontaneously
inherited disorders arising from canine disease genes have been reported which provide
useful models of human neuromuscular disorders (Barthelemy et al., 2019).
To this end, dogs provide valuable models to understand disease. Moreover, given dogs
suffer many disorders comparable to those in humans, they may also benefit from drugs,
including those targeting purinergic receptors, which are used to treat these same
disorders. However, understanding of the purinergic receptors in dogs is limited and as
such, this thesis endeavours to reduce the gap in this knowledge.
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1.2.

Purinergic signalling

The actions of purines on heart and blood vessel contractions were reported as early as
1929 (Drury & Szent-Györgyi, 1929). However, the concept of purinergic signalling was
not proposed until several decades later (Burnstock, 1972) after evidence was discovered
of adenosine-5'-triphosphate (ATP) acting as a neurotransmitter of the vagus nerves that
supply the gut (Burnstock et al., 1970). Purinergic signalling is now well established and
defines the events that occur in relation to a complex network of receptors, known as
purinergic receptors, which have numerous key roles in maintaining cellular homeostasis
(Burnstock, 2006). Purinergic receptors can be found within many neuronal and
non-neuronal cells and tissues throughout the body and are activated by the purine
nucleoside adenosine and its nucleotides, ATP, adenosine-5′-diphosphate (ADP) and
adenosine-5′-monophosphate

(AMP),

as

well

as

pyrimidine

nucleotides,

uridine-5′-triphosphate (UTP), uridine-5′-diphosphate (UDP) and UDP-glucose
(Burnstock & Knight, 2004). Based on pharmacological characterisation, these receptors
were originally divided into two major classes, the adenosine-sensitive P1 receptors and
the nucleotide-sensitive P2 receptors (Burnstock & Kennedy, 1985). The P2 receptors
were then later divided into two further subclasses, the ionotropic P2X receptors and the
metabotropic P2Y receptors (Fredholm et al., 1994; Fredholm et al., 1997).

1.2.1. P1 receptors
The four P1 receptor subtypes (adenosine A1, adenosine A2A, adenosine A2B & adenosine
A3) are G protein-coupled receptors (GPCR) with seven transmembrane domains and an
extracellular NH2 terminus and intracellular COOH terminus (Fredholm et al., 1994).
Adenosine A1 and adenosine A3 receptors couple to Gi/o proteins (Figure 1.1), leading to
downstream inhibition of adenylyl cyclase and a subsequent decrease in cyclic AMP
(cAMP), while both adenosine A2 receptor subtypes couple to Gs protein (Figure 1.1),
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stimulating cAMP production through activation of adenylyl cyclase (Fredholm et al.,
2000). All four P1 receptor subtypes are endogenously activated by adenosine, although
adenosine A1 and adenosine A2A receptors have a relatively high affinity for adenosine
compared to adenosine A2B and adenosine A3 receptors (Fredholm et al., 2011). P1
receptors are widely distributed throughout cells and tissues of mammalian nervous,
immune, cardiovascular, musculoskeletal and gastrointestinal systems (Fredholm et al.,
2011; Haskó et al., 2008; Headrick et al., 2013; Sheth et al., 2014). Given their widespread
distribution, studies have demonstrated roles for P1 receptors in number of neurological,
cardiovascular and inflammatory diseases (Borea et al., 2018; Ho & Rose'Meyer, 2013).
In dogs, adenosine A1 and adenosine A2A adenosine receptors were first cloned from
canine thyroid complimentary (c)DNA, with RNA transcripts of the adenosine A1
receptor found in the brain and testis, while transcripts of the adenosine A2A receptor were
limited to the brain (Libert et al., 1989). Subsequent studies characterised the cloned
canine adenosine A1 (Libert et al., 1991) and adenosine A2A receptors (Maenhaut et al.,
1990). Researchers have also provided evidence for functional adenosine A2A receptors
on dog coronary arteries (Gurden et al., 1993). The adenosine A2B receptor was identified
in a canine mastocytoma cell line, where it was involved in mediating mast cell
degranulation (Auchampach et al., 1997). However, the canine adenosine A2B receptor
was not cloned and characterised until several years later from dog intestine
(Auchampach et al., 2009). The canine adenosine A3 receptor was cloned and
characterised from canine mast cell cDNA library, while messenger (m)RNA transcripts
were found predominantly in the spleen, and to a lesser degree, in lung, liver and testis
(Auchampach et al., 1997).
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1.2.2. P2X receptors
The mammalian P2X receptors (P2X1-7) form ligand-gated, cation permeable channels
(Na+, K+ and Ca2+) which can exist as homotrimeric or heterotrimeric species
(Habermacher et al., 2016) that are activated primarily by ATP, as well as ATP analogues

Figure 1.1. The purinergic signalling pathway. (Bottom left) P2Y receptors coupled to Gq/11
are activated by ADP, ATP, UDP or UTP (P2Y receptor subtypes activated are labelled above
each nucleotide). Activation of Gq/11-coupled receptors stimulates the phospholipase C (PLC)mediated cleavage of phosphatidylinositol 4,5-bisphosphate (PIP2) into diacylglycerol (DAG) and
inositol 1,4,5-trisphosphate (IP3), resulting in the activation of protein kinase C (PKC) and an
increase in intracellular Ca2+, respectively. (Bottom middle) Activation of the Gs-coupled P2Y11
receptor activates adenylyl cyclase resulting in an increase in cAMP production, which in turn
activates protein kinase A (PKA). (Bottom right) Activation of the Gi/o-coupled P2Y12-14 receptors
inhibits adenylyl cyclase, preventing the formation of cAMP. (Top left) The ectoenzyme CD39
converts extracellular ATP/ADP to AMP, while CD73 converts AMP to adenosine, where it can
activate P1 adenosine receptors (top middle). (Top right) Activation of the P2X receptors by ATP
results in the opening of a channel which allows the influx of Ca2+ or Na+ and the efflux of K+.
Figure created using BioRender.
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(Table 1.1, Figure 1.1). P2X receptor subunits consist of intracellular NH2 and COOH
termini, linked by two transmembrane domains which are connected by a large
extracellular loop (Kawate et al., 2009). ATP binds in this extracellular domain (Dal Ben
et al., 2015; Hattori & Gouaux, 2012) and causes a conformational change from the
resting, closed state to the open, conducting state (Figure 1.2) which results in the flow
of cations across the membrane (Egan & Khakh, 2004).
P2X receptors are widely distributed throughout mammalian cells and tissues (Burnstock
& Knight, 2004). Despite this, only the P2X7 receptor subtype has been cloned and
characterised from dogs so far (Roman et al., 2009; Spildrejorde, Bartlett, et al., 2014).
P2X7 receptors are expressed on a number of canine haematopoietic cells (Faulks et al.,
2016; Jalilian, Peranec, et al., 2012; Sluyter, Shemon, Hughes, et al., 2007; Stevenson et
al., 2009), as well as in brain and colon tissue from dogs (Lee et al., 2005; Truve et al.,
2016). Additionally, mRNA transcripts of all other P2X receptors, except P2X1 and P2X6
receptors, have also been detected in brain and colon tissue from dogs (Lee et al., 2005).
Studies on the canine vagal reflex have suggested the presence of a functional heteromeric
P2X2/3 receptor on the left ventricular vagal nerve terminals of the dog heart (Xu et al.,
2005). Functional data also suggests that P2X1 and/or P2X3 receptors on canine smooth
muscle are responsible for vasoconstriction of canine coronary arteries (Buckwalter et al.,
2003; Buckwalter et al., 2004; Matsumoto et al., 1997a).
The first high resolution (<3 Å) crystal structure of a P2X receptor came from the
zebrafish P2X4 receptor in the ATP-unbound, closed state (Kawate et al., 2009). This
confirmed the trimeric structure of P2X receptors and further opened the purinergic field
for large-scale pharmacological analysis and drug development based on molecular
interactions. Elucidation of the structure of P2X receptors contributed to the
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Table 1.1. P2X receptor agonists and antagonists.
P2X
subtype

Agonists

Antagonists

References

P2X1

ATP,
BzATP,
2MeSATP, α,βmeATP, ATPγS,

NF499,
PPADS,
suramin, TNP-ATP

Bianchi et al. (1999); Kassack et al. (2004);
Virginio et al. (1998)

P2X2

ATP,
ATPγS,
2MeSATP

PPADS, suramin, TNPATP

Virginio et al. (1998)

P2X3

ATP,
BzATP,
2MeSATP, α,βmeATP, ATPγS

PPADS, TNP-ATP

Bianchi et al. (1999); Virginio et al. (1998)

P2X4

ATP,
ATPγS,
α,β-meATP,
BzATP

5-BDBD, BAY-1797,
BX430,
duloxetine,
NP-1815-PX,
paroxetine,
PPADS,
PSB-12054,
PSB12062, TNP-ATP

Ase et al. (2015); Balazs et al. (2013);
Bianchi et al. (1999); Hernandez-Olmos et
al. (2012); Jones et al. (2000); Matsumura et
al. (2016); Nagata et al. (2009); Virginio et
al. (1998); Werner et al. (2019); Yamashita
et al. (2016)

P2X5a

ATP, 2MeSATP,
α,β-meATP,
BzATP, ATPγS

BBG, PPADS, Suramin

Bo, Jiang, et al. (2003); Collo et al. (1996)

P2X6b

ATP, 2MeSATP,
α,β-meATP

PPADS, reactive blue
2, TNP-ATP

Collo et al. (1996); Jones et al. (2004); Lê et
al. (1998)

P2X7

ATP, BzATP

A-438079, A-804598,
AZ10606120,
AZ11645373,
BBG,
JNJ-47965567, KN-62,
PPADS, TNP-ATP

Bianchi et al. (1999); Michel et al. (2008);
Stokes et al. (2006); Virginio et al.
(1998);Bhattacharya et al. (2013); Chessell,
Michel, et al. (1998); Donnelly-Roberts,
Namovic, Han, et al. (2009); Gargett and
Wiley (1997); Jiang, Mackenzie, et al.
(2000); Spildrejorde, Bartlett, et al. (2014)

Abbreviations: 2MeSATP, 2-methylthio-ATP; 5-BDBD, 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4diazepin-2-one; A-438079, 3-[[5-(2,3-dichlorophenyl)-1H-tetrazol-1-yl]methyl]pyridine; A-804598, N-Cyano-N"[(1S)-1-phenylethyl]-N'-5-quinolinyl-guanidine; ATP, adenosine-5'-triphosphate; ATPγS, adenosine 5′-O-(3thio)triphosphate;
AZ10606120,
N-[2-[[2-[(2-hydroxyethyl)amino]ethyl]amino]-5-quinolinyl]-2tricyclo[3.3.1.13,7]dec-1-ylacetamide;
AZ11645373,
3-[1-[[(3'-nitro[1,1'-biphenyl]-4-yl)oxy]methyl]-3-(4pyridinyl)propyl]-2,4-thiazolidinedione;
BAY-1797,
N-[4-(3-Chlorophenoxy)-3-sulfamoylphenyl]-2phenylacetamide; BX430, 1-(2,6-dibromo-4-isopropyl-phenyl)-3-(3-pyridyl)urea; BzATP, 3'-O-(4-benzoyl)benzoyl
adenosine 5'-triphosphate; JNJ-47965567, 2-(phenylthio)-N-[[tetrahydro-4-(4-phenyl-1-piperazinyl)-2H-pyran-4yl]methyl-3-pyridinecarboxamide; KN-62, 4-[(2S)-2-[(5-isoquinolinylsulfonyl)methylamino]-3-oxo-3-(4-phenyl-1piperazinyl)propyl] phenyl isoquinolinesulfonic acid ester; NF499, 4,4',4'',4'''-[carbonylbis(imino-5,1,3-benzenetriylbis(carbonylimino))]tetrakis-1,3-benzenedisulfonic acid; NP-1815-PX; 5-[3-(5-thioxo-4H-[1,2,4]oxadiazol-3yl)phenyl]-1H-naphtho[1, 2-b][1,4]diazepine-2,4(3H,5H)-dione; PPADS, pyridoxalphosphate-6-azophenyl-2′,4′disulfonic
acid;
PSB-12054,
N-(benzyloxycarbonyl)phenoxazine;
PSB-12062,
N-(pmethylphenyl)sulfonylphenoxazine; TNP-ATP, 2’,3’-O-(2,4,6-trinitrophenyl)adenosine-5’- triphosphate; α,β-meATP,
α,β-methylene-ATP. aNon-functional splice variant in most humans. bDoes not form functional homotrimers in humans.

establishment of a number of important physiological and pathophysiological roles for
P2X receptors in infection and inflammation (Di Virgilio et al., 2017), neurodegeneration
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and neuroprotection (Burnstock, 2016a), pain signalling (Bernier et al., 2018), psychiatric
disorders (Krügel, 2016), cardiovascular regulation (Burnstock & Pelleg, 2015) and
signalling in the musculoskeletal system (Orriss, 2015).

1.2.3. P2Y receptors
There are currently eight known mammalian P2Y receptor subtypes (P2Y1, 2, 4, 6, 11, 12, 13 &
14),

each of which belong to the family of GPCRs (Abbracchio et al., 2003). The missing

numbers represent orthologues that belong to non-mammalian species or have some
sequence similarity but are functionally dissimilar to P2Y receptors in terms of nucleotide
binding (Abbracchio et al., 2006). Unlike P2X receptors, some members of the P2Y
receptor family can exhibit agonist sensitivity to pyrimidine nucleotides (UTP/UDP)
and/or purine nucleotides (ATP/ADP) (von Kugelgen & Hoffmann, 2016) (Table 1.2). In
response to activation by agonists, P2Y receptors that couple to Gq/11 (P2Y1, 2, 4, 6 & 11) or
Gs (P2Y11) can activate the phospholipase C (PLC)/inositol 1,4,5-trisphosphate (IP3)
pathway leading to a release of Ca2+ from endoplasmic reticulum stores, while activation
of P2Y receptors coupled to Gi/o proteins (P2Y12, 13 & 14) inhibits adenylyl cyclase activity
and leads to a reduction in cAMP (Abbracchio et al., 2006) (Figure 1.1).
Much like the P2X receptors, P2Y receptors are widely distributed throughout
mammalian cells and tissues (Burnstock & Knight, 2004). In dogs, a number of P2Y
receptors have been cloned and characterised, namely the P2Y1 (Hughes et al., 2003),
P2Y2 (Zambon et al., 2000) and P2Y11 receptors (Zambon et al., 2001), all of which were
cloned from Madin-Darby canine kidney (MDCK) cells.
These studies indicate receptor coupling to Gq/11 to increase Ca2+ mobilisation and protein
kinase C (PKC) activity, similar to that observed in other mammalian Gq/11-coupled P2Y
receptors. However, it was also reported that activation of the canine P2Y11 receptor could
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modulate adenylyl cyclase activity through Gs-coupling, leading to increased cAMP
formation (Insel et al., 2001; Torres et al., 2002). Of note, the canine P2Y11 receptor
demonstrated the opposite pharmacological profile to the human orthologue, where
diphosphate nucleotides were significantly more potent than triphosphate nucleotides
(Zambon et al., 2001). This shift has been associated with an arginine to glutamine
substitution at amino acid position 265 between the sixth transmembrane domain and the
third extracellular loop (Qi et al., 2001).
Despite the cloning of some canine P2Y receptors, direct evidence of P2Y receptor
expression in dogs is limited. mRNA transcripts of P2Y11 receptors were observed in
canine pancreatic duct epithelial cells (Nguyen et al., 2001) with functional data
supporting the expression of both P2Y2 and P2Y11 receptors on these cells (Nguyen et al.,
2001; Nguyen et al., 1998). Functional data demonstrating preference for UTP/UDPmediated vasoconstriction of canine epicardial coronary artery suggests expression of
P2Y2, P2Y4 and/or P2Y6 receptors on smooth muscle and endothelium (Matsumoto et al.,
1997b). This is consistent with numerous studies reporting nucleotide-mediated
contractions in canine tissues (Burnstock & Knight, 2004; Burnstock & Ralevic, 2014).
The presence of other canine P2Y receptors, such as P2Y12, P2Y13 and P2Y14 receptors,
is largely limited to identification of the genes coding these receptors through whole
genome studies (Lindblad-Toh et al., 2005). However, functional effects of P2Y12
receptor agonists and antagonists have been demonstrated during in vivo or ex vivo studies
on platelet activation and aggregation in dogs (Huang et al., 2000; Ravnefjord et al., 2012;
van Giezen et al., 2012; Wang et al., 2010; Wang et al., 2003).
The published crystal structure of the agonist- and antagonist-bound P2Y12 receptor
(Zhang, Zhang, Gao, Paoletta, et al., 2014; Zhang, Zhang, Gao, Zhang, et al., 2014), and
the antagonist-bound P2Y1 receptor (Zhang et al., 2015) confirmed the general features
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typical of GPCRs, including three extracellular and three intracellular loops and seven
transmembrane domains, which connect an extracellular and intracellular N- and Cterminus, respectively. These structural determinations have allowed deep analysis of the
mechanisms by which P2Y receptors act in different signal transduction pathways and
aided further development of P2Y receptor antagonists (Table 1.3). These developments
have revealed important information for further characterising the roles of P2Y receptors
in physiology and pathophysiology (Burnstock, 2017; von Kügelgen & Harden, 2011).
Table 1.2. P2Y receptor agonists.
P2Y subtype

Agonist

References

P2Y1

ADP,
2MeSADP,
MRS2365

ADPβS,

Bourdon et al. (2006); Chhatriwala et al. (2004);
Palmer et al. (1998); Ravi et al. (2002); Schachter
et al. (1996); Takasaki et al. (2001); Waldo and
Harden (2004)

P2Y2

UTP, ATP, ATPγS, MRS2698,
MRS2768, INS37217, Ap4A

Ko et al. (2008); Parr et al. (1994); Yerxa et al.
(2002)

P2Y4

UTP, UDP(h), ATP(r), ATPγS,
Ap4A(r), MRS4062

Bogdanov et al. (1998); Communi, Motte, et al.
(1996); Kennedy et al. (2000); Maruoka et al.
(2011)

P2Y6

UDP, MRS2693,
PSB0474, UTP

MRS2957,

Besada et al. (2006); Communi, Parmentier, et al.
(1996); El-Tayeb et al. (2006); Nicholas et al.
(1996)

P2Y11

ATP(h), 2MeSATP(h), ADP(d)
2MeSADP(d), BzATP, ATPγS,
ADPβS, AR-C67085, NF546

Communi et al. (1997); Communi et al. (1999);
Meis et al. (2010); Qi et al. (2001)

P2Y12

ADP , 2MeSADP

Foster et al. (2001); Hollopeter et al. (2001);
Takasaki et al. (2001)

P2Y13

ADP, 2MeSADP, ADPβS

Communi et al. (2001); Zhang et al. (2002)

P2Y14

UDP, UDP-glucose, MRS2690,
MRS2905

Chambers et al. (2000); Das et al. (2010); Ko et
al. (2007)

Abbreviations: 2MeSADP, 2-methylthio-ADP; 2MeSATP, 2-methylthio-ATP; ADP, adenosine-5'-diphosphate;
ADPβS, adenosine 5'-O-(2-thiodiphosphate); Ap4A, diadenosine tetraphosphate; AR-C67085, 2-propylthio-β,γdichloromethylene-ATP; ATP, adenosine-5'-triphosphate; ATPγS, adenosine 5′-O-(3-thio)triphosphate; INS37217, 2'desoxycytidine (5')tetraphospho(5')uridine (Denufosol); MRS2365, (N)-methanocarba-2MeSADP; MRS2690,
diphosphoric acid 1-α-D-glucopyranosyl ester 2-[(4'-methylthio)uridin-5"-yl] ester; MRS2693, 5-iodo-UDP;
MRS2698, 2'-amino-2-thio-UTP; MRS2768, uridine-5'-tetraphosphate δ-phenyl ester; MRS2905, α,β-methylene-2;
MRS2957, P1-(5'-uridine)-P3-(5'-N4-methoxycytidine)triphosphate; MRS4062, N4-(phenylpropoxy)-cytidine-5’triphosphate;
NF546,
4,4'-(carbonylbis
(imino-3,1-phenylene-carbonylimino-3,1-(4-methylphenylene)carbonylimino))-bis(1,3-xylene-α,α'-diphosphonic acid; PSB 0474, 3-phenacyl-UDP; UDP, uridine-5'diphosphate;
UTP,
uridine-5'-triphosphate.
Letters in parentheses indicate agonists with species-selective properties; h, human; r, rat; d, dog.
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Table 1.3. P2Y receptors antagonists.
P2Y subtype

Antagonist

References

P2Y1

A2P5P, MRS2179, MRS2279,
MRS2500, PPADS, reactive blue
2, suramin

Boyer et al. (2002); Kim et al. (2003); Moro et
al. (1998); O'Grady et al. (1996); Schachter et
al. (1996); Storey et al. (2000)

P2Y2

AR-C118925, reactive blue 2,
suramin,

Charlton et al. (1996a); Charlton et al. (1996b);
Kemp et al. (2004); Rafehi, Burbiel, et al.
(2017)

P2Y4

ATP(h), PSB16133,
reactive blue 2

PPADS,

Charlton et al. (1996a); Communi, Motte, et al.
(1996); Rafehi, Malik, et al. (2017)

P2Y6

MRS2575, MRS2578,
reactive blue 2

PPADS,

Mamedova et al. (2004); Robaye et al. (1997)

P2Y11

NF340, reactive blue 2, suramin

Communi et al. (1999); Meis et al. (2010)

P2Y12

2MeSAMP,
AR-C66096,
AZD1283, cangrelor, clopidogrel,
elinogrel, prasugrel, PSB0739,
reactive blue, selatogrel, suramin,
ticagrelor, ticlopidine

Baldoni et al. (2014); Boyer et al. (1994);
Fagura et al. (1998); Geiger et al. (1998);
Hechler, Eckly, et al. (1998); Hoffmann et al.
(2009); Hoffmann et al. (2014); Hollopeter et
al. (2001); Husted and Van Giezen (2009); Juif
et al. (2019); Savi et al. (2001); Storey et al.
(2000); Storey et al. (2002); Sugidachi et al.
(2001); Takasaki et al. (2001); Zhang et al.
(2001)

P2Y13

2MeSAMP and Ap4A (partial),
cangrelor, MRS2211, PPADS,
reactive blue 2, suramin

Kim et al. (2005); Marteau et al. (2003)

P2Y14

MRS4458, MRS4478, PPTN

Barrett et al. (2013); Yu et al. (2018)

Abbreviations: 2MeSAMP, 2-methylthio-AMP; A2P5P, adenosine-2'-phosphate-5'-phosphate; Ap4A, diadenosine
tetraphosphate; AR-C118925, 5-[[5-(2,8-dimethyl-5H-dibenzo[a,d]cyclohepten-5-yl)-3,4-dihydro-2-oxo-4-thioxo1(2H)-pyrimidinyl]methyl]-N-(1H-tetrazol-5-yl)-2-furancarboxamide; AR-C66096, 2-(propylthio)adenosine-5'-O(β,γ-difluoromethylene)triphosphate;
AZD1283,
ethyl
5-cyano-2-methyl-6-[4[[[(phenylmethyl)sulfonyl]amino]carbonyl]-1-piperidinyl]-3-pyridinecarboxylate;
MRS2179,
N6-methyl-2′deoxyadenosine
3′,5′-bisphosphate;
MRS2211,
2-[(2-chloro-5-nitrophenyl)azo]-5-hydroxy-6-methyl-3[(phosphonooxy)methyl]-4-pyridinecarboxaldehyde; MRS2279, (1R*,2S*)-4-[2-chloro-6-(methylamino)-9H-purin-9yl]-2-(phosphonooxy)bicyclo[3.1.0]hexane-1-methanol dihydrogen phosphate ester; MRS2500, 2-iodo-N6-methyl(N)-methanocarba-2'-deoxyadenosine 3',5'-bisphosphate; MRS2575, 1,4-phenylendiisothiocyanate; MRS2578, N,N"1,4-butanediylbis[N'-(3-isothiocyanatophenyl)thiourea; MRS4458, 3-[5-[(3-aminopropyl)carbamoyl]thiophen-2-yl]5-[4-[4-(trifluoromethyl)phenyl]-1H-1,2,3-triazol-1-yl]benzoic
acid;
MRS4478,
4'-carbamoyl-5-[4-[4(trifluoromethyl)phenyl]-1H-1,-2,3-triazol-1-yl]-[1,1'-biphenyl]-3-carboxylic acid; NF340, 4,4'-(carbonylbis (imino3,1-(4-methyl-phenylene)carbonylimino))bis (naphthalene-2,6-disulfonic acid; PPADS, pyridoxalphosphate-6azophenyl-2′,4′-disulfonic acid; PPTN, 4-(4-(piperidin-4-yl)-phenyl)-7-(4-(trifluoromethyl)-phenyl)-2-naphthoic acid;
PSB0739, 1-amino-9,10-dihydro-9,10-dioxo-4-[[4-(phenylamino)-3-sulfophenyl]amino]-2-anthracenesulfonic acid;
PSB16133,
1-amino-4-[4-(2,4-dimethylphenylthio)]-9,10-dioxo-9,10-dihydroanthracene-2-sulfonate.
Letters in parentheses indicate agonists with species-selective properties; h, human.

1.2.4. Ectoenzymes
An important regulatory component of purinergic signalling is the ability of cells to
metabolise extracellular nucleotides. Ectoenzymes are a family of cell surface enzymes
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that are responsible for the dephosphorylation of ATP to adenosine (Zimmermann, 2000).
This family of ectoenzymes consists of a number of different subtypes, including
ectonucleoside

triphosphate

diphosphohydrolases

(ENTPDases),

ectonucleotide

pyrophosphatase/phosphodiesterases, alkaline phosphatases, the ectonicotinamide
adenine dinucleotide glycohydrolase and the ecto-5’-nucleotidase, CD73 (Linden et al.,
2019).
Two of the key ectoenzymes which play a key role in the activation of purinergic
receptors are the ectonucleotidases CD39, which converts ATP and ADP to AMP (Heine
et al., 1999; Wang & Guidotti, 1996), and CD73 which converts AMP to adenosine
(Pearson et al., 1980) (Figure 1.1). In dogs, CD39 and CD73 expression and function has
not been well characterised, with the knowledge regarding canine CD39 primarily limited
to data from whole genome sequencing of dogs (Lindblad-Toh et al., 2005). CD73
expression on canine peripheral blood mononuclear cells (PBMC) and mesenchymal stem
cells from adipose tissue and bone marrow of dogs has been reported using both human
and canine antibodies (Ivanovska et al., 2017; Russell et al., 2016).

1.3.

The P2X4 receptor

The general structure and function of P2X receptors were described briefly in Section
1.2.2. However, as this thesis focuses on the characterisation of a number of canine P2
receptors, including the canine P2X4 receptor, a more detailed overview of the structure,
expression and pharmacology of the P2X4 receptor is discussed below.

1.3.1. P2X4 receptor structure
P2X4 receptors, encoded by the P2RX4 gene, were first cloned from rat (Bo et al., 1995)
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and human (Garcia-Guzman et al., 1997) brain cDNA, revealing a protein 388 amino
acids in length. Studies of the human P2X1 and rat P2X2 receptors have suggested that
the P2X4 receptor could contain up to ten disulphide-bonding cysteine residues in the
extracellular loop region (Clyne et al., 2002; Ennion & Evans, 2002). These cysteinecysteine interaction properties were later confirmed when the first high resolution (<3 Å)
crystal structure of the zebrafish P2X4 receptor was reported in the ATP-unbound, closed
state (Kawate et al., 2009) and soon after, in the ATP-bound, open state (Hattori &
Gouaux, 2012). These studies revealed the dolphin-like shape of P2X4 monomeric
subunits, with the tail submerged in the lipid membrane and extending out into the
cytoplasmic region of the cell, and the body, including dorsal fin, flippers and head
regions, extruding out into the extracellular (or hydrophobic) region (Figure 1.2).
Although X-ray crystallography of the zebrafish P2X4 receptor utilised truncated forms
which lacked the N- and C- terminus, these truncated receptors still demonstrated
functional P2X4 channel activity (Kawate et al., 2009). With these studies confirming the
trimeric structure of P2X4 receptors, researchers were able to identify key roles for
disulphide-bonding cysteine residues in P2X4 receptor ligand-binding pocket formation
and channel gating (Rokic et al., 2010).

1.3.2. P2X4 receptor expression and distribution
The P2X4 receptor was originally detected in rat (Bo et al., 1995; Soto et al., 1996) and
human brain tissue (Garcia-Guzman et al., 1997). Since then, functional P2X4 receptors
has been reported in a wide distribution of human or rodent cells and tissues (Bo, Kim, et
al., 2003), including those of the central nervous system (Amadio et al., 2007; Buell et
al., 1996; Tsuda et al., 2003; Ulmann et al., 2008; Vázquez-Villoldo et al., 2014) and in
peripheral endothelial cells where they play an important role in the regulation of vascular
tone (Stokes et al., 2011; Yamamoto et al., 2000; Yamamoto et al., 2006). P2X4 receptors
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have also been identified in a range of human or rodent immune cells including
monocytes (Layhadi & Fountain, 2017; Wang et al., 2004), B lymphocytes (Sluyter et al.,
2001), T cells (Ledderose et al., 2018; Manohar et al., 2012; Woehrle et al., 2010),
eosinophils (Paalme et al., 2019) and tissue-resident macrophages (Bowler et al., 2003;
Ulmann et al., 2010).

Figure 1.2. 3D structure and homology model of inactive and active states of the P2X4
receptor. (A) Side-on view of the P2X4 monomer depicting a dolphin shape with each region
labelled. (B-D) Homology model based on the zebrafish P2X4 crystal structure, depicting three
states of the receptor, (B) the inactive closed state unbound from ATP, (C) the open ATP-bound
state, and (D) a third high affinity binding state following prolonged activation where the receptor
remains desensitized. Images from Abdelrahman et al. (2017).

In dogs, the expression of the P2X4 receptors is limited to reports of transcripts in the
brain and gastrointestinal tissue (Lee et al., 2005) and in canine arteries (Delorey et al.,
2012). Earlier studies demonstrated that ATP could induce Ca2+ currents through
microsomal vesicles extracted from canine cerebellum (Bezprozvanny & Ehrlich, 1993;
Mészáros & Volpe, 1991), suggesting that P2X receptors may be expressed in canine
neuronal tissue. Despite this however, confirmation of P2X4 receptor expression in these
studies could not be confirmed at the time. P2X receptor-mediated contraction of dog
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urinary bladder smooth muscle has also been reported (Suzuki & Kokubun, 1994),
however, it remains unknown if this is mediated by P2X4 or other P2X receptors.
P2X4 receptors in human and rodent macrophages, microglia and endothelial cells are
reported to be expressed at both the cell surface and intracellularly (Boumechache et al.,
2009; Qureshi et al., 2007), where they are targeted to lysosomal compartments through
N-terminal di-leucine (L22I23) and C-terminal tyrosine-based (Y372XXV and Y378XXGL)
motifs (Qureshi et al., 2007; Royle et al., 2005; Xu et al., 2014). These motifs control the
constitutive, dynamin-dependent internalisation and recycling of P2X4 receptors
(Bobanovic et al., 2002; Toulmé et al., 2006), while disruption of these targeting motifs
resulted in an increase in the surface-expression of P2X4 receptors (Royle et al., 2005).
The P2X4 receptor contains seven N-linked glycosylation sites which further aid in
establishing expression at the cell surface (Hu et al., 2002) and in trafficking to- and
maintaining function within- lysosomal compartments, while also resisting degradation
(Qureshi et al., 2007). Luminal pH within lysosomes has also been demonstrated to have
regulatory effects on P2X4 receptors (Xu et al., 2014). It is in the lysosomes, as well as
in late-endosomal compartments, where P2X4 receptors are reported to control a number
of important physiological roles such as Ca2+ regulation, lysosomal fusion and receptor
re-sensitisation (Murrell-Lagnado & Frick, 2019).

1.3.3. P2X4 receptor agonists
The primary agonist of the P2X4 receptor, as with all other mammalian P2X receptor
subtypes, is ATP, with EC50 values reported in the low micromolar (1-10 µM) range
(Coddou et al., 2011; Khakh et al., 2001). Consistent with other P2X receptor subtypes,
activation of P2X4 receptors results in the influx of cations, such as Ca2+ and Na+,
although P2X4 receptors are most permeable to Ca2+ (Egan & Khakh, 2004). Following

43

activation, P2X4 receptors undergo relatively moderate desensitisation, which is
dependent on two key residues, Lys373 and Tyr374 (Fountain & North, 2006).
Pharmacological studies of cloned P2X4 receptors from rat brain reported maximal
activation of the receptor via ATP-induced currents, with similar EC50 values between
7-10 µM (Bo et al., 1995; Buell et al., 1996; Soto et al., 1996). These rat P2X4 receptors
were also activated by other nucleotide analogues in the following order of decreasing
potency: ATP > adenosine 5'-O-(3-thiotriphosphate) (ATPγS) > 2-methylthio-ATP
(2MeSATP) >> ADP ≈ α,β-methylene-ATP (α,β-meATP) (Bo et al., 1995; Buell et al.,
1996).
The agonist profile for the human P2X4 receptor expressed in Xenopus laevius oocytes
was found to be similar to that of the rat P2X4 receptor (ATP > 2MeSATP ≥
cytidine-5'-triphosphate (CTP) > α,β-meATP), with ATP-induced inward currents
revealing an EC50 of 7.4 µM. (Garcia-Guzman et al., 1997). Similar potencies for ATP
were observed in human embryonic kidney (HEK)293 cells expressing recombinant rat
(EC50 5.5 µM), mouse (EC50 2.3 µM) or human (EC50 1.4 µM) P2X4 receptors (Jones et
al., 2000), as well as recombinant human P2X4 receptors expressed in 1321N1 human
astrocytoma cells (EC50 0.5 µM) (Bianchi et al., 1999). Studies have also demonstrated
partial agonist activity of 3'-O-(4-benzoyl)benzoyl adenosine-5'-triphosphate (BzATP)
and diadenosine polyphosphates (AP4A and AP5A) at human and rodent P2X4 receptors
(Abdelrahman et al., 2017; Bianchi et al., 1999; Jones et al., 2000). Recombinant P2X4
receptors from a number of other species, including bovine, zebrafish and Xenopus have
since demonstrated sensitivity to ATP (Ase et al., 2019). Despite this, studies are yet to
publish pharmacological data regarding the canine P2X4 receptor.

1.3.4. P2X4 receptor positive modulators

44

A number of positive modulators of P2X4 receptors have been described with a range of
therapeutic benefits (Stokes et al., 2020). Ivermectin is a broad-spectrum anti-parasitic
drug that is commonly used in human and veterinary medicine (Laing et al., 2017).
Application of extracellular ivermectin (<10 µM) potentiated human and rodent P2X4
receptor-mediated currents and delayed channel deactivation (Bowler et al., 2003; Khakh
et al., 1999; Priel & Silberberg, 2004). ATP-induced currents potentiated by the
application of extracellular ivermectin led to the identification of a binding pocket within
the transmembrane domains of P2X4 receptors, of which was found to play a key role in
ivermectin recognition, binding and selectivity (Asatryan et al., 2010; Jelinkova et al.,
2006; Popova et al., 2013). Ivermectin has also demonstrated potentiation of
ATP-induced Ca2+ responses through native P2X4 receptors on human THP-1 cells
(Layhadi & Fountain, 2017) and human monocyte-derived macrophages (Layhadi &
Fountain, 2019; Layhadi et al., 2018). Other members of this family of lipophilic
compounds, known as avermectins, including abamectin and moxidectin, have also
demonstrated potentiation of P2X4 receptors (Asatryan et al., 2014; Huynh et al., 2017).
Although the sensitivity of ivermectin is greatest at P2X4 receptors, ivermectin can also
potentiate human, but not rodent, P2X7 receptors (Norenberg et al., 2012).
Recently, a number of novel positive allosteric modulators of P2X4 receptors were
identified from protopanaxadiol ginsenoside extracts of the Chinese medicinal plant,
Panax ginseng (Dhuna et al., 2019). These compounds, known as Rd and compound K
(CK), demonstrated a two-fold potentiation of ATP-induced responses in cells expressing
human P2X4 receptors across a range of techniques including electrophysiology, Ca2+
assays and fluorescent dye uptake assays (Dhuna et al., 2019). Despite this, these
ginsenosides can also potentiate ATP-induced responses at human and rodent P2X7
receptors (Bidula, Dhuna, et al., 2019; Bidula, Cromer, et al., 2019; Dhuna et al., 2019;
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Helliwell et al., 2015).
Cibacron blue, an isomer of reactive blue 2 and broad-spectrum P2X receptor inhibitor,
demonstrated positive modulation of the rat P2X4 receptor at concentrations between
3-30 µM (Miller et al., 1998). However cibacron blue did not potentiate ATP-induced
responses in cells expressing the human P2X4 receptor (Garcia-Guzman et al., 1997).

1.3.5. P2X4 receptor antagonists
The broad-spectrum P2 receptor antagonists suramin, pyridoxalphosphate-6-azophenyl2’,4’-disulfonic acid (PPADS) and reactive blue 2 (up to 50 µM) failed to inhibit
ATP-induced currents in Xenopus oocytes expressing the rat P2X4 receptor (Bo et al.,
1995). This lack of inhibition by PPADS was later found to be restored upon replacing
glutamic acid at position 249 with lysine, which is found at the equivalent position in
PPADS-sensitive P2X receptors (Buell et al., 1996). Compared to the rat P2X4 receptor,
the human P2X4 receptor demonstrated some sensitivity to suramin (IC50 178.1 µM) and
PPADS (IC50 27.5 µM) when expressed in Xenopus oocytes (Garcia-Guzman et al.,
1997). However other studies have found PPADS to be a poor inhibitor (IC50 > 100 µM)
of ATP-induced Ca2+ responses of recombinant human P2X4 receptors expressed in
1321N1 cells (Bianchi et al., 1999). Other non-selective P2 receptor antagonists such as
bromophenol blue and cibacron blue were also found to be more potent inhibitors of
ATP-induced currents at the human P2X4 receptor (IC50 78.3 and 39.2 µM, respectively)
in comparison with the rat P2X4 receptor (IC50 301.5 and 128.3 µM, respectively)
(Garcia-Guzman et al., 1997). Ethanol has also demonstrated inhibition of ATP-induced
currents through rodent P2X4 receptors, which in itself can be antagonised by ivermectin
(Asatryan et al., 2018; Ostrovskaya et al., 2011).
Inhibition of rat P2X4 receptor currents has also been observed with high concentrations
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of extracellular Zn2+ and Cd2+ (>100 µM) (Acuna-Castillo et al., 2000; Garcia-Guzman
et al., 1997), while at lower concentrations (10 µM) these divalent cations can potentiate
ATP-induced currents. In contrast, Cu2+ and Hg2+ have demonstrated time- and
concentration-dependent inhibition of ATP-induced currents through the rat P2X4
receptor (Acuna-Castillo et al., 2000; Coddou et al., 2005). In addition, rat and human
P2X4 receptor activity is also modulated by extracellular H+, where decreases in pH
(<6.5) inhibit P2X4 receptor activity, while increases above physiological pH potentiate
channel activity (Clarke et al., 2000; Wildman et al., 1999). The biological significance
of pH-mediated regulation of the P2X4 receptor is supported by its lysosomal distribution
(Qureshi et al., 2007), where the resting luminal pH of lysosomes (pH 4.6) can tightly
regulate P2X4 receptor activity (Huang et al., 2014).
The broad-spectrum P2X receptor antagonist 2’,3’-O-(2,4,6-trinitrophenyl)adenosine-5’triphosphate (TNP-ATP) (Lewis et al., 1998) has demonstrated competitive inhibition of
ATP-induced Ca2+ responses and inward currents through recombinant human and rodent
P2X4 receptors expressed in HEK293 and 1321N1 cells (IC50 1-5 µM) (Abdelrahman et
al., 2017; Balazs et al., 2013; Hernandez-Olmos et al., 2012). Nonetheless, TNP-ATP is
a much more effective antagonist of P2X1, P2X2 and P2X3 heterotrimeric and
homotrimeric receptors (Virginio et al., 1998). The selective serotonin reuptake inhibitor
(SSRI), paroxetine, has also been found to act as an allosteric antagonist of human (IC50
1.9 µM) and rat (IC50 2.5 µM) P2X4 receptors (Müller et al., 2010; Nagata et al., 2009).
Similarly, the serotonin-norepinephrine reuptake inhibitor (SNRI), duloxetine, also
inhibited human and rat P2X4 receptors with a similar potency (IC50 1.6 µM) (Yamashita
et al., 2016).
Several more potent and selective P2X4 receptor antagonists have been identified
recently and tested against the human and rodent P2X4 receptors. A chemical library
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screen identified 5-[3-(5-thioxo-4H-[1,2,4]oxadiazol-3-yl)phenyl]-1H-naphtho[1, 2b][1,4]diazepine-2,4(3H,5H)-dione (NP-1815-PX) as a novel antagonist of the human
P2X4 receptor (IC50 0.26 µM), with a similar inhibitory effect on ATP-induced Ca2+
responses of rodent P2X4 receptors (Matsumura et al., 2016). A number of compounds
derived from N-substituted phenoxazines have also been identified as selective P2X4
receptor antagonists (Hernandez-Olmos et al., 2012). The allosteric inhibitor N(benzyloxycarbonyl)phenoxazine (PSB-12054) blocked recombinant human, mouse and
rat P2X4 receptor-mediated Ca2+ responses in 1321N1 cells, with IC50 values of 0.2 µM,
1.8 µM and 2.1 µM, respectively (Hernandez-Olmos et al., 2012). Another study utilising
the same expression model reported similar potency at the human P2X4 receptor (IC50
0.1 µM) and a much greater selectivity (>30-fold) for P2X4 compared to other P2X
receptors (Tian et al., 2014). Whilst PSB-12054 is amongst one of the more potent P2X4
receptor antagonists, it is poorly water soluble, making it a difficult compound for both
in vitro and in vivo use. An analogue of this inhibitor with greater water solubility,
N-(p-methylphenyl)sulfonylphenoxazine (PSB-12062) was discovered to retain a similar
potency at human, mouse and rat P2X4 receptors (IC50 1.4 µM, 1.8 µM and 0.9 µM,
respectively) and displayed strong selectivity against other P2X receptors (HernandezOlmos et al., 2012).
The

selective

P2X4

receptor

antagonist,

5-(3-bromophenyl)-1,3-dihydro-2H-

benzofuro[3,2-e]-1,4-diazepin-2-one (5-BDBD; Fisher et al., 2005), was reported to
competitively inhibit ATP-induced currents and Ca2+ responses in HEK293 cells
expressing the recombinant human P2X4 receptor with an IC50 of 1.2 µM and 2 µM,
respectively (Balazs et al., 2013). More recently, a study tested this antagonist against
other recombinant P2X4 orthologues and reported that 5-BDBD was most potent at the
human receptor (IC50 0.35 µM) compared to the mouse (IC50 2 μM) and rat P2X4
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receptors (IC50 3.5 μM) (Abdelrahman et al., 2017). Using radioligand binding assays,
this study also demonstrated that 5-BDBD likely modulates P2X4 receptor activity
through an allosteric site, rather than through interaction with the orthosteric binding site
occupied by ATP (Abdelrahman et al., 2017). 5-BDBD has also recently been used to
inhibit native P2X4 receptors in rat odontoblasts (Lee et al., 2016). However, similar to
PSB-12054, 5-BDBD has a low water solubility which can severely hinder its suitability
as both an in vitro and in vivo P2X4 receptor antagonist (Jacobson & Müller, 2016).
The phenylurea, 1-(2,6-dibromo-4-isopropyl-phenyl)-3-(3-pyridyl)urea (BX430) was
also identified as an allosteric inhibitor at the human, but not mouse or rat P2X4 receptors
(IC50 0.5 µM) and displayed strong selectivity compared with other P2X receptors (Ase
et al., 2015). More recently, the selectivity of BX430 across a range of P2X4 receptor
orthologues was demonstrated to be regulated by a single amino acid (Ile312) which
forms a docking site with Asp88 and Tyr300, leading to reduced inhibitory effects at
rodent and other non-mammalian P2X4 receptors (Ase et al., 2019). In addition to their
effects on recombinant P2X4 receptors, a number of these selective P2X4 receptor
antagonists, including PSB-12062, 5-BDBD and BX430, have now demonstrated
inhibition of endogenous P2X4 receptors through blockade of ATP-induced Ca2+
responses in THP-1 cells and monocyte-derived macrophages (Layhadi & Fountain,
2017, 2019; Layhadi et al., 2018).
Most

recently,

a

potent,

orally

active

and

selective

N‑[4-(3-chlorophenoxy)-3-sulfamoylphenyl]-2-phenylacetamide

P2X4

antagonist

(BAY-1797)

was

discovered to have greatly improved potency at human and rodent P2X4 receptors in vitro
(IC50 100-300 nM), with little to no inhibitory effect on other P2X receptors (Werner et
al., 2019). This compound also demonstrated promising anti-inflammatory and antinociceptive effects in a mouse model of inflammatory pain (Werner et al., 2019).
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1.3.6. Missense variants of the P2RX4 gene
Over 300 human P2RX4 gene missense variants have been reported online (Ensembl
genome browser; https://www.ensembl.org/) through genome-wide sequencing projects
(Gerhard et al., 2004; Korenaga et al., 2001; Notay et al., 2018; Voight et al., 2010). A
number of mutations are also reported in the Catalogue of Somatic Mutations in Cancer
(COSMIC) database (https://cancer.sanger.ac.uk/cosmic). Despite this number of
missense variants, few have been functionally characterised. A human Tyr315Cys variant
(rs28360472) results in a substantial loss of P2X4 receptor function and has been
associated with an increase in pulse pressure (Stokes et al., 2011). The same variant, when
in linkage disequilibrium with a P2RX7 loss of function Gly150Arg variant (rs28360447)
confers increased susceptibility to age-related macular degeneration, which is suggested
to occur through a decrease in P2X7 receptor-mediated phagocytosis (Gu et al., 2013). A
human P2RX4 gain of function Gly135Ser variant (rs765866317), which forms a rare
three-variant haplotype with the P2RX7 variants Thr205Met (rs140915863) and
Asn361Ser (rs201921967), is associated with multiple sclerosis in a multi-incident family
(Sadovnick et al., 2017). However, the functional effect of this haplotype remain
unknown.
Studies utilising whole-genome sequencing in dogs have revealed at least nine P2RX4
coding variants (Freedman et al., 2014; Jagannathan et al., 2019; Lindblad-Toh et al.,
2005; Wang et al., 2013). However, details of these variants are limited to those in online
databases, such as the Ensembl genome browser, the EMBL-EBI European Variation
Archive (EVA) (https://www.ebi.ac.uk/eva/) and the iDOG Dog Genome SNP database
(https://bigd.big.ac.cn/idog/). To date, three missense variants of canine P2RX4 are
reported in these databases: Ala9Asp (no rsID); Arg231Cys (no rsID); and Leu345Val
(rs852294963). Six synonymous variants are also reported in these databases: Asn142 (no
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rsID); Gly251 (no rsID); Thr266 (rs85229496); Ser341 (no rsID); Leu343 (no rsID); and
Glu276 (no rsID). Despite these reported variants, none have been validated through
functional studies and as such, their effect on P2X4 function is currently unknown.

1.3.7. The role of P2X4 receptors in health and disease
From studies in human and rodent spinal cord microglia, it has been well established that
ATP-induced activation of P2X4 receptors stimulates p38 mitogen-activated protein
kinase (MAPK) to induce the release of brain-derived neurotrophic factor (BDNF) from
microglia (Trang et al., 2009; Tsuda et al., 2003; Ulmann et al., 2008). This release of
BDNF can activate transmembrane tyrosine kinase B (TrkB) on secondary sensory
neurons, downregulating the K+/Cl- transporter, KCC2, leading to a depolarising shift in
the anionic gradient and the release of γ-aminobutyric acid (GABA) from interneurons
(Coull et al., 2003). This dysregulation suppresses transmission through GABAergic
inhibitory synapses, leading to an opening of Cl- channels and pain hypersensitivity
through disinhibition of the spinal circuits (Coull et al., 2005). As such, microglial P2X4
receptors have been suggested to play important roles in the gating of neuropathic chronic
pain and tactile allodynia following peripheral nerve injury (Bernier et al., 2018; Jarvis,
2010; Trang & Salter, 2012) and in cancer-induced bone pain models (Meng et al., 2017;
Yan et al., 2019) (Figure 1.3).
Studies have found that P2X4 receptor expression and activation in spinal cord-derived
microglia is highly upregulated following peripheral nerve injury (Tsuda et al., 2005;
Tsuda et al., 2003), supporting a role for these receptors in neuropathic pain. This is
further supported by findings that P2X4 receptor deficient mice exhibit reduced responses
to chronic neuropathic pain caused by peripheral nerve injury, but show no pain response
defect to acute noxious stimuli or local tissue damage (Tsuda et al., 2009). In addition to
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this, P2X4 receptor inhibition with the SNRI duloxetine or the SSRI paroxetine, has been
demonstrated to reverse neuropathic pain in rats following nerve injury (Nagata et al.,
2009; Yamashita et al., 2016). Both of these clinically prescribed anti-depressants have
also been used to treat chronic neuropathic pain in humans, although the effectiveness of
duloxetine appears to be greater (Arnold, 2007; Finnerup et al., 2015; Hossain et al., 2016;
Lian et al., 2020; Malemud, 2009; Sultan et al., 2008; Wright et al., 2010) in comparison

Figure 1.3. Proposed mechanism of P2X4 receptor signalling on activated microglia in
neuropathic pain. Peripheral nerve injury drives the overexpression of P2X4 receptors through
gene upregulation and subsequent lysosomal exocytosis, recycling P2X4 receptors to the surface
for activation by ATP released from dorsal horn neurons. The subsequent Ca 2+ influx activates
p38 mitogen activated protein kinase (MAPK) which signals release of brain-derived
neurotrophic factor (BDNF). BDNF activates transmembrane tyrosine kinase B (TrkB) receptors
on secondary sensory neurons and downregulates chloride potassium symporter 5 (KCC2),
driving up luminal Cl-. The resulting shift in anion gradient, coupled with stimulation by γaminobutyric acid (GABA) opens up the Cl- channels to efflux, causing depolarisation of the
dorsal horn neurons and hyperexcitability, resulting in neuropathic pain from minor stimulations.
Figure adapted from Inoue (2018); Tsuda and Inoue (2016), and created using BioRender.

to paroxetine, which has often demonstrated mixed results regarding effectiveness in
reducing chronic pain (Patetsos & Horjales-Araujo, 2016; Patkar et al., 2007; Sindrup et
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al., 2005). Proposed mechanisms through which these compounds act include signalling
through neuronal transient receptor potential (TRP) channels (Demirdas et al., 2017) and
the Toll-like receptor 4 (TLR4) signalling pathway (Zhou et al., 2018).
Further to neuropathic pain, P2X4 deficient mice also exhibit reduced responses to
chronic inflammatory pain following nerve injury via a similar activation pathway
involving p38 MAPK stimulation (Tsuda et al., 2009). This process occurs within tissueresident macrophages which have been shown to express P2X4 receptors (Ulmann et al.,
2010). Activation of P2X4 receptors in tissue-resident macrophages results in an
enzymatic cascade of events, including the activation of cyclooxygenases and the
subsequent release of prostaglandin E2, a key mediator of inflammation (Ulmann et al.,
2010). In addition to this, tissues extracted from P2X4 knockout mice were completely
absent of inflammatory prostaglandin E2 (Ulmann et al., 2010), further supporting the
role of the P2X4 receptor in the production of this compound and its signalling of chronic
inflammatory pain.
A number of studies have demonstrated that P2X4 receptors also play a key role in alcohol
use disorders (Franklin et al., 2014). Ivermectin, which is known to antagonise the
ethanol-mediated inhibition of P2X4 receptors (Asatryan et al., 2010), has been assessed
in a Phase 1 clinical trial for treating alcohol use disorders (Roche et al., 2016). However,
despite demonstrating the safety of ivermectin (30 mg taken orally) in combination with
an intoxicating dosage of alcohol, this trial was unable to provide evidence for ivermectin
in effectively reducing alcohol craving or response to alcohol. Nonetheless, the authors
suggest additional studies with larger sampling and alternate dosing regimens are
warranted given the demonstrated safety of ivermectin, and its potential for treating
alcohol use disorders observed through in vivo studies in mice (Yardley et al., 2012).
Ivermectin has also demonstrated other potential therapeutic benefits outside of alcohol
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use disorders. Potentiation of P2X4 receptors with ivermectin revealed an anti-bacterial
effect and improved survival in a mouse model of sepsis (Csoka et al., 2018), while in a
mouse model of multiple sclerosis (autoimmune encephalomyelitis) potentiation of P2X4
receptors by ivermectin improved oligodendrocyte-mediated remyelination of neurons
(Zabala et al., 2018). In a dopamine depletion mouse model of Parkinson’s disease,
potentiation of P2X4 receptors by ivermectin enhanced motor behaviour in the presence
of levodopa (Khoja et al., 2016) a therapeutic agent used for the treatment of Parkinson’s
disease. This demonstrated the potential of ivermectin for the treatment of Parkinson’s
disease. Despite these studies, the full effects of ivermectin as a therapeutic agent for
neuroinflammatory and neurodegenerative diseases, such as multiple sclerosis and
Parkinson’s disease, requires further investigation.

1.4.

The P2X7 receptor

The general structure and function of P2X receptors were described briefly in Section
1.2.2. As this thesis focuses on a number of canine P2 receptors, including the canine
P2X7 receptor, a more detailed overview of the structure, expression and pharmacology
of the P2X7 receptor is discussed below.

1.4.1. P2X7 receptor structure
The P2X7 receptor, encoded by the P2RX7 gene, is a 595 amino acid protein which was
first cloned from rat brain (Surprenant et al., 1996) and subsequently from human
monocytes (Rassendren et al., 1997). Similar to P2X4 receptors, the P2X7 receptor
consists of a cytosolic N- and C- terminus, two hydrophobic transmembrane domains and
a long glycosylated extracellular loop which contains the binding sites for ATP (North,
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2002). In contrast to other P2X receptors, the P2X7 receptor has an extended C-terminal
tail which contains a number of established domains important for P2X7 receptor
expression and function (Costa-Junior et al., 2011). However, recent studies have
suggested that cell membrane lipid composition may play a larger role in P2X7 pore
formation and function (Karasawa et al., 2017).
The structure of P2X7 receptors (Jiang et al., 2013) was originally based on the previously
described crystal structure of the zebrafish P2X4 receptor (Hattori & Gouaux, 2012;
Kawate et al., 2009). However a recent study solved the crystal structure of a C-terminal
truncated mammalian P2X7 receptor (from giant panda) to ~3.5 Å resolution (Karasawa
& Kawate, 2016). This study revealed similarities to the crystal structure of zebrafish
P2X4 (Hattori & Gouaux, 2012; Kawate et al., 2009), confirming the trimeric structure
of mammalian P2X7 receptors. Additionally, this study demonstrated an allosteric
binding site for a number of structurally different P2X7 receptor antagonists (Karasawa
& Kawate, 2016).
The crystal structure of an N- and C-terminal truncated chicken P2X7 receptor in complex
with the broad-spectrum P2X receptor antagonist, TNP-ATP, was recently solved to
3.1 Å resolution (Kasuya et al., 2017). This study revealed a unique binding manner of
TNP-ATP to P2X7 receptors, which was distinct to that which has been reported for
human P2X3 in complex with TNP-ATP (Mansoor et al., 2016). Most recently,
cryoelectron microscopy of the full-length rat P2X7 receptor in the unbound (closed) and
ATP-bound (open) formation has revealed insights into the structure and function of the
cytoplasmic domain (McCarthy et al., 2019). This study reported a unique cytoplasmic
cysteine-rich region at the end of the second transmembrane domain which binds to
palmitoylated groups in the membrane and prevents receptor desensitisation (McCarthy
et al., 2019). Additionally, this study reported an unexpected cytoplasmic ballast domain
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which contained Zn2+ and guanosine nucleotide binding region (McCarthy et al., 2019),
however the role this domain plays in P2X7 receptor function remains unclear.
In addition to those described above, recombinant P2X7 receptors from a number of other
species, including mouse (Chessell, Simon, et al., 1998), guinea pig (Fonfria et al., 2008),
rhesus macaque (Bradley et al., 2011) and dog (Roman et al., 2009; Spildrejorde, Bartlett,
et al., 2014) have now been characterised. The canine P2X7 receptor shares 85%
sequence identity with the human P2X7 receptor and retains important conserved
domains for ligand-binding and cysteine residues for disulphide-bonding (Roman et al.,
2009). The canine P2X7 receptor differs from the human P2X7 receptor in that it contains
an additional threonine between Asn284 and Val285, while missing Val538 (Roman et
al., 2009). Although the effects of these amino acid differences have not been studied, the
canine P2X7 receptor is functional and current evidence suggests that these changes have
little effect on receptor function (Jiang et al., 2013).
Given that the canine P2X7 receptor has been relatively well-studied since its discovery
in dogs, the remainder of this section will maintain a focus on reviewing the literature on
the canine P2X7 receptor, with reference to the human or rodent P2X7 receptors where
relevant.

1.4.2. P2X7 receptor expression and distribution
While functional P2X7 receptors were originally thought to be primarily expressed on
haematopoietic cells, such as monocytes, macrophages and lymphocytes, it has now been
well established that P2X7 receptors are expressed in a wide range of cell types, including
erythrocytes, endothelial cells, muscle cells, epithelial cell and some cells of the central
nervous system (Burnstock & Knight, 2004; Sluyter, 2017). In dogs, the expression of
the P2X7 receptor has been demonstrated primarily in cells of haematopoietic lineage,
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including monocytes (Jalilian, Peranec, et al., 2012; Sluyter, Shemon, Hughes, et al.,
2007; Stevenson et al., 2009), T and B lymphocytes (Stevenson et al., 2009), and
erythrocytes (Faulks et al., 2016; Sluyter, Shemon, Hughes, et al., 2007; Stevenson et al.,
2009). Species differences in expression and subsequent function of the P2X7 receptor
have been reported, with increased activity on canine compared to human erythrocytes,
while the opposite has been reported on canine and human monocytes (Sluyter, Shemon,
Hughes, et al., 2007; Stevenson et al., 2009). P2X7 receptors have also been reported in
normal canine cerebral tissue (Lee et al., 2005; Truve et al., 2016), in glioblastomas,
oligodendrogliomas and astrocytomas in dogs presenting with glioma (Truve et al., 2016)
and in the myenteric plexus of the ileum and distal colon of dogs (Schafer et al., 2018).
The P2X7 receptor is also expressed on MDCK cells (Jalilian, Spildrejorde, et al., 2012),
where it possibly localises to the basolateral membrane (Bradley et al., 2010) and has
been suggested to play a role in the epithelial-mesenchymal transition (Zuccarini et al.,
2017).

1.4.3. P2X7 receptor agonists
Activation of human and rodent P2X7 receptors by ATP or BzATP results in the opening
of a non-selective cation channel, mediating the influx of Ca2+ and Na+ and efflux of K+
(Egan & Khakh, 2004; Rassendren et al., 1997; Surprenant et al., 1996). Prolonged
exposure to agonists (>30s) revealed formation of a pore which allowed the uptake of
organic cationic dyes, such as ethidium+ (Wiley et al., 1993) and YO-PRO-12+
(Surprenant et al., 1996). These permeability properties of P2X7 receptors, along with
ion flux assays, patch clamp recordings and cytokine release assays have been utilised to
study the pharmacology of the recombinant canine P2X7 receptors (Roman et al., 2009;
Spildrejorde, Bartlett, et al., 2014), as well as native P2X7 receptors on canine
haematopoietic (Sluyter, Shemon, Hughes, et al., 2007; Stevenson et al., 2009) and
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MDCK cells (Jalilian, Spildrejorde, et al., 2012).
Pharmacological characterisation of a P2X7 receptor cloned from dog heart cDNA of an
undisclosed breed revealed ATP and BzATP induced currents (EC50 3.2 mM and 0.5 mM,
respectively) in HEK293 cells stably expressing the canine P2X7 receptor (Roman et al.,
2009). Although agonist-induced inward current onset and desensitisation were notably
slower at canine, compared to rat or human P2X7 receptors, the reported potency was
consistent with inward currents in cells expressing human, but not rat P2X7 receptors
(Roman et al., 2009). Despite this, BzATP was reported as a partial agonist of P2X7
receptor-mediated ethidium+ uptake in cells transiently expressing this canine P2X7
receptor (Roman et al., 2009). This is in contrast to a study by our group which
characterised a P2X7 receptor cloned from PBMC cDNA of an English Springer Spaniel
and reported ATP to be a partial agonist (EC50 253 µM) compared to BzATP
(EC50 13 µM) (Spildrejorde, Bartlett, et al., 2014). Consistent with that observed for
human P2X7 receptors (Gargett et al., 1997), the canine P2X7 receptor was partially
activated (<10%) by ATPγS (Spildrejorde, Bartlett, et al., 2014).
In support of the above study by Spildrejorde, Bartlett, et al. (2014), activation of
endogenous P2X7 receptors on canine erythrocytes demonstrated that ATP, not BzATP,
was a partial agonist of 86Rb+ (as a substitute for K+) efflux (Stevenson et al., 2009). In
canine erythrocytes, measurements of
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Rb+ efflux revealed a rank order of potency of

agonists as follows; BzATP (EC50 7 µM) > ATP (EC50 309 µM) > 2MeSATP > ATPγS
(Sluyter, Shemon, Hughes, et al., 2007), mimicking results observed at recombinant dog
(Spildrejorde, Bartlett, et al., 2014), human (Rassendren et al., 1997) and rat (Surprenant
et al., 1996) P2X7 receptors. In contrast, adenosine, AMP, ADP and UTP all had no effect
on 86Rb+ efflux, excluding a role for P1 receptors, as well as a number of P2Y receptors
(Sluyter, Shemon, Hughes, et al., 2007). ATP (1-5 mM) also demonstrated ethidium+ and
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YO-PRO-12+ uptake into canine peripheral blood monocytes, T cells and B cells with
similar efficacy (Jalilian, Peranec, et al., 2012; Stevenson et al., 2009).
Studies have demonstrated functional roles for the canine P2X7 receptor through
ATP-induced release of the proinflammatory cytokine, interleukin (IL)-1β, in a time- and
ATP concentration-dependent manner from canine whole blood (Roman et al., 2009;
Spildrejorde, Curtis, et al., 2014) and canine monocytes (Jalilian, Peranec, et al., 2012).
Other reported functions of canine P2X7 receptors include ATP-induced externalisation
of phosphatidylserine on the outer surface of canine erythrocytes and haemolysis (Faulks
et al., 2016; Sluyter, Shemon, Hughes, et al., 2007). This is consistent with the activation
of the P2X7 receptor on human erythrocytes (Sluyter, Shemon, & Wiley, 2007;
Sophocleous et al., 2015).

1.4.4. P2X7 receptor positive modulators
Although studies have yet to investigate compounds that potentiate canine P2X7 receptor
activity, a number of compounds have been described as positive modulators of P2X7
receptors in other species such as humans or mice (Stokes et al., 2020). Clemastine, a first
generation anti-histamine, potentiates P2X7 receptor activity in human monocyte-derived
macrophages and murine bone-marrow-derived macrophages (Nörenberg et al., 2011).
Clemastine has also demonstrated potential clinical applications, delaying the onset of
ALS and improving survival of superoxide dismutase (SOD1)-G93A mice by
approximately 10% in a short treatment model (Apolloni et al., 2016). This therapeutic
effect is suggested to occur through upregulation of microglial P2X7 and P2Y12 receptors,
driving microglial polarisation and enhancing neuroprotection (Apolloni et al., 2016).
Clemastine can also potentiate zebrafish P2X7 receptor activity and boost antimycobacterial activity in a zebrafish model of Mycobacterium infection (Matty et al.,
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2019).
The P2X4 receptor positive allosteric modulator, ivermectin, has demonstrated
potentiation of ATP-induced currents and Ca2+ responses, although not YO-PRO-1+ dye
uptake, in HEK293 cells expressing recombinant human P2X7 receptors (Norenberg et
al., 2012). The ginsenoside compounds which have been reported as positive allosteric
modulators of P2X4 receptors (ginsenoside Rd and CK), have also demonstrated
potentiation of ATP-induced responses at human and rodent P2X7 receptors (Bidula,
Dhuna, et al., 2019; Bidula, Cromer, et al., 2019; Dhuna et al., 2019; Helliwell et al.,
2015). Given the pharmacological similarities between canine and human P2X7 receptors
(Roman et al., 2009; Spildrejorde, Bartlett, et al., 2014), it may be suggested that these
compounds could also potentiate canine P2X7 receptor activity, although this has yet to
be determined.

1.4.5. P2X7 receptor antagonists
The earliest demonstrated inhibitors of canine P2X7 receptor function include the
isoquinolinesulfonamide derivate KN-62, brilliant blue G (BBG) and oxidised ATP
(OxATP), which were reported to inhibit ATP-induced
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Rb+ efflux on canine

erythrocytes (Sluyter, Shemon, Hughes, et al., 2007). Studies have also demonstrated that
KN-62 can inhibit P2X7 receptor function on canine monocytes, T cells and B cells
(Stevenson et al., 2009), as well as in MDCK cells (Jalilian, Spildrejorde, et al., 2012).
This is further supported by data on recombinant canine P2X7 receptors, where KN-62
and BBG demonstrate potent inhibition of ATP-induced ethidium+ uptake into HEK293
cells expressing recombinant canine P2X7 receptors (Roman et al., 2009; Spildrejorde,
Bartlett, et al., 2014). While the potency of KN-62 at canine P2X7 receptors was similar
between these two studies (IC50 10 nM and 16 nM, respectively), the potency of BBG at
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canine P2X7 receptors differed substantially between the first and second studies
(IC50 50 nM and 1000 nM, respectively) (Roman et al., 2009; Spildrejorde, Bartlett, et
al., 2014). Despite the low IC50 of BBG in the first study, KN-62, but not BBG (up to
10 µM), inhibited IL-1β release from canine whole blood (Roman et al., 2009).
Broad-spectrum P2 receptor antagonists, such as suramin and PPADS, have demonstrated
weak to moderate inhibition of ATP-induced ethidium+ uptake into HEK293 cells
expressing the recombinant canine P2X7 receptor (IC50 >100 µM and 15 µM,
respectively) (Roman et al., 2009). Similar to that observed at the human P2X7 receptor
(Michel et al., 1999; Rassendren et al., 1997), Mg2+ has been demonstrated to inhibit the
P2X7 receptor in a concentration-dependent manner on canine erythrocytes (Stevenson
et al., 2009).
A tetrazole-based compound, A-438079, which is a known competitive inhibitor of the
human P2X7 receptor (Nelson et al., 2006), has demonstrated inhibition of the canine
P2X7 receptor (Jalilian, Peranec, et al., 2012; Jalilian, Spildrejorde, et al., 2012;
Spildrejorde, Bartlett, et al., 2014; Spildrejorde, Curtis, et al., 2014). A-438079 inhibited
ethidium+ uptake through the recombinant canine P2X7 receptor expressed in HEK293
cells (IC50 195 nM) (Spildrejorde, Bartlett, et al., 2014), while less potent (although still
effective) inhibition was reported at the recombinant canine P2X7 receptor expressed in
1321N1 cells as measured through Ca2+ flux assays (IC50 4 µM) (Bhattacharya et al.,
2013). Studies have also reported A-438079 targeting endogenous canine P2X7 receptors
through inhibition of ethidium+ uptake in MDCK cells (Jalilian, Spildrejorde, et al., 2012)
and IL-1β release from lipopolysaccharide (LPS)-primed canine whole blood
(Spildrejorde, Curtis, et al., 2014) and monocytes (Jalilian, Peranec, et al., 2012).
A potent, non-competitive antagonist of the human P2X7 receptor, AZ10606120 (Michel
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et al., 2008), has demonstrated potent inhibition of ATP-induced ethidium+ uptake in
HEK293 cells expressing a recombinant canine P2X7 receptor (IC50 60 nM), although
this compound was twenty-fold less potent compared to the human P2X7 receptor
(IC50 3 nM) (Roman et al., 2009). AZ10606120 has also demonstrated inhibition of ATPinduced IL-1β release from canine whole blood (Roman et al., 2009) and
phosphatidylserine externalisation on canine erythrocytes (Faulks et al., 2016). Another
selective, non-competitive P2X7 receptor antagonist, AZ11645373 (Stokes et al., 2006),
has been reported to inhibit ATP-induced ethidium+ uptake in HEK293 cells expressing
the recombinant canine P2X7 receptor with a similar potency to the human P2X7 receptor
(IC50 0.04 µM and 0.03 µM, respectively) (Michel et al., 2009). Other potent and selective
inhibitors of human P2X7 receptors, including JNJ-47965567 (Bhattacharya et al., 2013)
and A-804598 (Donnelly-Roberts, Namovic, Surber, et al., 2009) have been studied on
1321N1 cells expressing recombinant canine P2X7 receptors using Ca2+ flux assays. The
potency of JNJ-47965567 and A-804598 at the canine P2X7 receptor (IC50 3 nM and 32
nM, respectively) was comparable to that observed at the human P2X7 receptor (IC50 5
nM and 20 nM, respectively) (Bhattacharya et al., 2013).
An inhibitor of the pannexin-1 hemichannel, probenecid, which has been demonstrated
to inhibit the human P2X7 receptor through a pannexin-1-independent mechanism
(Bhaskaracharya et al., 2014), has also demonstrated inhibition of ATP-induced currents
and ethidium+ uptake in HEK293 cells expressing the recombinant canine P2X7 receptor
(Bartlett et al., 2017). This study also demonstrated that probenecid could inhibit
LPS-stimulated ATP-induced IL-1β release from canine blood (Bartlett et al., 2017).

1.4.6. Missense variants of the P2RX7 gene
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Around 500 missense variants of the human P2X7 receptor are reported on the Ensembl
genome browser, with at least 16 of these functionally characterised in humans and many
associated with susceptibility to human disease (Sluyter, 2017; Sluyter & Stokes, 2011).
One of the more extensively studied variants of the human P2RX7 gene, rs3751143, is a
loss-of-function variant which results in a glutamic acid to alanine substitution at position
496 (Gu et al., 2001) and has a minor allele frequency of 0.187 (NCBI dbSNP ALFA
global allele frequency; https://www.ncbi.nlm.nih.gov/snp/). This variant has known
functional roles in a range of P2X7-mediated cellular processes such as cation flux,
cytokine release and shedding, phospholipid reorganisation and cell death, and has been
associated with a number of musculoskeletal, inflammatory, cardiovascular and
psychiatric disorders (which are reviewed in detail in Sluyter & Stokes, 2011).
In dogs, fewer missense variants of the P2RX7 gene have been reported online, while
only five have been functionally characterised. A previous study by our group on a cohort
of 65 randomly sampled dogs identified four P2RX7 missense variants in dogs;
Phe103Leu (rs23314713), Arg270Cys (rs851148233), Arg365Gln (rs850760787) and
Pro452Ser (rs23315462) (Spildrejorde, Bartlett, et al., 2014). Ethidium+ uptake assays
revealed that rs23314713 and rs850760787 lead to partial loss of P2X7 receptor function,
while rs851148233 resulted in a near complete loss of P2X7 receptor function
(Spildrejorde, Bartlett, et al., 2014). In contrast, the rs23315462 variant had no effect on
P2X7 receptor function (Spildrejorde, Bartlett, et al., 2014). It is speculated that canine
P2RX7 missense variants, such as rs23314713 and rs23315462, may play a role in the
differential agonist sensitivity and efficacy observed between ATP and BzATP, or
inhibition of P2X7 receptors by antagonists such as BBG (Roman et al., 2009;
Spildrejorde, Bartlett, et al., 2014; Stevenson et al., 2009). Furthermore, it was noted that
the rs851148233 and rs850760787 variants appeared to be restricted to two dogs of
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Cocker Spaniel pedigree (one of which was from MDCK cells) and four dogs of Labrador
Retriever pedigree, respectively (Spildrejorde, Bartlett, et al., 2014).
In addition to the four canine P2RX7 variants described above, a partial gain of function
Leu440Phe variant was also identified in the P2X7 receptor cloned from an English
springer spaniel (Spildrejorde, Bartlett, et al., 2014). However, this variant is yet to be
reported in any other studies or in online databases (Ensemble genome browser, EVA,
iDOG) and is found in a known conserved regulatory region of the P2X7 receptor (Becker
et al., 2008). As such it is unknown if this variant is a true missense variant observed in
English Springer Spaniels or if it was introduced during the cloning process.

1.4.7. The roles of P2X7 receptors in canine health and disease
The P2X7 receptor has well-established roles in human physiology and pathophysiology,
including inflammation, immunity and cancer (Di Virgilio et al., 2017; Savio et al., 2018),
neural function and psychological disorders (Ribeiro et al., 2019; Stokes et al., 2015),
pain (Taidi et al., 2019; Zhang, Zhu, et al., 2019), as well as bone formation and resorption
(Agrawal & Gartland, 2015; Jorgensen, 2018). Although studies have yet to establish a
role for P2X7 receptors in canine disorders, activation of canine P2X7 receptors mimics
downstream signalling events in humans, such as cation homeostasis, cytokine release
and membrane lipid reorganisation (Grahames et al., 1999; Sluyter et al., 2004; Sluyter,
Shemon, & Wiley, 2007; Sophocleous et al., 2015). Given this, the canine P2X7 receptor
has been proposed as a therapeutic target for a range of disorders, including inflammatory
disease, cancer and osteoporosis (Bartlett et al., 2014).
Although further evidence is required, studies suggest that canine P2RX7 variants may be
associated with, or contribute to, disease. Truve et al. (2016) revealed that the rs23314713
variant was associated with increased susceptibility to glioma, a disease more frequently
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observed in brachycephalic dogs (Hayes et al., 1975; Snyder et al., 2006; Song et al.,
2013). Canine brachycephaly is a skeletal deformation resulting in the shortening of the
muzzle, flat facial conformation and widening of the skull that is observed in many
common domestic breeds such as the Pug, Bulldog and Staffordshire Bull Terrier (Asher
et al., 2009; Bannasch et al., 2010). Despite their popularity, severe restructuring of the
facial conformation can lead to brachycephalic obstructive airway syndrome (Packer et
al., 2015) and has been associated with the spatial reorganisation of the brain in
brachycephalic dogs (Roberts et al., 2010).
Notably, the canine rs851148233 loss of function variant lies at the same position as a
human partial loss of function P2RX7 variant (rs7958311, Arg270His; Stokes et al., 2010)
that was associated with reduced pain in two independent cohorts of post-mastectomy
breast cancer patients and patients with osteoarthritis (Sorge et al., 2012). This may
suggest that this canine P2RX7 variant may play a role in pain signalling. Similarly, a
canine P2RX7 Arg276His variant has been reported in the iDOG database which results
in the same amino acid change as that observed in a human P2RX7 loss of function variant
(rs7958316, Arg276His; Stokes et al., 2010). However, the Arg276His variant has yet to
be associated with disease in humans, nor has it been reported in dogs from other studies
or functionally characterised, so it is unknown what effect this variant has in dogs.

1.5.

The P2Y1 and P2Y12 receptors

The general structure and function of P2Y receptors were described briefly in Section
1.2.3. As the final focus of this thesis is on the platelet P2Y receptors, P2Y1 and P2Y12,
of dogs, a more detailed overview of the structure, expression and pharmacology of these
two receptors is discussed below.
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1.5.1. The platelet P2Y receptors
The P2Y1 and P2Y12 receptors have been identified as the primary P2Y receptors involved
in platelet activation, haemostasis and thrombosis in humans and rodents (Hechler &
Gachet, 2015). Activation of the platelet P2Y1 receptor mediates Ca2+ mobilisation from
intracellular stores, leading to a change in platelet shape and initiation of platelet
aggregation (Hechler, Léon, et al., 1998; Jin et al., 1998; Savi et al., 1998). Activation of
the platelet P2Y12 receptor inhibits adenylyl cyclase, causing a decrease in cAMP
production which subsequently amplifies and sustains the platelet aggregation response
mediated by the P2Y1 receptor, leading to thrombus growth and stabilisation (Daniel et
al., 1998; Hechler, Eckly, et al., 1998). Platelets also express other P2 receptors, including
the P2X1 receptor (Vial et al., 1997) and the P2Y14 receptor (Dovlatova et al., 2008).
P2X1 receptors play a role in amplification of platelet aggregation through activation by
ATP released from dense granules (Hechler et al., 2003), leading to Ca2+ influx and
transient shape change (Fung et al., 2007; Rolf & Mahaut-Smith, 2002). Meanwhile, the
function of P2Y14 receptors on platelets is not well known and may be limited to the
recruitment of neutrophils at the site of blood clots (Amison et al., 2017).

1.5.2. P2Y1 and P2Y12 receptor structure
The crystal structure of the human P2Y1 receptor was solved in complex with the
nucleotide antagonist MRS2500 at a resolution of 2.7 Å, and with the non-nucleotide
antagonist N-[2-[2-(1,1-dimethylethyl)phenoxy]-3-pyridinyl]-N'-[4-(trifluoromethoxy)phenyl]urea (BPTU) at 2.7 Å (Zhang et al., 2015). This revealed two ligand binding
pockets, distinct from one another and demonstrated the stabilisation of the P2Y1 receptor
in a similar inactive conformation with both compounds (Zhang et al., 2015). The
antagonist, MRS2500, was bound within the seven transmembrane (TM) bundle, while
BPTU appeared to act as an allosteric modulator, binding an external region between the
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membrane and TM1/TM3 (Zhang et al., 2015). In comparison, the published crystal
structure of the human P2Y12 receptor in complex with the nucleotide agonist, 2MeSADP
(Zhang, Zhang, Gao, Paoletta, et al., 2014), and the non-nucleotide antagonist, AZD1283
(Zhang, Zhang, Gao, Zhang, et al., 2014), identified key differences between the platelet
P2Y receptors. Despite both P2Y1 and P2Y12 receptors recognising the same endogenous
agonist (ADP), the mechanism by which they recognise and interact with this ligand is
quite distinct. This suggestion of different ligand binding mechanisms is supported by
mutagenesis studies, whereby these pockets lie within important regions containing
conserved agonist-binding residues of the P2Y1 (Jiang et al., 1997) and P2Y12 receptors
(Hoffmann et al., 2009; Hoffmann et al., 2014; Schmidt et al., 2013). As such, it is
suggested that mutations in these positions may lead to altered P2Y receptor agonist
binding and activity.

1.5.3. P2Y1 and P2Y12 receptor expression and distribution
P2Y1 receptors were first cloned from chicken brain (Filtz et al., 1994) then subsequently
in a number of other species including turkey (Simon et al., 1995), cow (Henderson et al.,
1995), rodent (Tokuyama et al., 1995) and human (Ayyanathan et al., 1996). However
for some time after the identification of the P2Y1 receptor, it was understood that platelets
expressed another P2Y receptor (described as P2TAC or SP1999 prior to cloning) that was
coupled to the inhibition of adenylyl cyclase rather than to the activation of PLC (Hechler,
Eckly, et al., 1998; Jantzen et al., 1999; Jin et al., 1998; Takasaki et al., 2001). This P2Y
receptor was later identified as the P2Y12 receptor after it was cloned and characterised
from human and rat platelet cDNA libraries (Hollopeter et al., 2001).
Other than platelets, P2Y1 and P2Y12 receptors have also been reported on other cells and
tissues. P2Y1 receptors are expressed ubiquitously in the human brain, as well as in
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placenta and prostate tissue (Moore et al., 2001; Takasaki et al., 2001), THP-1 myeloid
cells and monocytes (Micklewright et al., 2018), and in monocyte-derived macrophages
(Layhadi & Fountain, 2019; Layhadi et al., 2018). P2Y12 receptors have been reported on
vascular smooth muscle cells where they stimulate contraction of blood vessels
(Wihlborg et al., 2004) and on macrophages where they play a role in cell motility
(Kronlage et al., 2010). Studies have also reported P2Y12 receptors on nasal mucosa
(Shirasaki et al., 2013), leukocytes (Diehl et al., 2010), THP-1 cells and monocytes
(Micklewright et al., 2018) and microglia (Kobayashi et al., 2008; Tozaki-Saitoh et al.,
2008), where microglial P2Y12 receptors are suggested to have a role in
neuroinflammation (Mildner et al., 2017).
The recombinant human P2Y1 and P2Y12 receptors (as well as the P2Y11 and P2Y14
receptors) have been reported to localise to the basolateral membrane of cells (Wolff et
al., 2005). Furthermore, it has been demonstrated that a region of charged amino acids at
the C-terminus of P2Y1 receptors are responsible for these basolateral-targeting signals
and can override an apical-targeting signalling region in the body of the receptor (Wolff
et al., 2010). Studies have also demonstrated P2Y1 and P2Y12 receptors interact with lipid
rafts, while platelet antagonists act to disrupt their localisation within these lipid rafts,
leading to a decrease in receptor function (Rabani et al., 2018; Savi et al., 2006).
P2Y1 receptors have also been reported in a number of cell lines used to study both
recombinant and endogenous purinergic receptors, including HEK293 cells (Fischer et
al., 2005; Schachter et al., 1997) and MDCK cells (Hughes et al., 2003; Post et al., 1998;
Zambon et al., 2000). Cloning of the P2Y1 receptor from MDCK cells revealed a
functional canine P2Y1 receptor (Hughes et al., 2003), however no canine P2Y12 receptors
have been cloned and characterised to date. The expression of endogenous P2Y1 and
P2Y12 receptors on dog platelets is primarily limited to our understanding of the genes
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encoding these receptors (Lindblad-Toh et al., 2005) and studies utilising canine models
of thrombosis or cardiovascular events to trial human P2Y12 receptor-targeting drugs
(Bjorkman et al., 2013; Caroff et al., 2015; Huang et al., 2000; Mellett et al., 2011; Niitsu
et al., 2008; Ravnefjord et al., 2012; Springthorpe et al., 2007; van Giezen et al., 2012;
van Giezen et al., 2009; Wang et al., 2010; Wang et al., 2007). Thus, direct
characterisation of both platelet P2Y1 and P2Y12 receptors is required.

1.5.4. P2Y1 and P2Y12 receptor agonists
Pharmacological characterisation of the cloned human P2Y1 receptor revealed ADP to be
its primary endogenous agonist (EC50 400 nM), with an agonist profile in the following
order of decreasing potency: 2MeSADP > ADP >> ATP (Chhatriwala et al., 2004; Léon
et al., 1997; Palmer et al., 1998; Schachter et al., 1996; Waldo & Harden, 2004).
Pharmacological studies of the cloned human P2Y12 receptor revealed similarities to that
observed for the P2Y1 receptor, with ADP identified as the primary endogenous agonist
(EC50 100 nM) and an agonist profile in the following order of decreasing potency;
2MeSADP > ADP > ATP (Hollopeter et al., 2001; Kauffenstein et al., 2004; Takasaki et
al., 2001; Zhang et al., 2001). While ADP has been identified as the primary endogenous
agonist of human P2Y1 and P2Y12 receptors, 2MeSADP is often used for in vitro studies
for its extremely potent agonist properties which has allowed strong, selective
characterisation of the P2Y1 and P2Y12 receptors (EC50 45 nM and 1 nM, respectively).
ATP and its analogues act only as partial agonists at human P2Y1 and P2Y12 receptors
(Takasaki et al., 2001; Waldo & Harden, 2004). A highly potent and commercially
available 2MeSADP derivative (MRS2365, IC50 0.4 nM) has been reported to selectively
activate the human P2Y1 receptor, with little activation of human P2Y12 receptors
(Chhatriwala et al., 2004).
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Although no recombinant canine P2Y12 receptor has been studied to date, ADP was
identified as the endogenous agonist of the canine P2Y1 receptor cloned from MDCK
cells (EC50 370 nM), while ATP and ATP analogues (2MeSATP and ATPγS) were
determined to be partial agonists (Hughes et al., 2003). Early studies also identified
ADP-induced aggregation of canine platelets, where it was noted that canine platelet
activation differed noticeably from human platelets, particularly inhibition by BzATP
(Soslau et al., 1993). Since then, studies have utilised canine models of thrombosis to
determine the anti-platelet effects of human P2Y12 antagonists on ex vivo aggregation of
canine platelets (Bjorkman et al., 2013; Ravnefjord et al., 2012; van Giezen et al., 2009;
Wang et al., 2007). Although these studies typically only report the percent of inhibition
of ADP-induced platelet aggregation, these reports suggest that ADP is an endogenous
agonist of the canine P2Y12 receptor. Moreover, a recent study demonstrated that
2MeSADP (50-200 nM) can induce ex vivo aggregation of canine platelets (Chaudhary
& Kim, 2019).

1.5.5. P2Y1 and P2Y12 receptor antagonists
The broad-spectrum P2 receptor antagonists, suramin (IC50 3 µM) and reactive blue 2
(IC50 0.025-0.8 µM) act as potent antagonists of recombinant human P2Y1 and P2Y12
receptors (Boyer et al., 1994; Charlton et al., 1996b; Hoffmann et al., 2008; Takasaki et
al., 2001). PPADS inhibits P2Y1 receptors (IC50 5 µM) (Charlton et al., 1996b; Waldo et
al., 2002), however demonstrates species-specific inhibitory effects towards bovine
(IC50 1.7 µM), but not rat or human P2Y12 receptors (Ennion et al., 2004; Kolen & Slegers,
2004; Takasaki et al., 2001). Notably, in addition to acting as partial agonists, ATP and
its analogues have also been demonstrated to act as partial antagonists of P2Y12 receptors
(IC50 13.5 µM and 838 µM for 2MeSATP and ATP, respectively) (Kauffenstein et al.,
2004). However, earlier studies on P2Y12 receptor agonists may be confounded due to
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cross-reactivity with P2Y1 receptors, which have a similar agonist profile to the P2Y12
receptor.

An

endogenous

antagonist,

farnesyl

pyrophosphate,

also

inhibits

ADP-stimulated platelet aggregation, albeit with low affinity binding to the P2Y12
receptor (Högberg et al., 2012).
Although the P2Y1 receptor is not currently targeted for therapeutic treatment of
thrombosis and haemostasis, a number of bisphosphate analogues have been developed
including MRS2179 (IC50 150 nM), MRS2279 (IC50 52 nM) and MRS2500 (IC50 8.4 nM)
which demonstrate highly selective and potent P2Y1 receptor antagonism. (Boyer et al.,
2002; Boyer et al., 1996; Kim et al., 2003). In contrast, P2Y12 receptors are highly targeted
for controlling thrombotic and cardiovascular events and as such, a number of selective
antagonists have been developed for both clinical and research purposes. Historically, the
P2Y12 receptor has long been targeted by active metabolites of clinically prescribed
thienopyridine compounds, including ticlopidine (Maffrand et al., 1988), clopidogrel
(Herbert et al., 1993) and prasugrel (Sugidachi et al., 2000), which act irreversibly at the
ADP binding site to prevent P2Y12 receptor activation and subsequently downregulate
cAMP production (von Kugelgen & Hoffmann, 2016). These drugs however, require
active metabolic conversion within the liver (Cattaneo, 2010), limiting their use for in
vitro studies.
Cangrelor (AR-C69931) is a clinically prescribed, competitive and highly potent
antagonist of the human P2Y12 receptor (IC50 2.5 nM) (Ingall et al., 1999; Takasaki et al.,
2001). Newer generation anti-platelet drugs such as cangrelor do not require metabolic
conversion prior to blocking the P2Y12 receptor and are thus beneficial for in vitro studies.
However, cangrelor has also been demonstrated to inhibit recombinant human P2Y13
receptors expressed in 1321N1 cells (Marteau et al., 2003). Cangrelor was also found to
competitively inhibit the binding of metabolites from other P2Y12 antagonists such as
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clopidogrel and prasugrel (Judge et al., 2016). Ticagrelor (AZD6140), an
orally-administered and highly potent nucleoside analogue acts as a competitive
antagonist at the P2Y12 receptor (IC50 3 nM) (Hoffmann et al., 2014; Husted & Van
Giezen, 2009). This compound binds directly at sites distal to the ADP-binding sites and
thus, its inhibitory effects are therefore reversible (Cannon et al., 2007; Husted & Van
Giezen, 2009; James et al., 2009; Springthorpe et al., 2007; Storey et al., 2007). However,
like cangrelor, ticagrelor has also been demonstrated to bind and inhibit P2Y13 receptors,
although this does not appear to effect proplatelet formation from megakaryocytes in vitro
or platelet counts in patients (Bjorquist et al., 2016). A novel class of potent,
reversibly-binding P2Y12 antagonists were recently reported (IC50 5 nM) (Caroff et al.,
2015), which has led to the first clinically used subcutaneous platelet P2Y12 antagonist,
selatogrel (Storey et al., 2019).
Other potent, high affinity P2Y12 receptor antagonists have been described for the use in
platelet research, such as AZD1283 (IC50 11 nM) (Bach et al., 2013; Zhang, Zhang, Gao,
Zhang, et al., 2014), the reactive blue 2 analogue PSB0739 (IC50 0.2 nM) (Baqi et al.,
2009; Hoffmann et al., 2009; Horvath et al., 2014), an ATP derivative AR-C66096 (IC50
13 nM) (Humphries et al., 1994), as well as a number of AP4A derivatives (Yanachkov
et al., 2016).

1.5.6. Variants of the P2RY1 and P2RY12 genes
Although both P2Y1 and P2Y12 receptors have over 200 reported missense variants each
on the Ensembl genome browser, much of the literature published regarding missense
variants of these platelet P2Y receptors is on the P2Y12 receptor. A number of P2RY12
gene missense variants have been identified in humans (Lecchi et al., 2016). Most of these
reported missense variants have little-to-no effect on receptor expression or trafficking,
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but primarily result in reduced platelet activation and subsequent bleeding disorders.
These include the Arg122Cys (rs557043245; Patel et al., 2014), Lys174Glu (Daly et al.,
2009), His187Glu (Lecchi et al., 2015), Pro258Thr (Remijn et al., 2007), and Arg265Trp
variants (rs121917886; Cattaneo et al., 2003). A patient with a Pro341Ala variant
presenting with a bleeding disorder was also reported, with in vitro characterisation of
this variant revealing a trafficking defect that reduced P2Y12 receptor internalisation and
recycling, which was associated with reduced cell surface expression and decreased
function (Nisar et al., 2011).
A genetic study on purinergic receptors in glycemic homeostasis identified a P2RY1
variant, rs16864613, that was associated with elevated 2 hour (hr) blood glucose
concentrations (Todd et al., 2015). However, this variant lies in the 3’ untranslated region
of the P2RY1 gene and the effect on receptor expression and function remains unknown.
This finding however supports data demonstrating abnormal glucose homeostasis in
p2ry1 knockout mice (Léon et al., 2005). Additionally, studies have identified
associations between a number of P2RY1 and P2RY12 intronic variants with platelet
reactivity in patients with coronary artery disease (Timur et al., 2012) and ischemic stroke
patients (Janicki et al., 2017).
Aside from clinical trials of P2Y12 antagonists in dogs, reports published regarding the
functional effect of P2Y receptor variants in dogs is limited to a single variant in the
canine P2RY12 gene (Boudreaux & Martin, 2011). A Greater Swiss Mountain dog, which
presented to a Canadian animal clinic with a suspected platelet function disorder
following postoperative haemorrhaging, was reported to encode a homozygous, three
base-pair deletion resulting in the absence of serine 173 from the second loop of the
extracellular domain (Boudreaux & Martin, 2011). The mutation was subsequently
identified in four other dogs of familial descent, however all were heterozygous and had
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presented no signs of platelet function disorder. While this deletion has been shown to
impair ADP-induced platelet function and has been associated with post-operative
haemorrhage in these dogs (Flores et al., 2017), the effect of this deletion on P2Y12
receptor function has yet to be investigated. A small number of uncharacterised canine
missense variants of the platelet P2Y receptors are also reported in online databases
(Ensembl, EVA and iDOG) from whole genome sequencing projects. These include an
Ala33Thr P2RY1 variant reported in one Korean Jindo and two North American wolves
(Jagannathan et al., 2019), an Ala43Ser P2RY1 variant reported in one undisclosed breed
(Freedman et al., 2014), and an Ala147Val P2RY12 variant reported in one Border Collie
(Jagannathan et al., 2019). The functional effect of these variants, if any, is yet to be
determined.

1.5.7. P2Y1 and P2Y12 receptors in health and disease

1.5.7.1. The P2Y12 receptor and thrombosis

The P2Y12 receptor is best known for its role on platelets in thrombosis and haemostasis,
where it contributes to myocardial infarction, ischemic stroke, and other thrombotic
events in patients with cardiovascular disease (Maffrand, 2012). These thrombotic events
pose a serious health issue in both humans (Koupenova et al., 2017) and companion
animals such as dogs (de Laforcade, 2012). The P2Y12 receptor antagonist ticlopidine has
been marketed as an antiplatelet drug since 1978 (Maffrand, 2012), despite its mechanism
of action as an ADP inhibitor not being understood until many years later (Maffrand et
al., 1988). Since then, several new generations of P2Y12 receptor antagonists (see Section
1.5.4) have been developed and tested for the successful clinical treatment of thrombotic
events in humans (Gachet & Hechler, 2020). These new generation inhibitors, such as
cangrelor and ticagrelor, have demonstrated significant reductions in stent thrombosis,
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myocardial infarctions and cardiovascular death, even compared with earlier generation
drugs such as clopidogrel (Gan et al., 2015). Additionally, while the primary treatments
for thrombotic events in dogs is currently limited to heparin and aspirin (Smith, 2012),
preliminary studies and pre-clinical trials in dogs have demonstrated the safety and
therapeutic potential of many of these P2Y12 receptor inhibitors for canine use (Bjorkman
et al., 2013; Huang et al., 2000; Ingall et al., 1999; Mellett et al., 2011; Ravnefjord et al.,
2012; van Giezen et al., 2012; van Giezen et al., 2009; Wang et al., 2010).
P2Y12 receptor antagonists, such as clopidogrel and ticagrelor, are commonly used in
combination with aspirin to inhibit cyclooxygenase 1 (Antithrombotic Trialists’
Collaboration, 2009) in what is known as dual antiplatelet treatment (DAPT). DAPT is
known to decrease the risk of major adverse cardiovascular events in patients with acute
coronary syndrome, as well as contribute to the secondary prevention of coronary artery
disease (Degrauwe et al., 2017). However, particularly with irreversible inhibitors like
clopidogrel, DAPT can be problematic in the case of high on-treatment platelet reactivity
(HTPR), which refers to events in which DAPT fails due to the inability of antiplatelet
drugs to inhibit their respective targets (Cattaneo, 2013). For DAPT, ticagrelor currently
has the benefit over other irreversibly-binding antiplatelet drugs such as clopidogrel, in
that it can bind reversibly to P2Y12 receptors (Husted & Van Giezen, 2009; James et al.,
2009; van Giezen & Humphries, 2005). Nevertheless, the effects of ticagrelor can still
last up to seven days after discontinuing treatment (AstraZeneca, 2016). As such, the
major concern of all available antiplatelet treatments is the increased risk of bleeding
(Meadows & Bhatt, 2007; Tantry et al., 2013). This further complicates therapeutic
strategies for patients who are prone to adverse bleeding events, haemorrhage, or those
requiring emergency surgical procedures, as the establishment of haemostasis becomes
challenging in patients on anti-platelet treatments (Ducrocq et al., 2013). Recently, a new
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antibody-based compound (PB2452) has successfully completed Phase 2a clinical trials,
demonstrating rapid (< 5 min) and sustained reversal of antiplatelet effects caused by
ticagrelor (Bhatt et al., 2019).
A topic of much debate in the use of P2Y12 antagonists in DAPT, is the standardisation
of the assessment of HTPR in patients. Assessing platelet reactivity of patients needs to
be carried out to determine if a patient has HTPR, and if so, whether treatment should be
altered to avoid adverse effects such as bleeding (Spiliopoulos & Pastromas, 2015). The
primary issue however remains that platelet function testing can be conducted using a
variety of techniques with differing outcomes and non-standardised cut-off values
(Bonello et al., 2010). These tests include bleeding time, light transmission aggregometry
(LTA), impedance platelet aggregometry or flow cytometric analysis of vasodilatorstimulated phosphoprotein phosphorylation (Cattaneo, 2013; Fox et al., 2019; Paniccia et
al., 2015; Spiliopoulos & Pastromas, 2015). Although LTA is the “gold standard” clinical
test method for evaluating platelet function and HTPR, it has been difficult to implement
into clinical practice, with many opting for more standardized, less time and labour
intensive methods such as the VerifyNow system (Jeong et al., 2012). Additionally, the
assessment of HTPR in clinics is complicated by a lack of consistency between tests in
determining antiplatelet drug effects (Lordkipanidze et al., 2008; Lordkipanidze et al.,
2007), the lack of flexibility compared to a multi-well plate aggregometry assay
(Armstrong et al., 2009; Lordkipanidze et al., 2014), as well as a limited availability of
standard reference guidelines for determination of HTPR using different systems
(Paniccia et al., 2015). To combat this, recent evidence has suggested that composite
advice be utilised based on a panel of at least three platelet function tests for the
identification of HTPR (Zwart et al., 2019). Despite these issues, to this day, DAPT with
P2Y12 antagonists, such as ticagrelor and cangrelor, remains one of the most widely used
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anti-platelet therapies worldwide.

1.5.7.2. The P2Y12 receptor and chronic pain

Although P2Y12 receptors are predominantly expressed on platelets where they are
involved in thrombosis and haemostasis (Section 1.5.7.1), studies have demonstrated that
P2Y12 receptors are upregulated on spinal cord microglia after nerve damage and
subsequently follow a similar activation cascade (p38 MAPK stimulation) to P2X4
receptors to signal neuropathic pain following peripheral nerve injury (Kobayashi et al.,
2008; Tozaki-Saitoh et al., 2008). Furthermore, activation of the P2Y12 receptor in rats
causes pain-like behaviours which mimic that observed in rats with nerve injury, while
pharmacological inhibition and genetic knockout of the P2Y12 receptor both reduce
neuropathic pain (Gu et al., 2016; Horvath et al., 2014; Kobayashi et al., 2008; TozakiSaitoh et al., 2008). Microglia of P2Y12 receptor knockout mice also show reduced
capacity for migration, suggesting roles in microglia control and motility signalling
(Haynes et al., 2006; Koizumi et al., 2013). Notably, a recent retrospective study on
patients undergoing abdominal surgery has reported that administration of the P2Y12
receptor antagonist, clopidogrel, reduced severe post-operative pain compared to aspirin
(Tsuchida et al., 2020), suggesting a potential role for P2Y12 receptor antagonists or
derivative compounds as post-operative analgesics.

1.5.7.3. The P2Y1 receptor as a potential therapeutic target

While the role of the P2Y1 receptor in platelet activation and thrombosis is well known,
it has yet to be established as a target for clinically prescribed antithrombotic drugs
(Gachet & Hechler, 2020). However, studies have suggested that targeting the P2Y1
receptor on platelets may be still have therapeutic benefits, with one compound
demonstrating promising inhibition of thrombus formation with low bleeding time
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(Karim Zubair et al., 2015), although other benefits over current drugs are limited. Despite
this, the P2Y1 receptor has also been implicated in astrocyte hyperactivity in a mouse
model of Alzheimer’s disease (Delekate et al., 2014), with P2Y1 antagonism
demonstrating promising therapeutic results for neuroprotection (Reichenbach et al.,
2018). Studies have also suggested that P2Y1 receptors may contribute to the signalling
and development of neuropathic (Barragan-Iglesias et al., 2016) and inflammatory pain
(Ando et al., 2010). Given these potential therapeutic applications, the demand for novel,
potent and bioavailable compounds targeting the P2Y1 receptor has increased. Recently,
structure-based ligand discovery techniques have been applied to identify P2Y1 receptor
ligands with superior binding affinity and targeting efficacy, resulting in a number of
compounds with potential anti-cancer properties (Le et al., 2019), however further testing
will be required to determine their effectiveness as therapeutics.

1.6.

Canine cell models for studying purinergic signalling

Some of the earliest suggestions of endogenous purinergic signalling came from studies
of nucleosides and nucleotides in dogs or dog tissues (Drury & Szent-Györgyi, 1929;
Emmelin & Feldberg, 1948; Luduena & Grigas, 1972; Parker et al., 1977; Parker & Snow,
1972). A number of other studies prior to the cloning of the P2 receptors identified
contractile or vasodilatory responses in a number of different canine blood vessels in
response to nucleotides (reviewed in detail in Burnstock & Knight, 2004). Since then a
small number of commercially available established canine cell lines have emerged for
use in research, which provide useful cell models for studying endogenous canine
purinergic receptor signalling.
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1.6.1. MDCK cells
MDCK cells, originally isolated from a Cocker Spaniel (Dukes et al., 2011), were one of
the earliest, and now possibly most well-established, cell models of canine purinergic
signalling. Evidence for purinergic signalling in MDCK cells arose through observations
that Cl- secretion could be mediated by extracellular ATP (Simmons, 1981).
Subsequently, nucleotide-evoked currents were reported using a range of extracellular
nucleotides, including 2MeSATP, ATP and UTP (Zegarra-Moran et al., 1995). The
polarised activation of MDCK cells by apical and basolateral application of ATP in the
absence and presence of Ca2+ was then demonstrated (Gordjani et al., 1997). This resulted
in basolateral, but not apical, mobilisation of Ca2+, indicating the activation of a
Gq/11-coupled receptor, which was later supported through identification of
IP3-dependent nucleotide-induced Ca2+ mobilisation (Jan et al., 1998).
Cloning and further characterisation of the purinergic receptors on MDCK cells revealed
the expression of P2Y1, P2Y2 and P2Y11 receptors (Hughes et al., 2003; Zambon et al.,
2001; Zambon et al., 2000), which were expressed at either the basolateral (P2Y1 and
P2Y11) or apical membrane (P2Y2) (Wolff et al., 2005), while expression of low levels of
functional P2X7 receptors was also reported (Jalilian, Spildrejorde, et al., 2012). MDCK
cells have also contributed to our understanding of species-specific differences in
purinergic receptor signalling, whereby the MDCK P2Y11 receptor was reported to be
selective for ADP in contrast to the human P2Y11 receptor, which was selective for ATP
(Torres et al., 2002; Zambon et al., 2001). Notably, MDCK cells have often been used for
the heterologous expression of purinergic receptors (Bradley et al., 2010; Wolff et al.,
2005). Thus, given the presence of the above endogenous purinergic receptors in this cell
line, previous studies of heterologously expressed receptors in MDCK cells should be
carefully interpreted.
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1.6.2. DH82 macrophage cells
The DH82 cell line is a canine macrophage cell line isolated from a 10 year old Golden
Retriever with malignant histiocytosis (Wellman et al., 1988). This cell line is a useful
model of canine macrophage physiology with similarities to a resting (M0) macrophage
subtype, with demonstrated ability for polarisation towards either a classically activated
pro-inflammatory (M1) (via LPS and IFNγ stimulation) or an alternatively activated antiinflammatory (M2a) macrophage subtype (via IL4 and IL13 stimulation) (Herrmann et
al., 2018). Despite its recent use as an in vitro model of viral and protozoan infection
(Armando et al., 2020; Mendonça et al., 2017; Nadaes et al., 2020), the purinergic
signalling characteristics of DH82 cells is limited to a single report describing ATP- and
adenosine-induced cytokine release (Fujimoto et al., 2012), although no further
mechanism was investigated. Similar human and murine macrophage cell lines (such as
THP-1 and RAW264.7, respectively) have provided useful models for studying
endogenous purinergic receptors that are commonly expressed on macrophages, such as
P2X4, P2X7 and P2Y12 receptors (Ase et al., 2015; Honore et al., 2009; Humphreys et
al., 1998; Layhadi & Fountain, 2017; Micklewright et al., 2018; Muzzachi et al., 2013;
Tu et al., 2017; Zhang, Hao, et al., 2019). Thus, DH82 cells may also serve as a valuable
model to study endogenous P2 receptors.

1.7.

Summary and key aims

Members of the P2 purinergic receptor family are expressed almost ubiquitously
throughout the human body where they have a range of physiological and
pathophysiological roles. Despite this, knowledge regarding the expression and function
of many canine P2 receptors is limited. To expand on the field of knowledge regarding
purinergic receptors in dogs, this thesis aims to:
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1. Examine canine P2RX7 missense variants and determine the distribution of these
variants in a canine cohort, combined with a previous study of 65 dogs
(Spildrejorde, Bartlett, et al., 2014).
2. Sequence and examine the canine P2RX4 gene to identify genetic variants and
determine the distribution of these variants in a canine cohort.
3. Characterise the expression, sub-cellular localisation and function of the
recombinant canine P2X4 receptor and compare this with the recombinant human
P2X4 receptor.
4. Characterise endogenous P2 receptors of the canine DH82 macrophage cell line
to establish it as a cell model of endogenous canine purinergic signalling.
5. Establish and implement a small-volume, 384-well plate light transmission
aggregometry assay to study the activation and aggregation of canine platelets in
response to agonists and antagonists of the human P2Y1 and P2Y12 receptors.
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Chapter 2: Materials and Methods
2.1.

Materials and reagents

DMEM/F12 medium, ExoSAP-IT, Fura-2 AM, GlutaMAX, Lipofectamine 3000
transfection reagent, Opti-MEM I reduced serum medium, penicillin-streptomycin,
Subcloning Efficiency DH5α Competent Cells, TrypLE Express and 0.05% trypsinethylenediaminetetraacetic acid (EDTA) were from ThermoFisher Scientific (Melbourne,
Australia). ABI PRISM BigDye Terminator v3.1 Cycle Sequencing Kit was from Applied
Biosystems (Carlsbad, USA). Agarose, deoxynucleoside triphosphate (dNTP) mix,
Hyperladder II, MangoTaq DNA polymerase and MgCl2 were from Bioline (London,
UK). GelRed Nucleic Acid Gel Stain was from Biotium (Fremont, USA). Mini-Protean
TGX Stain-Free gels, Precision Plus Protein Dual Colour standards and nitrocellulose
membrane were from Bio-Rad (Hercules, USA). FBS (heat-inactivated) was from
Bovogen Biologicals (East Keilor, Australia). Wizard Genomic DNA Purification and
Wizard Plus SV Minipreps DNA Purification kits were from Promega (Madison, USA).
6-Aminohexanoic acid, apyrase (cat. no. A6535), 1,2-bis(o-aminophenoxy)ethaneN,N,N′,N′-tetraacetic acid (BAPTA-AM), cOmplete EDTA-free protease inhibitor
cocktail, n-dodecyl β-D-maltoside, EDTA, hexokinase from Saccharomyces cerevisae,
MEM non-essential amino acid solution, paraformaldehyde, phosphate buffered saline
(PBS), poly-D-lysine hydrobromide (5 µg.mL-1 working stock), pluronic F-127,
phenylmethylsulphonyl fluoride (PMSF), saponin and 0.4% trypan blue were from
Sigma-Aldrich (St Louis, USA). Bovine serum albumin (BSA), dithiothreitol (DTT),
ethidium bromide, ethylene glycol tetraacetic acid (EGTA), glycerol and reagents for
preparing Ca2+ response assay buffers, tris-acetate-EDTA (TAE) buffer, Tyrode’s buffer
or buffers for sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE)
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and western blotting were from Amresco (Solon, USA). Primers for polymerase chain
reaction (PCR) and sequencing (Table 2.5 and Table 2.6) were obtained from GeneWorks
(Hindmarsh, Australia), Integrated DNA Technologies (Coralville, USA) or SigmaAldrich.

2.2.

Agonists, antagonists and modulators

Compounds including agonists, antagonists and modulators used throughout this thesis
are listed below Table 2.1, Table 2.2 and

Table 2.3. Stock solvent indicates the concentration of solvent that the initial stock was
solubilised in. Further dilutions of compounds were diluted in the respective buffers
relevant to the assay described in each Figure (see results chapters 5-7).

Table 2.1. Agonists of P2 receptors.
Nucelotide

Supplier

Stock solvent

Catalogue number

Lot number

2MesADP·Na3

Tocris

10 mM in H2O

1624

Batch 9A

ADP·Na

Sigma

30 mM in H2O

A2754

SLBL1267V

ATP·Na2(H2O)

Sigma

100 mM in H2O

A7699

051M7014V

BzATP·Et3NH+

Sigma

40 mM in H2O

B6396

128K5061

UDP·Na2

Cayman

20 mM in H2O

18137

05168173

UTP·Na3(H2O)

Sigma

30 mM in H2O

U6625

SLB56959

Abbreviations: 2MeSATP, 2-methylthio-ATP; ADP, adenosine-5'-diphosphate; ATP, adenosine-5'-triphosphate;
BzATP, 3'-O-(4-benzoyl)benzoyl adenosine 5'-triphosphate; Et, triethyl; UDP, uridine-5'-diphosphate; UTP, uridine5'-triphosphate.
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Table 2.2. Modulators of P2 receptors.
Compound

Primary Target

Supplier

Ivermectin

P2X4
positive
modulator

Sigma

Stock
solvent

Catalogue
number

Lot number

3 mM in
DMSO

18898

MKB98353V

Table 2.3. Antagonists of P2 receptor and other associated pathways.
Compound

Primary target/s

Supplier

Stock solvent

Catalogue
number

Lot number

5-BDBD

P2X4

Sigma

10 mM in DMSO

3579

Batch 2

BX430

P2X4

Tocris

30 mM in DMSO

5545

Batch 1

Duloxetine

P2X4

Sigma

10 mM in H2O

SML0474

034M4747V

Paroxetine

P2X4, P2X7

Sigma

30 mM in DMSO

P1372

053M4606V

TNP-ATP

Non-selective
P2X

Tocris

10 mM in H2O

2464

Batch 8A

MRS2159

P2X1,P2X7

Sigma

10 mM in H2O

M7684

MRS2179

P2Y1

Cayman

5 mM in H2O

10011450

0540634-4

AR-C118925

P2Y2

Tocris

30 mM in DMSO

4890

5A/217562

Suramin

Non-selective P2

Sigma

30 mM in H2O

S2671

SLBV6986

Ticagrelor

P2Y12

Cayman

10 mM in DMSO

15425

0494081

2-APB

IP3 receptor

Cayman

50 mM in DMSO

64970

0533188-4

U-73122

PLC

Cayman

10 mM in DMSO

70740

0508924-26

Thapsigargin

SERCA

Tocris

10 mM in DMSO

1138

Abbreviations: 2-APB, 2-aminoethgoxydiphenylborate; AR-C118925, 5-[[5-(2,8-dimethyl-5Hdibenzo[a,d]cyclohepten-5-yl)-3,4-dihydro-2-oxo-4-thioxo-1(2H)-pyrimidinyl]methyl]-N-(1H-tetrazol-5yl)-2-furancarboxamide; 5-BDBD, 5-(3-bromophenyl)-1,3-dihydro-2H-benzofuro[3,2-e]-1,4-diazepin-2one; BX430, 1-(2,6-dibromo-4-isopropyl-phenyl)-3-(3-pyridyl)urea; MRS2159, pyridoxal-α5-phosphate6-phenylazo-4′-carboxylic acid; MRS2179, N6-methyl-2′-deoxyadenosine 3′,5′-bisphosphate; SERCA,
sarco/endoplasmic reticulum Ca2+ ATPase; TNP-ATP, 2’,3’-O-(2,4,6-trinitrophenyl)adenosine-5’triphosphate; U-73122, 1-[6-[[(17β)-3-methoxyestra-1,3,5(10)-trien-17-yl]amino]hexyl]-1H-pyrrole-2,5dione.
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2.3.

Antibodies

A list of antibodies used throughout this thesis are detailed below in Table 2.4.
Table 2.4. Antibodies for western blotting and immunocytochemistry.
Antibody
target

Conjugate

Raised
against

Host
species

Conc.

Supplier

RRID

Catalogue
number
or
clone

Primary antibodies
Anti-actin

-

Human

Rabbit

1:2000

Sigma

AB_476693

A2066

Anti-CD61

APC

Human

Mouse

1:20

BD

AB_2738645

564174/VIPL2

Anti-LAMP1

-

Human

Mouse

1:100

DSHB

AB_2296838

H4A3

Anti-P2X4

-

Human

Goat

1:250

Sigma

AB_10604119

SAB2500734

Anti-P2Y1

-

Mouse

Rabbit

1:250

Alomone

AB_10919250

APR-021

Anti-P2Y2

-

Rat

Rabbit

1:250

Alomone

AB_2756769

APR-102

Anti-P2Y12

-

Mouse

Rabbit

1:250

Alomone

AB_11121048

APR-020

Secondary antibodies
Anti-goat

AF594

Goat

Donkey

1:200

Abcam

AB_2782994

ab150136

Anti-goat

HRP

Goat

Mouse

1:5000

Thermo

AB_228370

31400

Anti-mouse

PE

Mouse

Sheep

1:200

Chemicon

N/A

AQ326H

Anti-mouse

HRP

Mouse

Goat

1:5000

Thermo

AB_228307

31430

Anti-rabbit

AF594

Rabbit

Goat

1:200

Abcam

AB_2650602

ab150080

Anti-rabbit

HRP

Rabbit

Goat

1:5000

Rockland

AB_218567

611-103-122

Abbreviations: AF, Alexa Fluor; APC, allophycocyanin; BD, BD Biosciences (North Ryde, Australia); conc.,
concentration; DSHB, Developmental Studies Hybridoma Bank (Iowa City, USA); HRP, horseradish peroxidase; PE,
phycoerythrin; RRID, Research Resource Identifier.

2.4.

Cells and cell culture

2.4.1. Established cell lines and culturing conditions
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1321N1 human astrocytoma cells (ECACC cat. no. 86030402, RRID:CVCL_0110),
DH82 canine macrophage cells (ECACC cat. no. 94062922 , RRID: CVCL_2018),
HEK293 cells (ECACC cat. no. 85120602, RRID:CVCL_0045) and Madin-Darby canine
kidney (MDCK) cells (ATCC cat. no. CRL-6253, RRID: CVCL_0422) were maintained
in DMEM/F12 medium supplemented with 10% (DH82, HEK293 and MDCK) or 15%
(1321N1) FBS, 2 mM GlutaMAX, 100 U/mL penicillin, 100 µg/mL streptomycin and
1% non-essential amino acids. All established cell lines were maintained in vented T75
flasks (Greiner Bio-One, Frickenheisen, Germany) at 37°C/5% CO2. Cells were cultured
until approximately 70-80% confluent, then passaged. Adherent cells were detached from
the flask by washing with 5 mL of PBS followed by the addition of 3-5 mL of 0.05%
trypsin-EDTA and incubation at 37°C for up to 5 min. Cells were gently agitated to aid
detachment and the enzymatic reaction was stopped by addition of an equal volume of
culture medium. Cells were centrifuged at 300x g for 5 min at room temperature and the
supernatant discarded. Cell pellets were resuspended in culture medium and transferred
back to a T75 flask at an appropriate dilution for continued culture. For transfection,
viable cells were manually counted using trypan blue and a haemocytometer and
transferred to a separate plate as described below.

2.4.1.1. Plating and transfection of 1321N1 and HEK293 cell lines

Human 1321N1 and HEK293 cells were plated at 3.5 x 105 and 2.5 x 105 cells per well,
respectively, in a poly-D-lysine-coated six-well plate (Greiner Bio-One) and transfected
the following day with canine or human P2X4-emerald green fluorescent protein
(EmGFP) or an EmGFP empty vector (see section 2.5.1) using Lipofectamine 3000.
Transfection mixtures were prepared as per the manufacturer’s instructions. In detail, a
solution containing 0.4 µg of plasmid DNA (or sterile Milli-Q H2O for mock
transfection), 4 µL of P3000 reagent and 125 µL of Opti-MEM per well to be transfected
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were prepared in a microcentrifuge tube (Greiner Bio-One). A second solution containing
5 µL of Lipofectamine 3000 reagent and 125 µL of Opti-MEM per well to be transfected
were prepared in a separate microcentrifuge tube. An equal volume of each solution was
then combined, inverted gently once to mix and incubated at room temperature for 15
min. Following incubation, 250 µL of the transfection mixture was added dropwise to
each well and the plate was rocked gently by hand to ensure even application of the
transfection mixture. Cells were incubated at 37°C/5% CO2 in transfection mixture for up
to 24 (HEK293) or 48 hr (1321N1). For Ca2+ response assays, transfected cells were
detached from the plate by trypsinisation, as described above (section 2.4.1), transferred
into a poly-D-lysine-coated black-walled µClear bottom 96-well plate (Greiner Bio-One)
at 5 x 104 cells per well and incubated at 37°C/5% CO2 overnight. For
immunocytochemistry and confocal microscopy, transfected cells were detached from the
plate by trypsinisation, transferred onto poly-D-lysine-coated 18 mm glass coverslips at 1
x 105 cells per coverslip and incubated at 37°C/5% CO2 overnight. For SDS-PAGE and
western blotting, transfected cells were processed as described below directly from the
six-well plate without further replating.
For experiments involving non-transfected cell lines, cells were detached from the flask
by trypsinisation and plated at 5 x 104 (HEK293) or 6 x 104 (DH82) cells per well in a
poly-D-lysine-coated black-walled µClear bottom 96-well plate for Ca2+ response assays,
or at 1 x 105 cells per 18 mm glass coverslip for confocal microscopy, and incubated at
37°C/5% CO2 overnight. Where non-transfected cells were prepared for SDS-PAGE,
cells were sub-cultured into a separate T75 flask until approximately 70% confluent then
processed as described below.
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2.4.2. Primary cells

2.4.2.1. Collection of peripheral blood from dogs, cats and humans

All blood from human and animal donors was collected and studied in compliance with
institutional (University of Wollongong) and ARRIVE guidelines, with approval by the
Animal (protocols AE10/01, AE14/09 and AE17/11) and Human (protocol HE10/063)
Ethics Committees of the University of Wollongong. Peripheral blood from dogs, cats
and humans was collected into VACUETTE lithium heparin tubes (for DNA extraction
only; Greiner Bio-One) or BD Vacutainer 3.2% sodium-citrate tubes (for platelet isolation
and aggregation; BD Biosciences). Collection of dog and cat blood was carried out by
trained veterinary clinicians from Albion Park Veterinary Hospital (Albion Park,
Australia), Oak Flats Veterinary Clinic (Oak Flats, Australia) or Balgownie Vet Hospital
(Balgownie, Australia). Collection of blood from healthy human donors was carried out
by trained phlebotomists from the Illawarra Health and Medical Research Institute in
Wollongong (Wollongong, Australia). Informed consent was obtained from all pet
owners and human donors. Animal donors were randomly selected with no exclusion
regarding pedigree status, breed, age or sex. Determination of animal breed was
conducted by veterinarians in consultation with pet owners. Pedigree (pure-bred) animals
were classified as brachycephalic as reported in other studies (Bannasch et al., 2010;
Marchant et al., 2017; Packer et al., 2015; Roberts et al., 2010; Schoenebeck et al., 2012).
Mixed-pedigree dogs were assigned as brachycephalic based on known ancestry and/or
apparent brachycephalic features.

2.4.3. Isolation of platelets from whole blood
Platelets were isolated from whole blood using differential centrifugation as described
(Lordkipanidze et al., 2014). Peripheral blood in sodium-citrate tubes was centrifuged at
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200x g at room temperature for 20 min with the brake off to isolate the platelet-rich
plasma (PRP). The top PRP layer was gently pipetted from the tube and transferred to a
sterile 15 mL tube and placed on a shaker to gently agitate the PRP until ready for use.
The remaining blood and plasma in the citrate tube was centrifuged at 1000x g for 10 min
to obtain the platelet poor plasma (PPP). The PPP layer was then transferred to a sterile
15 mL tube. Platelets counts were conducted using a haemocytometer to ensure platelet
concentration was within a normal range of 2-4 x 108 platelets.mL-1. PRP and PPP
(15 µL per well) were then transferred to a gelatin-coated (0.75% w/v) 384-well plate
(Greiner Bio-One) for assessment of platelet aggregation.

2.5.

Isolation, amplification and detection of DNA and RNA

2.5.1. Synthesis and subcloning of plasmid DNA
Synthetic canine and human P2RX4 cloned into pUC57 plasmids were purchased from
Sigma-Aldrich and subcloned into a mammalian pEGFP-N3 vector with a C-terminal
EmGFP tag connected by a 3x(GGGGS) flexible linker by Dr. Tracey Berg (University
of Wollongong, Wollongong, Australia). Plasmid DNA was amplified by transformation
into DH5α competent cells and isolated using the Wizard Plus SV Minipreps DNA
Purification kit (Promega, Madison, USA) according to manufacturer’s instructions.
Plasmid DNA was sequenced as described below using primer pairs listed in Table 2.6.

2.5.2. Isolation of genomic DNA
To identify missense mutations in P2RX4 and P2RX7 of dogs, genomic DNA (gDNA)
was first isolated from peripheral blood of dogs using the Wizard Genomic DNA
Purification Kit (Promega, Madison, USA) according to manufacturer’s instructions.
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Quality and concentration of gDNA was confirmed using a NanoDrop 2000c
spectrophotometer (Thermo Fischer Scientific) to determine the A260/280 ratio, with a
ratio of ~1.8-2.0 considered a good quality DNA yield. Genomic DNA samples were
stored at 4°C for short-term use and at -80°C for long-term storage.

2.5.3. RNA isolation and complementary DNA synthesis
To determine the P2 receptor messenger RNA (mRNA) expression profile of DH82 cells,
total RNA was extracted using the ISOLATE II RNA Mini Kit (Bioline, Alexandria,
Australia) according to manufacturer’s instructions. Quality and concentration of RNA
was confirmed using a NanoDrop 2000c spectrophotometer to determine the A260/280
ratio, with a ratio of ~2.0-2.2 considered a good quality RNA yield. Complementary DNA
(cDNA) was then synthesised from RNA using the qScript cDNA SuperMix Kit (Quanta
Biosciences, Gaithersburg, USA) according to manufacturer’s instructions and stored at
-20°C.

2.5.4. Reverse transcription polymerase chain reaction
Reverse transcription-polymerase chain reaction (RT-PCR) amplification of cDNA and
gDNA was carried out using MangoTaq DNA polymerase kit (Bioline) and a
Mastercycler Pro S (Eppendorf, Hamburg, Germany). Unless stated otherwise (see Table
2.4) PCR reactions were carried out in a total volume of 20 µL containing 5x MangoTaq
reaction buffer, 1.2 U MangoTaq, 125 µM dNTP mix, 2.5 mM MgCl2 and 0.25 µM of
each respective forward and reverse primer. PCR cycling conditions for amplification
included initial denaturation at 95°C for 2 min, followed by 30-40 cycles of denaturation
at 95°C for 30 s, annealing at 49-67°C for 30-60 s (see Table 2.5 and Table 2.6 for specific
annealing temperatures), and extension at 72°C for 1 min. After cycling was complete, a
final extension was carried out at 72°C for 5 min then amplicons were incubated with
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ExoSAP-IT at 37oC for 15 min, followed by heat inactivation at 80oC for 15 min. Primers
and specific cycling conditions used for amplification of gDNA are outlined in Table 2.5.
Primers and specific cycling conditions used for amplification of cDNA are outlined in
Table 2.6. All primer annealing conditions were first optimised by temperature-gradient
PCR ranging approximately ±5°C of the calculated Tm. Primers were designed using
Primer3 software (Untergasser et al., 2012).
Table 2.5. Primers used for amplification and sequencing of P2RX4 or P2RX7 from canine
gDNA.
Gene

Annealing

Product

conditions

size (bp)

CGCTCACCCGATGACGTAGGCC

67°C for 30 s

145

CTGCCTGCTTCTGGTTATCA

TGTCTGCACTGCTTTCTTGG

58.9°C for 30 s

391

Exon 3-5

GTGGCTTGGCTTGACTCTTC

AGGGTTAACATCCCCACCAT

61°C for 60 s

889

Exon 6-8

TTACGTAAGAATGGGAGTATATGT

TGGGACCTAAGCTCACACCT

62.3°C for 60 s

650

Exon 9-11

TTTTCCATCCTCCTTTCCCTA

GGTGGCCTACCTGCTCATAA

58.8°C for 60 s

807

Exon 12

ATGGTCCAGGCTTACCTGTG

GTGCTGTGCTCTGATGAGGA

58.8°C for 30 s

166

Exon 3

AGTCCAAGTTGCTCCCAGAC

GAGGACAGAAGAGGGAAAAGA

63.1oC for 30 s

349

Exon 8

TTTAATCTGCGTTCCCCTCT

AAGCCTTTTGCATTCATCTTG

63.1oC for 30 s

368

Exon 11

CTCACTAACTCGCACTGAT

TGATTTTGGCCTTATTTTTGC

62.2oC

for 30 s

262

Exon 13

GAACCTTAGGGGTGGTCACT

CAAGCTCAGGTGCAAACAAA

64.1oC for 60 s

600

Forward primer (5’-3’)

Reverse primer (5’-3’)

P2RX4
Exon 1

GTGCATGGCGGGCTGCTGCG

Exon 2

target/ exon

P2RX7

Abbreviations: bp, base pair

2.5.5. Detection of amplicons by agarose gel electrophoresis
To confirm amplification of correct RT-PCR products, amplicons from cDNA or gDNA
described above were separated on a 1.5% (w/v) agarose gel in TAE buffer (20 mM acetic
acid, 1 mM EDTA, 40 mM Tris, pH 8) buffer using a Mini-Sub Cell GT electrophoresis
system (Bio-Rad). Amplicons were visualised using GelRed and the Gel Doc XR+
(Bio-Rad). Amplicon size was determined using the HyperLadder II molecular weight
marker.

91

Table 2.6. Primers used for amplification and sequencing of canine (c) or human (h) cDNA.
Gene
target/ exon

Forward primer (5’-3’)

Reverse primer (5’-3’)

TGGTGCAAGAGTCAGGACAG
CAGTTCTCCAAGGGCAACAT
CTTGCACGAGAAGGCTTACC
CAACCTGGACAGAACCTCCTC
CGGCACCCACAGCAACGGAGTCT
TCCGCACGCTGATGAAAGCCTA
ATTCAACGGTACCCACAGGA
TGCCTCCCATCCCAGCTCCC
TCGTGCTCATCCTGGGCTGCTA
TTTGTCACCACCAGCGTGCG
TCAGCTCGGCAATCATGGGGTT
ACAGGCATCCAGCGTAATCGCA
ACAAGGCATTGAGACCAGCAGCAG
AGTGATGCCAAGCTGGGAACAGGA
TCACCGGCATCCTGTTGAACACT
AGGGTCTCCGCTGTGCTCTTCTAT
GGAGAAAGCTGCCAAATATG

ATTGGTCCCATTTTCCACAA
GTCCAGGTCACAGTCCCAGT
ATCCTTGCATCTGGTTTTCG
CGCACGCTCATCAAGGCCTA
TGTATCGAGGCGGCGGAAGGAGTA
AAGAAAGCCCCAGCACCCATGA
AGTAAGTGGCATCCCAGGTG
GGCGCTTTGGCTCCCAGGAC
TGTAGGACACGGCGAAGACCGT
AGCGCGTAGCACACCAGGAT
TGCGGTTGATGTGGAAAGGCAC
AAAGGGCAGCAGAAAGCCGATGA
TGGTCCCCGAACAGGTCTTTGTGT
AGGTTGTTGGGGCTGGACGTCTTA
ACACGAAGGCTCTGAGTTGCCA
AGCATGAGCACCCACACCATCA
ACCAGGAAATGAGCTTGACA

cP2RX1
cP2RX2
cP2RX3
cP2RX4
hP2RX4
cP2RX5
cP2RX6
cP2RX7
cP2RY1
cP2RY2
cP2RY4
cP2RY6
cP2RY11
cP2RY12
cP2RY13
cP2RY14
GAPDH
Abbreviations: bp, base pair

Annealing

Product

conditions

size (bp)

50°C for 30 s
56°C for 30 s
51.5°C for 30 s
58°C for 30 s
63°C for 30 s
60°C for 30 s
54.5°C for 30 s
60.8°C for 30 s
61°C for 30 s
59°C for 30 s
58°C for 30 s
59°C for 30 s
60°C for 30 s
60°C for 30 s
58°C for 30 s
59°C for 30 s
49°C for 30 s

206
195
188
159
433
133
185
240
132
149
195
114
138
167
180
167
200

2.5.6. DNA sequencing
To determine genomic DNA sequences of canine P2RX4 and P2RX7, or to confirm P2X4
plasmid sequences, sequencing PCR reactions were carried out on purified amplicons
from gDNA (for canine P2RX4 and P2RX7 gene sequencing) or cDNA (for P2X4 plasmid
sequencing) respectively, using the Applied Biosystems (Foster City, USA) ABI PRISM
BigDye Terminator v3.1 Cycle Sequencing Kit and the respective primer pairs listed in
Table 2.4 or Table 2.5. Sequencing PCR cycling conditions were initial denaturation at
95°C for 2 min, followed by 30 cycles of denaturation at 96°C for 30 s, annealing at 55°C
for 15 s and extension at 60°C for 4 min. Sequencing PCR reactions were purified using
sodium acetate-ethanol precipitation (3 M sodium acetate, 125 mM EDTA and 100%
ethanol) and DNA sequences were determined by automated capillary sequencing
(carried out by Margaret Phillips, University of Wollongong) using a 3130xl Genetic
Analyser (ThermoFisher Scientific). Resulting sequence chromatograms were compared
to the ENSEMBL reference transcript for canine P2RX4 (canine P2RX4-201
ENSCAFT00000013312.3) or the NCBI reference transcript for canine P2RX7
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(NM_001113456.1) using the DNA Baser DNA Sequence Assembler v4 software
(Heracle BioSoft) to identify single nucleotide polymorphisms (SNP). For some dogs, not
all exons were able to be amplified or sequenced despite numerous attempts and
successful amplification and sequencing of other exons from the same DNA sample.

2.6.

Measurement of P2 receptor function by Fura-2 Ca2+ response

assay
P2 receptor function was assessed using Fura-2 measurements of nucleotide-induced
changes in intracellular Ca2+ as described (Ma et al., 2009). Cells, plated in 96-well
plates, were washed with extracellular Ca2+ solution (ECS; 145 mM NaCl, 2 mM CaCl2,
1 mM MgCl2, 5 mM KCl, 13 mM glucose and 10 mM HEPES, pH 7.4) then preincubated
with Fura-2 AM loading buffer (2.5 µM Fura-2 AM/0.2% pluronic acid in ECS) in the
dark for 30 min at 37°C. Before recording fluorescence, excess Fura-2 loading buffer was
removed and cells were washed with ECS, or with Ca2+ free solution (145 mM NaCl,
1 mM MgCl2, 5 mM KCl, 13 mM glucose and 10 mM HEPES, pH 7.4) for recordings in
the absence of Ca2+, then incubated for a further 20 min to allow for complete
de-esterification. Fura-2 fluorescence emission at 510 nm was recorded every 5 s using a
Flexstation3 (Molecular Devices, Sunnyvale, USA) following excitation at 340 and 380
nm (six reads per well, photomultiplier tube setting medium). Baseline recordings were
taken for 15 s prior to the addition of nucleotide or vehicle (up to a final volume of 100
µL per well). For recordings in absence of extracellular Ca2+, 2 mM EGTA final was
added 30 s prior to the addition of nucleotide to avoid cell detachment from the plate.
Where indicated, modulators, antagonists or respective vehicle controls were added to
each column of the 96-well plate at regularly spaced intervals, then following 5, 20 or 30
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min of pre-incubation (as indicated), Fura-2 fluorescence was recorded at room
temperature or 37°C as indicated. Compound additions were carried out using the
Flexstation3 built-in fluidics. Compound vehicles are described in Tables 2.1, 2.2 and 2.3,
and in respective Figure legends. In some experiments, hexokinase (4.5 U.mL-1) was
incubated with 1.5 mM ADP (or ATP) for 60 min at 37°C prior to addition of nucleotides.
Data were acquired using SoftMax Pro 7 software (Molecular Devices). A detailed
description of data analysis for Fura-2 Ca2+ response assays is described below in Section
2.11.3.

2.7.

Measurement of P2X4 receptor function by automated patch

clamp
Automated patch clamp measurements were kindly performed by Dr. Rocio FinolUrdaneta (Electrophysiology Facility for Cell Phenotyping and Drug Discovery,
Wollongong, Australia). HEK293 cells transfected with canine or human P2X4, were
detached using TrypLE and resuspended in cold standard external recording solution
(140 mM NaCl, 5 mM Glucose, 4 mM KCl, 2 mM CaCl2, 1 mM MgCl2 and 10 mM
HEPES, 298 ± 3 mOsm, pH 7.4 with NaOH) containing 1 U.mL-1 apyrase. Cells were
kept in suspension by automatic pipetting at 4°C. Patch clamp measurements were
performed on an NPC-16 Patchliner (Nanion Technologies, Munich, Germany) using
multihole medium resistance NPC-16 chips with an average resistance of 1.1 MΩ.
Recordings were made in the whole-cell configuration with internal solution (60 mM
CsF, 50 mM CsCl, 20 mM NaCl, 10 mM HEPES and 10 mM EGTA, 285 ± 3 mOsm,
pH 7.2 with CsOH) and external recording solution in absence of apyrase. Seal formation
was enhanced by brief treatment with seal enhancement solution (80 mM NaCl, 3 mM
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KCl, 10 mM MgCl2, 35 mM CaCl2 and 10 mM HEPES, 298 ± 3 mOsm, pH 7.3 with
NaOH) until stable seals were obtained and replaced with standard external solution.
Solutions were 0.2-μm membrane filtered. Recordings where seal resistance (SR) was
>500MΩ and access resistance was <3xSR were considered acceptable. Chip and wholecell capacitance were fully compensated, and series resistance compensation (70%) was
applied using the automated series resistance function. Recordings were acquired with
PatchMaster (HEKA Elektronik, Lambrecht/Pfalz, Germany) and stored on a computer
running PatchControlHT software (Nanion Technologies GmbH, Munich, Germany). A
test pulse in control bath solution application (0 mM ATP) was used to subtract leak
currents. Solutions were puffed (~1 s) during a 5 s test pulse from a holding potential (Vh)
of -70mV. All recordings were conducted at room temperature.

2.8.

Platelet activation and aggregation assays

2.8.1. Measurement of platelet P2Y1 and P2Y12 receptor function by a 384-well
plate light transmission aggregometry assay
P2Y receptor-mediated platelet aggregation was assessed using a high-throughput,
384-well plate light transmission aggregometry (LTA) assay modified from the 96-well
Optimul assay as described (Chan et al., 2011; Lordkipanidze et al., 2014). Assay design
was modified, where appropriate, in line with the recommendations for the
standardization of light transmission aggregometry (Cattaneo et al., 2013). PRP or PPP
in 384-well plates were incubated in the absence (Tyrode’s buffer; 134 mM NaCl, 12 mM
NaHCO3, 2.9 mM KCl, 0.34 mM Na2HPO4, 10 mM HEPES, 10 mM glucose, pH 7.4) or
presence of ADP or 2MesADP (prepared in Tyrode’s buffer) then incubated in a
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SPECTROstar Nano microplate reader (BMG Labtech, Ortenberg, Germany) at 37°C
with orbital shaking at 700 rpm for 10 s cycles. Absorbance at 595 nm was measured
before each 10 s shaking cycle, continuing for up to 60 cycles. In some experiments,
samples were pre-incubated in the absence or presence of the P2Y1 receptor antagonist
MRS2179 or the P2Y12 receptor antagonist ticagrelor, for 20 min prior to activation with
ADP or 2MeSADP. To ensure pipetting accuracy all volumes were dispensed using an
Integra Viaflo electronic pipette (Integra Biosciences, Zizers, Switzerland) with reverse
pipetting capability.

2.8.2. Measurement of CD61 expression on platelets by flow cytometry
The cell surface marker used for identifying platelet populations (CD61), was examined
by immunofluorescent labelling and flow cytometry of platelets before and after
nucleotide-induced LTA. The antibodies used (Table 2.4) are known to bind to human
dog and cat CD61 (BD Biosciences; Huskens et al., 2018; Wills et al., 2006). Immediately
following the LTA assay, platelets were placed on ice to prevent further activation. PRP
incubated in the absence or presence of nucleotide during LTA, as well as PRP not subject
to LTA, was labelled with APC-conjugated anti-CD61 antibody or with APC-conjugated
isotype controls at 4°C for 20 min. PRP was washed once with Tyrode’s buffer (1000x g
for 5 min) and data collected using a BD LSR II Flow Cytometer (using band pass filters
575/26 for PE and 660/20 for APC) or a BD Fortessa-X20 (using band pass filters 586/15
for PE or 670/30 for APC). The MFI of PE or APC, and the relative percentage of cells
were analysed using FlowJo software v8.7.1 (TreeStar Inc. Ashland, USA).
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2.9.

Western blotting

2.9.1. Cell lysis
Cultured cells were washed three times with ice-cold PBS and harvested by mechanical
scraping and centrifugation (300x g for 5 min). Platelets were harvested from PRP by
centrifugation (1000x g for 10 min) then washed three times with ice-cold PBS.
Following incubation in complete lysis buffer (50 mM BisTris, 750 mM 6-aminohexanoic
acid, 1 mM PMSF, 1% n-dodecyl β-D-maltoside and 1 cOmplete EDTA-free protease
inhibitor cocktail tablet, pH 7.0) at 4°C with gentle agitation for 60 min, cells were
sheared 10 times through an 18 gauge needle and centrifuged at 16,000x g for 15 min at
4°C (Constantinescu et al., 2010). Supernatants were collected and the concentration
determined using the Pierce BCA Protein Assay Kit (ThermoFisher Scientific) according
to manufacturer’s instructions. Supernatants were then diluted in 4x SDS-lysis buffer
(250 mM Tris pH 7.4, 8% SDS, 40% glycerol and 100 mM DTT) and heated at 94°C for
3 min prior to separation.

2.9.2. SDS-PAGE and western blotting
Proteins in cell lysate supernatants were separated by denaturing SDS-PAGE under
reducing conditions (10 mM DTT) using 4-20% Mini-Protean TGX Stain-Free gels
(Bio-Rad) in SDS-PAGE running buffer (192 mM glycine, 3.5 mM SDS, 25 mM
tris(hydroxymethyl)methylamine) at 160 V for 50 min. The gel was then activated under
UV light for 5 min then visualised using the Gel Doc XR+ system to confirm separation
and total protein loading. Proteins were then transferred onto a nitrocellulose membrane
using the Trans-Blot Turbo Blotting system (Bio-Rad) in chilled transfer buffer (192 mM
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glycine, 20% v/v methanol, 25 mM tris(hydroxymethyl)methylamine) at 100 V for 60
min. The membrane was washed three times in Tris-buffered saline solution containing
Tween-20 (TBST) (20 mM Tris, 500 mM NaCl, 0.1% Tween-20, pH 7.5) and blocked in
blocking buffer (TBST containing 5% skim milk powder) for 60 min at room temperature
or overnight at 4°C. The membrane was incubated with primary antibody in blocking
buffer overnight at 4°C. The membrane was then washed three times for 5 min with TBST
and incubated with HRP-conjugated secondary antibody in blocking buffer at room
temperature for 60 min. The membrane was washed as described above and visualised
using chemiluminescent substrate and an Amersham Imager 600RGB (GE Healthcare
Lifesciences). All antibodies used for western blotting are detailed in Table 2.4 and
relevant primary and secondary antibodies are indicated in each relevant figure.

2.10. Immunocytochemistry and confocal microscopy
Cells grown on glass coverslips were fixed with 3% (w/v) paraformaldehyde at 4°C for
15 min then washed three times with PBS. For staining of total protein (intracellular and
cell surface), cells were permeabilised with 0.1% (w/v) saponin resuspended in a blocking
buffer containing 2% (w/v) BSA in PBS (2% BSA/PBS) at room temperature for 15 min
and then incubated in presence or absence (secondary antibody control) of primary
antibody (as indicated) in 2% BSA/PBS at room temperature for 2 hr. Cells were washed
three times with PBS and then incubated with secondary antibody in 2% BSA/PBS at
room temperature for 60 min. For staining of cell surface proteins only, antibody
incubations were carried out as described above but without permeabilisation. Washed
coverslips were mounted onto a glass slide using 50% glycerol in PBS and sealed with
nail polish. Cells were visualised on a Leica (Mannheim, Germany) SP5 confocal
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microscope. Co-localisation analysis and calculation of Pearson’s coefficient was
performed using the JACoP (Just Another Co-localization Plugin) tool for ImageJ (Bolte
& Cordelieres, 2006; Rueden et al., 2017).

2.11. Data presentation and statistical analysis

2.11.1. General data analyses and statistics
Data are presented throughout this thesis as mean ± standard error of the mean (SEM).
All experimental data and statistics presented are independent experiments only, derived
from the mean of two to four biological replicates per independent experiment to control
for intra-assay variation. Nucleotide-induced concentration-response curves were plotted
by first subtracting the response in absence of nucleotide, then applying a non-linear
regression

fit

to

a

four-parameter

Hill

equation

(Y

=

Bottom + (Top-

Bottom)/(1+10^((LogEC50-X) x Hill Slope))) using the least squares method. Halfmaximal effective and inhibitory concentrations (EC50 and IC50, respectively) are
expressed as their negative logarithm (pEC50/pIC50) ± SEM. Where there was no
significant variance in homogeneity (Bartlett’s or F test for equal variance), data were
compared using a Student’s t test or one-way ANOVA with Bonferroni post hoc test for
single or multiple comparisons, respectively. Where data were determined to deviate
significantly from the Gaussian distribution (determined by a D'agostino-Pearson
omnibus K2 test) or were normalised to a 100% control with no variance, a non-parametric
Mann-Whitney U test was used for comparisons to minimise potential type 2 errors
(Qualls et al., 2010). Multiple comparisons involving two interdependent variables were
analysed using a two-way ANOVA with Bonferroni post hoc test. Statistical comparisons
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were performed only on independent values, including outliers, using GraphPad Prism
for Windows v5.01 (GraphPad Software, San Diego, CA) with P < 0.05 considered
statistically significant. Assays and data analysis were performed unblinded and nonrandomised, however where possible, plate structure was routinely altered to mitigate
positioning bias within data sets.

2.11.2. Analysis of sequence and single nucleotide polymorphism data
Sequence alignments and per cent identity between species were calculated using Clustal
O v1.2.4 (Madeira et al., 2019) and Jalview 2.11.0 (Waterhouse et al., 2009). Differences
in homozygosity, heterozygosity, variant prevalence and mutant allele frequency for
canine P2RX4 or canine P2RX7 exonic variants were compared using a Fisher’s exact
test (GraphPad Prism). Calculations for differences in variant prevalence included
numbers of heterozygous and homozygous dogs combined. Calculations for differences
in variant allele frequency included total allele numbers.

2.11.3. Calculation and analysis of Ca2+ response data
The relative change in intracellular Ca2+ (ΔCa2+) was expressed as the ratio of Fura-2
fluorescence following excitation at 340 nm and 380 nm (F340/380) then normalised to the
mean basal fluorescence according to the formula ΔCa2+ = ΔF/F = (F − Frest)/Frest, where
F is the F340/380 at a given time and Frest is the mean fluorescence of the given well prior
to the addition of nucleotides (Paredes et al., 2008). To minimise potential caveats of
high-throughput fluorescence-based assays such as large, erroneous ΔCa2+ measurements
(Heusinkveld & Westerink, 2011), peak nucleotide-induced ΔCa2+ responses were
defined by the median of five readings surrounding the peak nucleotide-induced ΔCa2+
response. To control for variations in heterologous P2X4 receptor expression (Chapter 5),
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the peak nucleotide-induced ΔCa2+ response was normalised to the response to 10 µM
ATP alone (per cent of maximum), which was measured for both canine and human P2X4
receptors for each independent experiment. To allow for analysis of endogenous P2X
receptor- and P2Y receptor-mediated Ca2+ responses in DH82 canine macrophages
(Chapter 6), both the peak Ca2+ response (F340/380) and the net Ca2+ movement (calculated
as area under the curve using GraphPad Prism) were calculated and, where indicated,
used for fitting concentration-response curves. Decay time (τ, time constant) was
calculated from the peak F340/380 using the nonlinear regression one phase decay model
for GraphPad Prism, however decay could not be calculated where no response to
agonists was recorded. Where antagonist IC50 was calculated against the approximate
EC80 of ATP or UTP, responses were normalised to the response in absence of antagonist
to allow data to be fit to a curve.

2.11.4. Calculation and analysis of automated patch clamp data
Offline analysis was performed using Igor Pro-6.37 (WaveMetrics Inc.). Automated
patch clamp recordings were analysed by calculating area under the curve, as described
by the inward currents in response to the ATP puff used for quantification of agonistinduced responses. Concentration-response curves were plotted as charge density
(pC.pF-1) normalised to current at 1 mM ATP.

2.11.5. Calculation and analysis of platelet aggregation data
Platelet aggregation was calculated as the per cent change in light transmittance of PRP
at any given time relative to PPP according to the formula; % aggregation = (max PRP
A595– PRPt)/(max PRP A595 – min PPP A595) x 100, where max PRP A595 represents 0%
aggregation of a given PRP well, PRPt is the A595 of PRP in the well at any given time,
and min PPP A595 represents 100% aggregation (Hvas & Favaloro, 2017). Antagonist
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concentration response curves were plotted as the percent of aggregation response in
absence of inhibitor.

102

Chapter 3: Missense variants of the canine P2RX7 gene
3.1.

Introduction

The P2X7 receptor, encoded by the P2RX7 gene, is a trimeric adenosine-5’-triphosphate
(ATP)-gated cation channel that is expressed in a range of different cells and tissues
(Sluyter, 2017). The P2X7 receptor has established roles in inflammation, immunity and
cancer (Di Virgilio et al., 2017; Savio et al., 2018), neural function and psychological
disorders (Ribeiro et al., 2019; Stokes et al., 2015) as well as bone formation and
resorption (Agrawal & Gartland, 2015; Jorgensen, 2018). In dogs, the P2X7 receptor is
expressed in haematopoietic cells including monocytes, T and B lymphocytes, and
erythrocytes (Faulks et al., 2016; Jalilian, Peranec, et al., 2012; Sluyter, Shemon, Hughes,
et al., 2007; Stevenson et al., 2009), normal cerebral tissue (Lee et al., 2005; Truve et al.,
2016), glioblastomas, oligodendrogliomas and astrocytomas in dogs presenting with
glioma (Truve et al., 2016), as well as in the myenteric plexus of the ileum and distal
colon (Schafer et al., 2018). The P2X7 receptor is also expressed on MDCK cells (Jalilian,
Spildrejorde, et al., 2012), where it has been suggested to have a role in the epithelialmesenchymal transition (Zuccarini et al., 2017). Other studies have demonstrated
functional roles for the canine P2X7 receptor in the release of IL-1 from monocytes
(Jalilian, Peranec, et al., 2012) and whole blood (Roman et al., 2009; Spildrejorde, Curtis,
et al., 2014), as well as in the externalisation of phosphatidylserine and haemolysis of
erythrocytes (Faulks et al., 2016; Sluyter, Shemon, Hughes, et al., 2007). Although
studies are yet to report additional cellular functions of the canine P2X7 receptor,
activation of this receptor in dogs currently mimics downstream signalling events in
humans (Grahames et al., 1999; Sluyter et al., 2004; Sluyter, Shemon, & Wiley, 2007;
Sophocleous et al., 2015), where it has been implicated as a therapeutic target for a range
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of disorders, including inflammatory disease, cancer and osteoporosis (De Marchi et al.,
2016).
A previous study by our group on a cohort of 65 randomly sampled dogs identified four
missense variants in the canine P2RX7 gene, covering exons 3 (rs23314713; Phe103Leu),
8 (rs851148233; Arg270Cys), 11 (rs850760787; Arg365Gln) and the first half of 13
(rs23315462; Pro452Ser) (Spildrejorde, Bartlett, et al., 2014). The rs23314713 and
rs850760787 variants resulted in a partial loss of P2X7 function, while the rs851148233
variant resulted in complete loss of P2X7 function (Spildrejorde, Bartlett, et al., 2014). In
contrast, the rs23315462 variant does not appear to alter P2X7 function (Spildrejorde,
Bartlett, et al., 2014). Notably, the rs851148233 and rs850760787 variants appeared to be
restricted to two dogs of Cocker Spaniel pedigree (one of which was from MDCK cells)
and four dogs of Labrador Retriever pedigree, respectively (Spildrejorde, Bartlett, et al.,
2014). However, despite this observation, the limited number of dogs representing these
two variants made it difficult to make any strong associations. Subsequently, Truve et al.
(2016) revealed that the rs23314713 variant was associated with increased susceptibility
to glioma, a disease more frequently observed in brachycephalic dogs (Hayes et al., 1975;
Snyder et al., 2006; Song et al., 2013). Canine brachycephaly is a skeletal deformation
resulting in the shortening of the muzzle, flat facial conformation and widening of the
skull that is observed in many common domestic breeds such as the Pug, Bulldog and
Staffordshire Bull Terrier (Asher et al., 2009; Bannasch et al., 2010). Despite their current
popularity, severe restructuring of the facial conformation commonly leads to
brachycephalic obstructive airway syndrome (Packer et al., 2015) and has been associated
with the spatial reorganisation of the brain in brachycephalic dogs (Roberts et al., 2010).
Given the known presence of at least four P2RX7 gene missense variants in domestic
dogs and that P2RX7 gene missense variants are associated with various diseases in
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humans (Jiang et al., 2013; Sluyter & Stokes, 2011), such variants in dogs may also be
associated with a number of diseases or breed-specific traits in dogs. Therefore, this
chapter aimed to examine P2RX7 missense variants in a cohort consisting of a further 69
randomly sampled dogs. These data were then combined with the earlier study of
Spildrejorde, Bartlett, et al. (2014) to determine the distribution of these variants in this
combined sample of the canine population.

3.2.

Results

3.2.1. Distribution of four missense variants of the canine P2RX7 gene

Researchers from our group have previously sequenced the canine P2RX7 gene from 69
different dogs, including MDCK cells, which revealed the presence of four missense
variants:

rs23314713

(Phe103Leu),

rs851148233

(Arg270Cys),

rs850760787

(Arg365Gln) and rs23315462 (Pro452Ser) (Spildrejorde, Bartlett, et al., 2014). To further
establish the distribution of these missense variants, the protein-coding regions of the
canine P2RX7 gene covering these variants were sequenced using genomic DNA from an
additional 69 dogs, including DH82 cells, and combined with the existing sequence data
(Table 3.1). All four of the above variants were identified in the new cohort, although no
new missense variants were identified in the protein-coding regions covering these
variants (exons 3, 8, 11 and part of 13). Analysis of the combined 134 dogs revealed a
variant prevalence of 47%, 40%, 4% and 3% and a mutant allele frequency of 0.36, 0.26,
0.02 and 0.01 for rs23314713, rs23315462, rs850760787 and rs851148233, respectively
(Table 3.2). The prevalence and allele frequency of each of the four variants were similar
when analysed amongst pedigree (pure bred) dogs only (Table 3.2). Additionally, linkage
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disequilibrium analysis (courtesy of Dr Leanne Stokes, University of East Anglia,
Norwich, UK) demonstrated that none of the alleles were in strong linkage disequilibrium
(Figure 3.1), with the strongest association observed between rs23314713 and
rs23315462 (D’ = 0.605 and r2 = 0.088).
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Table 3.1. Distribution of P2RX7 gene missense variants in a random sample of dogs.
Exon 3

Exon 8

Exon 11

Exon 13

rs23314713

rs851148233

rs850760787

rs23315462

Brachycephalicb

Sexc

Phe103Leu

Arg270Cys

Arg365Gln

Pro452Ser

Breed

Pedigree

Cladea

Alaskan Malamute

Yes

Asian Spitz

No

M

WT

WT

WT

Pro/Ser

Alaskan Malamute

Yes

Asian Spitz

No

MN

WT

WT

WT

Pro/Ser

Alaskan Malamute and Siberian Husky cross

No

No

M

WT

WT

Pro/Ser

American Bulldog, Bull Arab and Greyhound cross

No

Yes

M

WT

WT

WT

WT

American Staffordshire Terrier

Yes

European Mastiff

Yes

M

Phe/Leu

WT

WT

Pro/Ser

American Staffordshire Terrier

Yes

European Mastiff

Yes

F

Phe/Leu

WT

WT

WT

American Staffordshire Terrier

Yes

European Mastiff

Yes

F

Leu/Leu

WT

WT

WT

American Staffordshire Terrier

Yes

European Mastiff

Yes

Leu/Leu

WT

WT

WT

American Staffordshire Terrier

Yes

European Mastiff

Yes

F

WT

WT

Australian Bulldog

Yes

European Mastiff

Yes

F

Leu/Leu

WT

WT

WT

Australian Bulldog

Yes

European Mastiff

Yes

M

Leu/Leu

WT

WT

WT

Australian Bulldog

Yes

European Mastiff

Yes

M

WT

WT

WT

Australian Cattle Dog

Yes

UK Rural

No

M

Phe/Leu

WT

WT

Australian Cattle Dog and Kelpie cross

No

No

M

WT

Basenji

Yes

Not determined

No

MN

WT

WT

WT

WT

Beagle

Yes

Scent Hound

No

M

WT

WT

WT

Ser/Ser

Beagle

Yes

Scent Hound

No

M

WT

WT

WT

WT

Beagle

Yes

Scent Hound

No

F

WT

WT

Beagle

Yes

Scent Hound

No

MN

Pro/Ser

WT

WT
WT
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Exon 3

Exon 8

Exon 11

Exon 13

rs23314713

rs851148233

rs850760787

rs23315462

Brachycephalicb

Sexc

Phe103Leu

Arg270Cys

Arg365Gln

Pro452Ser

Breed

Pedigree

Cladea

Border Collie

Yes

UK Rural

No

F

WT

WT

WT

Pro/Ser

Border Collie

Yes

UK Rural

No

F

WT

WT

WT

WT

Border Collie

Yes

UK Rural

No

FN

WT

WT

WT

Border Collie

Yes

UK Rural

No

M

WT

Border Collie and Australian Cattle Dog cross

No

No

M

WT

Boxer and Bull Terrier cross

No

Yes

M

British Bulldog

Yes

Yes

F

Bull Arab

Yes

No

Bull Terrier

Yes

European Mastiff

Bull Terrier

Yes

Bull Terrier (miniature)

Yes

Bull Terrier cross

WT
WT

WT

WT

WT

WT

WT

Leu/Leu

WT

WT

WT

M

Phe/Leu

WT

WT

WT

No

FN

Leu/Leu

WT

WT

WT

European Mastiff

No

M

Leu/Leu

WT

WT

WT

European Mastiff

No

FN

Leu/Leu

WT

WT

WT

No

No

MN

Phe/Leu

WT

WT

WT

Bullmastiff cross

No

Yes

FN

WT

WT

WT

WT

Cavalier King Charles Spaniel

Yes

Spaniel

Yes

Leu/Leu

WT

WT

WT

Cavalier King Charles Spaniel

Yes

Spaniel

Yes

M

WT

WT

WT

Ser/Ser

Cavalier King Charles Spaniel and Cocker Spaniel cross

No

Yes

M

WT

Arg/Cys

WT

Ser/Ser

Chihuahua and Dachshund (miniature) cross

No

Yes

M

Phe/Leu

WT

WT

WT

Cocker Spaniel

Yes

Spaniel

No

WT

Arg/Cys

WT

WT

Cocker Spaniel

Yes

Spaniel

No

WT

WT

WT

WT

European Mastiff

F
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Exon 3

Exon 8

Exon 11

Exon 13

rs23314713

rs851148233

rs850760787

rs23315462

Brachycephalicb

Sexc

Phe103Leu

Arg270Cys

Arg365Gln

Pro452Ser

WT

WT

WT

Breed

Pedigree

Cladea

Cocker Spaniel

Yes

Spaniel

No

M

WT

Cocker Spaniel

Yes

Spaniel

No

MN

WT

Cocker Spaniel

Yes

Spaniel

No

MN

Cocker Spaniel (MDCK cells)

Yes

Spaniel

No

F

WT

Arg/Cys

WT

Pro/Ser

Cocker Spaniel and Poodle cross

No

No

M

WT

Arg/Cys

WT

Ser/Ser

Corgi cross

No

No

FN

Phe/Leu

WT

WT

Pro/Ser

Dachshund

Yes

Scent Hound

No

FN

WT

WT

WT

WT

Dachshund (miniature)

Yes

Scent Hound

No

FN

Leu/Leu

WT

WT

Ser/Ser

Dachshund (miniature)

Yes

Scent Hound

No

M

Leu/Leu

WT

WT

Ser/Ser

Dachshund (miniature)

Yes

Scent Hound

No

FN

WT

WT

WT

Ser/Ser

Dachshund (miniature)

Yes

Scent Hound

No

MN

WT

WT

WT

Ser/Ser

Dalmatian and Pitbull Terrier cross

No

No

F

WT

WT

Fox Terrier (miniature)

Yes

American Terrier

No

MN

Phe/Leu

WT

WT

Pro/Ser

Fox Terrier (miniature)

Yes

American Terrier

No

F

Phe/Leu

WT

WT

WT

Fox Terrier (miniature)

Yes

American Terrier

No

F

WT

WT

WT

Pro/Ser

German Shepherd Dog

Yes

New World

No

M

Leu/Leu

WT

WT

German Shepherd Dog

Yes

New World

No

FN

WT

WT

WT

German Shepherd Dog

Yes

New World

No

FN

WT

WT

WT

German Shepherd Dog cross

No

No

F

Phe/Leu

WT

WT

WT

WT
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Exon 3

Exon 8

Exon 11

Exon 13

rs23314713

rs851148233

rs850760787

rs23315462

Brachycephalicb

Sexc

Phe103Leu

Arg270Cys

Arg365Gln

Pro452Ser

Breed

Pedigree

Cladea

German Shorthaired Pointer

Yes

Pointer Setter

No

F

WT

WT

WT

Ser/Ser

Golden Retriever

Yes

Retriever

No

F

WT

WT

WT

Pro/Ser

Golden Retriever

Yes

Retriever

No

M

WT

WT

WT

Golden Retriever

Yes

Retriever

No

FN

WT

WT

Golden Retriever (DH82 cells)

Yes

Retriever

No

M

WT

Golden Retriever and Labrador Retriever cross

No

No

M

Leu/Leu

Hungarian Vizsla

Yes

Not determined

No

F

Jack Russell Terrier

Yes

Terrier

No

Jack Russell Terrier

Yes

Terrier

Jack Russell Terrier cross

WT

WT

WT

Arg/Gln

WT

WT

WT

WT

WT

F

Leu/Leu

WT

WT

WT

No

F

WT

WT

WT

Pro/Ser

No

No

F

Leu/Leu

WT

WT

WT

Jack Russell Terrier cross

No

No

MN

Leu/Leu

WT

WT

WT

Jack Russell Terrier cross

No

No

F

WT

WT

WT

WT

Kelpie

Yes

UK Rural

No

M

WT

WT

WT

WT

Kelpie

Yes

UK Rural

No

M

WT

WT

Pro/Ser

Labrador Retriever

Yes

Retriever

No

F

Phe/Leu

WT

WT

WT

Labrador Retriever

Yes

Retriever

No

F

Leu/Leu

WT

WT

WT

Labrador Retriever

Yes

Retriever

No

F

Leu/Leu

WT

WT

Labrador Retriever

Yes

Retriever

No

F

WT

WT

Arg/Gln

Pro/Ser

Labrador Retriever

Yes

Retriever

No

F

WT

WT

Arg/Gln

Pro/Ser
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Exon 3
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Brachycephalicb

Sexc

Phe103Leu

Arg270Cys

Arg365Gln

Pro452Ser

Breed

Pedigree

Cladea

Labrador Retriever

Yes

Retriever

No

F

WT

WT

Arg/Gln

WT

Labrador Retriever

Yes

Retriever

No

F

WT

WT

WT

Pro/Ser

Labrador Retriever

Yes

Retriever

No

M

WT

WT

WT

Pro/Ser

Labrador Retriever

Yes

Retriever

No

M

WT

WT

WT

WT

Labrador Retriever

Yes

Retriever

No

F

WT

Arg/Gln

Ser/Ser

Maltese

Yes

Poodle

No

F

WT

WT

WT

WT

Maltese

Yes

Poodle

No

M

WT

WT

WT

WT

Maltese

Yes

Poodle

No

MN

WT

WT

WT

Maltese

Yes

Poodle

No

FN

WT

Maltese and Fox Terrier cross

No

No

M

Maltese and Poodle cross

No

No

F

Phe/Leu

WT

WT

Maltese cross

No

No

MN

Phe/Leu

WT

WT

Maltese cross

No

No

F

WT

Maltese cross

No

No

MN

WT

Maltese Shih Tzu

Yes

Poodle/Asian Toy

Yes

M

Phe/Leu

Maltese Shih Tzu

Yes

Poodle/Asian Toy

Yes

FN

WT

WT

WT

Pro/Ser

Maltese Shih Tzu

Yes

Poodle/Asian Toy

Yes

M

WT

WT

WT

Pro/Ser

Maltese Shih Tzu

Yes

Poodle/Asian Toy

Yes

F

WT

WT

WT

Ser/Ser

Maltese Shih Tzu

Yes

Poodle/Asian Toy

Yes

MN

WT

WT

WT

WT

WT

WT

WT
WT
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Cladea

Exon 3

Exon 8

Exon 11

Exon 13

rs23314713

rs851148233

rs850760787

rs23315462

Brachycephalicb

Sexc

Phe103Leu

Arg270Cys

Arg365Gln

Pro452Ser

Yes

M

Leu/Leu

WT

WT

WT

WT

WT

WT

Breed

Pedigree

Mastiff and American Staffordshire Bull Terrier cross

No

Newfoundland

Yes

Retriever

No

MN

Pitbull Terrier

Yes

Not determined

No

F

WT

WT

WT

Pomeranian

Yes

Small Spitz

No

FN

WT

WT

WT

Poodle and Cocker Spaniel cross

No

No

M

WT

WT

WT

Ser/Ser

Pug and Beagle cross

No

Yes

F

Leu/Leu

WT

WT

Ser/Ser

Pug and Pomeranian cross

No

Yes

M

Phe/Leu

WT

WT

Pro/Ser

Rhodesian Ridgeback

Yes

No

F

WT

WT

WT

Pro/Ser

Rhodesian Ridgeback and Australian Cattle Dog cross

No

No

MN

WT

WT

WT

WT

Rottweiler

Yes

No

F

WT

WT

WT

Ser/Ser

Rottweiler cross

No

No

F

Rottweiler cross

No

Yes

FN

Schnauzer

Yes

No

M

Schnauzer (miniature) and Bulldog cross

No

No

Shar-Pei

Yes

Shih Tzu and Pug cross

No

Siberian Husky

Yes

Siberian Husky
Staffordshire Bull Terrier

European Mastiff

Drover

WT
WT

WT

WT

WT

WT

WT

FN

Phe/Leu

WT

WT

Pro/Ser

No

M

WT

WT

WT

Pro/Ser

Yes

M

WT

WT

WT

Asian Spitz

No

F

WT

WT

WT

Pro/Ser

Yes

Asian Spitz

No

F

WT

WT

WT

Pro/Ser

Yes

European Mastiff

Yes

M

Phe/Leu

WT

WT

WT

Schnauzer

Asian Spitz
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Brachycephalicb

Sexc

Phe103Leu

Arg270Cys

Arg365Gln

Pro452Ser

Breed

Pedigree

Cladea

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

F

Leu/Leu

WT

WT

WT

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

F

Leu/Leu

WT

WT

WT

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

F

Leu/Leu

WT

WT

WT

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

F

Leu/Leu

WT

WT

WT

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

F

Leu/Leu

WT

WT

WT

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

F

Leu/Leu

WT

WT

WT

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

F

Leu/Leu

WT

WT

WT

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

F

Leu/Leu

WT

WT

WT

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

FN

Leu/Leu

WT

WT

WT

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

MN

Leu/Leu

WT

WT

WT

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

Leu/Leu

WT

WT

WT

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

F

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

F

WT

WT

WT

Staffordshire Bull Terrier

Yes

European Mastiff

Yes

WT

WT

Staffordshire Bull Terrier and Kelpie cross

No

Yes

F

Phe/Leu

WT

WT

WT

Staffordshire Bull Terrier cross

No

Yes

F

Phe/Leu

WT

WT

Pro/Ser

Staffordshire Bull Terrier cross

No

Yes

FN

Phe/Leu

WT

WT

Pro/Ser

Staffordshire Bull Terrier cross

No

Yes

F

Leu/Leu

WT

WT

Pro/Ser

Staffordshire Bull Terrier cross

No

Yes

F

Leu/Leu

WT

WT

WT

Leu/Leu
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Breed

Pedigree

Cladea

Brachycephalicb

Sexc

Exon 3

Exon 8

Exon 11

Exon 13

rs23314713

rs851148233

rs850760787

rs23315462

Phe103Leu

Arg270Cys

Arg365Gln

Pro452Ser

Staffordshire Bull Terrier cross
No
Yes
F
Leu/Leu
WT
WT
WT
dogs were assigned into clades according to Parker et al. (2017)
bMixed-pedigree dogs were assigned as brachycephalic based on known ancestry and/or display of brachycephalic characteristics (shortening of the muzzle, flat facial conformation and
widening of the skull). Only one breed could be assigned in some dogs of mixed pedigree when the ancestry of a cross was not fully known or could not be ascertained by visual observation.
cSex: F, female; FN, neutered female; M, male; MN, neutered male.
Empty fields indicate sex unknown or exons not sequenced.
aPedigree
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Table 3.2. Prevalence and allele frequency of P2RX7 gene missense variants.
Genotype (n of dogs)
Variant

Amino acid

Dogs

Reference

Heterozygous

Homozygous

Prevalence

Allele

change

(n)

sequence

variant

variant

rs23314713

Phe103Leu

117

62

20

35

47%

0.38

rs851148233

Arg270Cys

121

117

4

0

3%

0.02

rs850760787

Arg365Gln

130

125

5

0

4%

0.02

rs23315462

Pro452Ser

106

64

28

14

40%

0.26

rs23314713

Phe103Leu

88

51

9

27

41%

0.36

rs851148233

Arg270Cys

89

87

2

0

2%

0.01

rs850760787

Arg365Gln

93

89

4

0

4%

0.02

rs23315462

Pro452Ser

79

48

21

10

39%

0.26

frequency

All dogs

Pedigree
dogs

Figure 3.1. Linkage disequilibrium analysis of the canine P2RX7 gene missense variants.
Linkage disequilibrium analysis of the four missense variants of the canine P2RX7 gene were
kindly analysed by Dr. Leanne Stokes (University of East Anglia, Norwich, UK) using Haploview
(https://www.broadinstitute.org/haploview/haploview). SNP1, rs23314713 (Phe103Leu); SNP2,
rs851148233 (Arg270C); SNP3, rs850760787 (Arg365Gln); SNP4, rs23315462 (Pro452Ser).
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3.2.2. The rs23314713 (Phe103Leu) variant is observed more frequently in female
dogs
The above sequence analyses revealed four canine P2RX7 variants amongst the 134 dog
samples sequenced and identified no difference between analyses including or excluding
mixed-pedigree dogs. To determine if there was any association between sex and any of
the canine P2RX7 variants, data from all dogs (Table 3.1) was grouped by sex (female or
male, irrespective of neutering) and the distribution of these variants was analysed.
Sequence analysis revealed that the rs23314713 variant was similarly prevalent in female
and male dogs, respectively (Table 3.3; 52% and 38%, respectively, P = 0.131). However,
this revealed a significantly greater allele frequency of the rs23314713 variant in female
dogs compared to male dogs (Table 3.3; 0.45 and 0.27, respectively, P = 0.0082).
Additionally, this difference in allele frequency was influenced by a significant increase
in the number of homozygous variants, but not heterozygous variants, in female dogs
compared to male dogs (Table 3.3; P = 0.0280). It was noted however, that Staffordshire
Bull Terriers represented a significant proportion of this sample (n = 19 with both sex and
rs23314713 variant data available), of which 89% were female with 100% prevalence of
the rs23314713 variant (Table 3.1). In contrast to the rs23314713 variant, no associations
were observed between sex and prevalence or allele frequency of rs851148233,
rs850760787 or rs23315462 variants (Table 3.3).
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Table 3.3. Prevalence and allele frequency of P2RX7 gene variants amongst female and male
dogs.
Genotype (n of dogs)
Variant

rs23314713

rs851148233

rs850760787

rs23315462

Sex

Dogs

Reference

Heterozygous

Homozygous

Prevalence

Allele

(n)

sequence

variant

variant

Female

65

31

10

24a

52%

0.45b

Male

48

30

10

8

38%

0.27

Female

69

68

1

0

1%

0.01

Male

47

45

2

0

4%

0.02

Female

71

67

4

0

6%

0.03

Male

54

53

1

0

2%

0.01

Female

60

36

17

7

40%

0.26

Male

42

24

11

7

43%

0.30

frequency

aP

= 0.0280 compared to proportion of homozygous male dogs (excludes heterozygous dogs).
= 0.0082 compared to allele frequency in male dogs.
All statistical comparisons by Fisher’s Exact test.
bP

3.2.3. The rs23314713 (Phe103Leu) variant is associated with brachycephalic dogs
The above data revealed that the rs23314713 variant was more frequently observed
amongst female dogs (Table 3.3). However, the strong prevalence of the rs23314713
variant in Staffordshire Bull Terriers may suggest a breed-specific association. A previous
study has demonstrated that the rs23314713 variant is associated with susceptibility to
glioma (Truve et al., 2016), which is more commonly observed in brachycephalic breeds
such as the Bulldog, Mastiff or Staffordshire Bull Terrier (Hayes et al., 1975; Snyder et
al., 2006; Song et al., 2013). Therefore, to determine if this commonly occurring variant
was associated with brachycephalic breeds, the distribution of the rs23314713 variant was
compared in brachycephalic and non-brachycephalic dogs. Sequence analysis of the
combined data from both pedigree and mixed-pedigree dogs (Table 3.4) revealed that the
rs23314713 variant was significantly more prevalent in brachycephalic dogs than in nonbrachycephalic dogs (Table 3.4; 76% and 31%, respectively, P < 0.0001). Similarly,
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brachycephalic dogs had a significantly greater rs23314713 variant allele frequency
compared to non-brachycephalic dogs (Table 3.4; 0.65 and 0.23, respectively). However,
to ensure that this was association was not impacted by subjectivity around the
classification of brachycephalic traits in mixed-pedigree dogs, data were also analysed
amongst pedigree dogs only. Nonetheless, when mixed-pedigree dogs were excluded
from the analysis, the rs23314713 variant prevalence and allele frequency were still
significantly greater (P < 0.0001) in brachycephalic dogs (Table 3.4; 79% and 0.71,
respectively) compared to non-brachycephalic dogs (Table 3.4; 23% and 0.19,
respectively).

Table 3.4. Prevalence and allele frequency of rs23314713 (Phe103Leu) variants in
brachycephalic and non-brachycephalic dogs.
Genotype (n of dogs)
Group

All dogs

Pedigree
dogs only

Brachycephalic

Dogs

Reference

Heterozygous

Homozygous

Prevalence

Allele

(n)

sequence

variant

variant
23b

76%c

0.65d

frequency

Yes

42

10

9a

No

75

52

11

12

31%

0.23

Yes

28

6

4e

18b

79%c

0.71d

No

60

46

5

9

23%

0.19

aP

= 0.0136 compared to proportion of heterozygous non-brachycephalic dogs (excludes homozygous dogs).
< 0.0001 compared to proportion of homozygous non-brachycephalic dogs (excludes heterozygous dogs).
cP < 0.0001 compared to prevalence in non-brachycephalic dogs.
dP < 0.0001 compared to allele frequency in non-brachycephalic dogs.
eP = 0.0323 compared to proportion of heterozygous non-brachycephalic dogs (excludes homozygous dogs).
All statistical comparisons by Fisher’s Exact test.
bP

Moreover, amongst all dogs, there was a significantly greater proportion of
brachycephalic dogs that were heterozygous (P = 0.0136) or homozygous (P < 0.0001)
for the rs23314713 variant compared to non-brachycephalic dogs (Table 3.4). Similar
findings were also revealed amongst pedigree dogs only, with a significantly greater
proportion of brachycephalic dogs with a heterozygous (P = 0.0323) or homozygous (P
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< 0.0001) rs23314713 variant compared to non-brachycephalic dogs (Table 3.4).
Collectively, this data suggests an association between the rs23314713 variant and
brachycephalic dogs.

3.2.4. The rs23315462 (Pro452Ser) variant is associated with non-brachycephalic
dogs
This chapter, combined with sequence data from a previous study (Spildrejorde, Bartlett,
et al., 2014), revealed that the commonly occurring rs23315462 variant was present in
both brachycephalic and non-brachycephalic breeds (Table 3.1, Table 3.2). Therefore, to
determine if there was a positive or negative association between the rs23315462 variant
and brachycephaly in dogs, the distribution of the rs23315462 variant was also compared
in brachycephalic and non-brachycephalic dogs. Sequence analysis amongst all dogs
revealed that the rs23315462 variant was less prevalent in brachycephalic dogs than in
non-brachycephalic dogs (Table 3.5; 28% and 47%, respectively), although this
difference failed to reach statistical significance (P = 0.0650, Fisher’s Exact test).
Similarly, amongst all dogs, there was a reduced rs23315462 variant allele frequency in
brachycephalic dogs compared to non-brachycephalic dogs (Table 3.5; 0.19 and 0.31,
respectively), however this difference was also not statistically significant (P = 0.0547,
Fisher’s Exact test). In contrast, when mixed-pedigree dogs were excluded from the
analysis, the rs23315462 variant prevalence and allele frequency were significantly less
in brachycephalic dogs compared to non-brachycephalic dogs (Table 3.5; P = 0.0141 and
P = 0.0124, respectively). Collectively, this data suggests an association between the
rs23315462 variant and non-brachycephalic dogs.
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Table 3.5. Prevalence and allele frequency of rs23315462 (Pro452Ser) variants in
brachycephalic and non-brachycephalic dogs.
Genotype (n of dogs)
Group

All dogs

Pedigree
dogs only

Brachycephalic

Dogs

Reference

Heterozygous

Homozygous

Prevalence

Allele

(n)

sequence

variant

variant

Yes

40

29

7

4

28%

0.19

No

66

35

21

10

47%

0.31

Yes

26

21

3a

2

19%b

0.13c

No

53

27

18

8

49%

0.32

frequency

aP

= 0.0269 compared to proportion of heterozygous non-brachycephalic dogs (excludes homozygous dogs).
= 0.0141 compared to prevalence in non-brachycephalic dogs.
cP = 0.0124 compared to allele frequency in non-brachycephalic dogs.
All statistical comparisons by Fisher’s Exact test.
bP

3.2.5. The rs851148233 (Arg270Cys) variant is limited to dogs of Cocker Spaniel
pedigree
Due to the low prevalence of the rs851148233 and rs850760787 variants in our cohort
(Table 3.3), comparisons of these variants with brachycephaly were not performed.
However, a previous study by our group identified that the rs851148233 variant appeared
to be limited to dogs of Cocker Spaniel pedigree (Spildrejorde, Bartlett, et al., 2014).
Although numbers of available Cocker Spaniels were small, data from this chapter
combined with data from this previous study, revealed that the rs851148233 variant was
limited to dogs of Cocker Spaniel pedigree, including two Cocker Spaniels, one Cavalier
King Charles Spaniel and Cocker Spaniel cross, and one Cocker Spaniel and Poodle cross
(Table 3.1). To determine if the rs851148233 variant was associated with Cocker Spaniel
breeds, variant prevalence and allele frequency were compared between dogs of Cocker
Spaniel and non-Cocker Spaniel pedigree. Sequence analysis revealed that the
rs851148233 variant, which was only observed in heterozygosity, was significantly more
prevalent in Cocker Spaniel breeds than in non-Cocker Spaniel breeds (Table 3.6; 57%
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and 0%, respectively, P < 0.0001). Similarly, Cocker Spaniel breeds had a significantly
greater rs851148233 variant allele frequency compared to non-Cocker Spaniel breeds
(Table 3.6; 0.29 and 0, respectively, P < 0.0001). Despite this however, the rs851148233
variant was not observed in two additional Cocker Spaniels and one Poodle and Cocker
Spaniel cross, while the genotype of two further Cocker Spaniels could not be identified
despite multiple sequencing attempts (Table 3.1, Table 3.6). Collectively this data,
although limited in sample size, suggests that an association exists between the
rs851148233 variant and dogs of Cocker Spaniel pedigree, and that this variant may be
limited to Cocker Spaniels.

Table 3.6. Prevalence and allele frequency of the rs851148233 (Arg270Cys) variant in dogs
of Cocker Spaniel pedigree.
Genotype (n of dogs)
Pedigree

Cocker

Dogs

Reference

Heterozygous

Homozygous

(n)

sequence

variant

variant

7a

3

4

114c

114

0

Prevalence

Allele
frequency

0

57%b

0.29b

0

0%

0

Spaniel
Non-Cocker
Spaniel
aIncludes

four Cocker Spaniels, one Cavalier King Charles Spaniel and Cocker Spaniel cross, one Cocker Spaniel and
Poodle cross, and one Poodle and Cocker Spaniel cross.
bP < 0.0001 compared to non-cocker Spaniels.
cIncludes two Cavalier King Charles Spaniels, and one Maltese and Poodle cross.
All statistical comparisons by Fisher’s Exact test.

3.2.6. The rs850760787 (Arg365Gln) variant is limited to dogs of Labrador
Retriever pedigree
Combined data from this chapter and from Spildrejorde, Bartlett, et al. (2014) has
revealed the presence of the rs850760787 variant in five dogs; four of Labrador Retriever
pedigree, and one Golden Retriever and Labrador Retriever cross (Table 3.1). To
determine if there was an association between the rs850760787 variant and dogs of
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Labrador Retriever pedigree, variant prevalence and allele frequency were compared in
dogs of Labrador Retriever and non-Labrador Retriever pedigree. Sequence analysis
revealed that the rs850760787 variant, which was only observed in heterozygosity, was
significantly more prevalent in Labrador Retriever breeds than in non-Labrador Retriever
breeds (Table 3.7; 45% and 0%, respectively, P < 0.0001). Similarly, Labrador Retriever
breeds had a significantly greater rs850760787 variant allele frequency compared to nonLabrador Retriever breeds (Table 3.7; 0.23 and 0, respectively, P < 0.0001). Collectively,
this data suggests that there is an association between dogs of Labrador Retriever pedigree
and the rs850760787 variant, and that this variant may be limited to Labrador Retrievers.

Table 3.7. Prevalence and allele frequency of the rs850760787 (Arg365Gln) variants in dogs
of Labrador Retriever pedigree, respectively.
Genotype (n of dogs)
Pedigree

Labrador

Dogs

Reference

Heterozygous

Homozygous

(n)

sequence

variant

variant

11a

6

5

119c

119

0

Prevalence

Allele
frequency

0

45%b

0.23b

0

0%

0

Retriever
Non-Labrador
Retriever
aIncludes

10 Labrador Retrievers, and one Golden Retriever and Labrador Retriever cross.
< 0.0001 compared to non-Labrador Retrievers.
cIncludes four Golden Retrievers.
All statistical comparisons by Fisher’s Exact test.
bP

3.3.

Discussion

This chapter has confirmed the presence of four missense variants, rs23314713
(Phe103Leu), rs851148233 (Arg270Cys), rs850760787 (Arg365Gln) and rs23315462
(Pro452Ser), in the canine P2RX7 gene. Combined with sequencing data from a
previously published study by our group (Spildrejorde, Bartlett, et al., 2014), this chapter
demonstrates that the commonly observed rs23314713 and rs23315462 variants were

122

more prevalent in brachycephalic and non-brachycephalic breeds, respectively. In
contrast, the rs851148233 and rs850760787 variants were less common and found only
in dogs of Cocker Spaniel and Labrador Retriever pedigrees, respectively.
The data presented in this chapter confirmed previous reports that the rs23314713 variant
was a commonly occurring variant in dogs (Spildrejorde, Bartlett, et al., 2014). It was
revealed that the rs23314713 variant occurred more frequently in female compared to
male dogs. This however, appeared to be influenced by a disproportionate number of
female dogs of a single brachycephalic breed (Staffordshire Bull Terrier), all of which
encoded the rs23314713 variant. Studies have previously observed sex differences in
humans in association with an increased prevalence of P2RX7 gain of function variants
(rs1621388 and rs2230912) in females but not males with bipolar disorder (Winham et
al., 2019). Thus, whether canine P2RX7 gene variants are more prevalent in one sex
compared to another remains to be determined. Further analyses revealed that the
rs23314713 variant was significantly more prevalent in brachycephalic dogs compared to
non-brachycephalic dogs. In support of this, the rs23314713 variant has previously been
associated with glioma in dogs (Truve et al., 2016), a disease more frequently observed
in brachycephalic breeds (Snyder et al., 2006; Song et al., 2013). However, dogs included
in this study did not suffer from glioma at the time of presentation, nor were health records
tracked post-sampling and as such, no association between glioma and the rs23314713
variant or brachycephaly can be derived from the data presented in this chapter.
Despite the increased prevalence of the rs23314713 variant in brachycephalic dogs, it
remains to be determined if the rs23314713 variant is broadly associated with
brachycephalic dogs, or more specifically with brachycephalic dogs of a given ancestry,
such as Bulldog ancestry, which includes Staffordshire Bull Terriers and other Bull
Terrier breeds (Ostrander et al., 2017). In support of a more clade-specific association,
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the three Bull Terriers analysed in this chapter (defined as non-brachycephalic dogs with
bulldog ancestry; VonHoldt et al., 2010) were homozygous for the rs23314713 variant,
whilst four of the five Maltese Shih Tzu analysed in this chapter (defined as
brachycephalic dogs without bulldog ancestry; VonHoldt et al., 2010) were homozygous
for the reference allele at this position. Thus, it remains to be determined if the
rs23314713 variant contributes to presence of brachycephalic features in dogs, although
observations in mice do not support this. Despite the known roles of P2X7 receptors in
bone formation and homeostasis (Agrawal & Gartland, 2015), strains of mice with a loss
of function P2RX7 missense variant (Pro451Leu) (Syberg et al., 2012) and P2RX7
knockout mice (Ke et al., 2003) do not display brachycephalic features compared to mice
with normal P2X7 receptor function.
This chapter has also revealed that the rs23315462 variant was significantly more
prevalent in non-brachycephalic dogs, an observation that mirrors the increased
prevalence of the rs23314713 variant in brachycephalic dogs and is supported by
incomplete linkage disequilibrium between the two alleles. Although both the
rs23314713 and rs23315462 variants were commonly found in both pedigree and
mixed-pedigree dogs, the number of individual dogs, as well as the number of different
breeds they represent, were relatively small compared to other studies. A previous study
involving 576 dogs (spread across 62 different breeds) revealed a causal link between
brachycephalic phenotypes and a Phe452Leu missense variant in the bone morphogenetic
protein 3, encoded by the BMP3 gene (Schoenebeck et al., 2012). Another study that
analysed 375 dogs (spread across 83 different breeds) revealed an association between
brachycephaly and a retrotransposon-mediated missplicing event in the SMOC2 gene,
which encodes the SPARC-related modular calcium-binding protein 2 (Marchant et al.,
2017). However, it is yet to be determined how these genetic variants contribute to
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brachycephalic phenotypes in dogs, despite their potential roles in bone formation
(Marchant et al., 2017; Schoenebeck et al., 2012).
Data presented in this chapter suggests that the rs851148233 variant is limited to, but not
present in all, dogs of Cocker Spaniel Pedigree. Cocker Spaniels form a unique clade with
other dogs such as Cavalier King Charles Spaniels and English Springer Spaniels (Parker
et al., 2017). Although this variant was not detected in any pure Cavalier King Charles
Spaniels, nor in the previously cloned English Springer Spaniel (Spildrejorde, Bartlett, et
al., 2014), it was observed in heterozygosity in one Cavalier King Charles Spaniel and
Cocker Spaniel cross, suggesting that this variant may be present in other dogs of this
clade. Nonetheless, further samples from dogs of Cocker Spaniel pedigree, or from the
Spaniel clade, are required to determine if the rs851148233 variant is derived exclusively
from Cocker Spaniels.
Similarly, this chapter has also revealed an association between the rs850760787 variant
and dogs of Labrador Retriever pedigree. This variant has also been reported on the iDOG
database (http://bigd.big.ac.cn/idog/) in a single Labrador Retriever sample of European
origin, sourced from a canine genome sequencing study of 51 dogs (Auton et al., 2013).
Labrador Retrievers are part of a unique Retriever clade with other dogs including Golden
Retrievers and Newfoundlands (Parker et al., 2017). Therefore, given the presence of this
variant in one Golden Retriever and Labrador Retriever cross, it cannot be excluded that
this variant may also be found in Golden Retrievers or other breeds of the Retriever clade.
Nonetheless, only one Newfoundland sample was available in this cohort, in which this
variant was not detected, while other breeds that form the Retriever clade, such as FlatCoated Retrievers or Irish Water Springer Spaniels (Parker et al., 2017) were not
available. It has previously been demonstrated that 80% of haplotypes with an observed
allele frequency of at least 0.05 in one breed, were also present in other breeds (Lindblad-
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Toh et al., 2005). Given the rs850760787 variant allele frequency of 0.23 amongst dogs
of Labrador Retriever pedigree, it remains a possibility that this variant may also be found
in breeds such as Golden Retrievers or dogs of Newfoundland pedigree. In support of
this, a recently published whole genome sequencing study of 582 dogs (Jagannathan et
al., 2019; data accessed from the European Variation Archive, https://www.ebi.ac.uk/eva)
revealed the presence of the rs850760787 variant in two male Labrador Retrievers, as
well as one Landseer, a breed often identified by National Kennel Clubs as a
Newfoundland based on black and white coat colour (Bondeson, 2015).
Although no new missense variants were reported in any dogs presented in this chapter,
sequence data were only analysed from four of the 13 exons of canine P2RX7. The
possibility remains that other missense variants may exist in the coding regions that were
not sequenced. Nonetheless, this data contrasts the large polymorphic variation observed
in the human P2RX7 gene, with at least 16 missense variants which result in either loss
or gain of function P2X7 receptors (Sluyter, 2017) and a number of other missense
variants in the human P2RX7 gene reported online (Fuller et al., 2009). The limited
polymorphic variation of the canine P2RX7 gene compared to the human P2RX7 gene is
consistent with genome-wide decreases in genetic variation occurring as a result of
population bottlenecks associated with domestication, local population history and breed
creation (Ostrander et al., 2017).
Although the biological significance of these P2RX7 variants in canine disease is yet to
be determined, several studies have previously demonstrated associations between human
P2RX7 variants and diseases such as tuberculosis (Fernando et al., 2007), toxoplasmosis
(Jamieson et al., 2010), accelerated bone loss and risk of fracture (Gartland et al., 2012;
Jorgensen et al., 2012), reduced cardiovascular risk (Gidlof et al., 2012) and insulin or
glucose homeostasis in type 2 diabetes (Todd et al., 2015; Uresti-Rivera et al., 2018). Of
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note is the canine P2RX7 rs851148233 (Arg270Cys) variant, which lies at the same
position as a human partial loss of function P2RX7 variant (rs7958311, Arg270His;
Stokes et al., 2010), that was associated with reduced pain in two independent cohorts of
post-mastectomy breast cancer patients and patients with osteoarthritis (Sorge et al.,
2012). As such, future studies relating canine P2X7 receptor function to P2RX7
haplotype, or studies with a focus on specific breeds (or clades), may assist in revealing
further associations with canine traits and disorders, as observed with the rs23314713
variant in glioma through genome-wide association mapping and targeted massive
parallel sequencing (Truve et al., 2016).
In conclusion, this chapter demonstrates that two canine P2RX7 missense variants,
rs23314713 and rs23315462, are commonly found in dogs and are associated with
brachycephalic and non-brachycephalic traits in dogs, respectively. Additionally, two less
commonly observed P2RX7 missense variants, rs851148233 and rs850760787, were
associated with dogs of Cocker Spaniel and Labrador Retriever pedigree, respectively.
This study highlights the possibility that P2RX7 genetic variants may be associated with,
or contribute to, canine traits or disorders, and that these variants may be consistent with
increased prevalence in specific breeds of dogs.
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Chapter 4: Variants of the canine P2RX4 gene
4.1.

Introduction

The P2X4 receptor, encoded by the P2RX4 gene, is a trimeric adenosine-5’-triphosphate
(ATP)-gated cation channel that is expressed primarily in cells and tissues of the immune
and central nervous systems (CNS) where it has established roles in regulating
neuroinflammation (Stokes et al., 2017; Suurväli et al., 2017). Changes in P2X4 receptor
function have been associated with the transmission of inflammatory and neuropathic
chronic pain (Bernier et al., 2018; Inoue, 2019), remyelination in the CNS (Domercq &
Matute, 2019) and alcohol use disorders (Franklin et al., 2014). In mice, genetic ablation
and pharmacological blockade of P2X4 receptors protects against neuronal damage
following ischemic stroke (Srivastava et al., 2020; Verma et al., 2017). Functional P2X4
receptors are also present on endothelial cells where they are associated with blood
flow-dependent Ca2+ signalling (Yamamoto et al., 2000; Yamamoto et al., 2006).
The majority of our understanding of P2X4 receptors comes from studies in rodents and
humans. In dogs however, the expression of the P2X4 receptors is limited to reports of
P2X4 transcripts in the brain and gastrointestinal tissue (Lee et al., 2005) and canine
arteries (Delorey et al., 2012). Earlier studies also provide indirect evidence of canine
P2X4-like receptors through ATP-gated Ca2+ channel activity in canine cerebellum
(Bezprozvanny & Ehrlich, 1993; Mészáros & Volpe, 1991), however it remains to be
determined if P2X4 receptors were involved.
Over 300 human P2RX4 missense variants have been reported online (Ensembl genome
browser; https://www.ensembl.org/) through genome-wide sequencing projects (Gerhard
et al., 2004; Korenaga et al., 2001; Notay et al., 2018; Voight et al., 2010), with several
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of these validated through functional studies (Gu et al., 2013; Sadovnick et al., 2017;
Stokes et al., 2011) (Table 4.1). A Tyr315Cys variant (rs28360472) results in a substantial
loss of P2X4 receptor function and has been associated with an increase in pulse pressure
(Stokes et al., 2011). The same variant, when in linkage disequilibrium with a P2RX7 loss
of function Gly150Arg variant (rs28360447) confers increased susceptibility to agerelated macular degeneration, which is suggested to occur through a decrease in P2X7
receptor-mediated phagocytosis (Gu et al., 2013). A human P2RX4 gain of function
Gly135Ser variant (rs765866317), forms a rare three-variant haplotype with the P2RX7
variants Thr205Met (rs140915863) and Asn361Ser (rs201921967), and is associated with
multiple sclerosis in a multi-incident family (Sadovnick et al., 2017). In dogs however,
few P2RX4 variants have been reported online through genome-wide sequencing projects
(Jagannathan et al., 2019; Lindblad-Toh et al., 2005; Wang et al., 2019) and unlike P2RX4
in humans, none of these variants have been validated by functional data or targeted
sequencing of the P2RX4 gene in canine cohorts.
Evidence of canine P2RX7 variants published by our group (Spildrejorde, Bartlett, et al.,
2014) and in this thesis (Chapter 3: Missense variants of the canine P2RX7 gene), as well
as the aforementioned presence of human P2RX4 missense variants, suggest that P2RX4
variants may also be present in dogs. The above links between human P2RX4 missense
variants and disorders such as increased pulse pressure, age-related macular degeneration
and multiple sclerosis, indicate that P2RX4 genetic variants may contribute to similar
disorders or breed-specific traits in dogs, however very little data is available regarding
the presence or distribution of missense variants in the canine P2RX4 gene. Therefore,
this chapter aimed to sequence the P2RX4 gene from a cohort of 101 randomly sampled
dogs to identify P2RX4 gene missense variants and determine their distribution amongst
this sample of the canine population.
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Table 4.1. Missense variants of the human P2RX4 gene which alter P2X4 receptor function
and/or are associated with disorders.
Amino

Amino

acid

acid

change

position

rs200492184

Gly>Cys

3

rs1044249

Ala>Ser

6

Variant ID

Minor

Effect on

allele

P2X4

frequency

function

G>T

0.00421

Unknown

(Sadovnick et al., 2017)

G>T

0.00003

No effect

(Korenaga et al., 2001; Stokes

cDNA
change

References

et al., 2011)
rs28360470

Ile>Val

119

A>G

N/A

No effect

(Stokes et al., 2011)

rs765866317

Gly>Ser

135

G>A

0.00002

GOF

(Sadovnick et al., 2017)

rs25644

Ser>Gly

242

A>G

0.12156

No effect

(Gerhard et al., 2004; Gidlof
et al., 2012; Notay et al., 2018;
Sadovnick et al., 2017; Stokes
et al., 2011; Voight et al.,
2010)

rs28360472

Tyr>Cys

315

A>G

0.010797

LOF

(Gu et al., 2013; Sadovnick et
al., 2017; Stokes et al., 2011)

Abbreviations; GOF, gain of function; LOF, loss of function.

4.2.

Results

4.2.1. The canine P2RX4 gene is highly conserved amongst dogs
To determine the presence of exonic variants of the canine P2RX4 gene, genomic DNA
extracted from randomly selected dogs (n = 101) was amplified and sequenced by Sanger
sequencing using primers flanking exonic regions of canine P2RX4 as detailed in Table
2.5. Canine samples that were successfully amplified and sequenced across five or more
exons were included in the analysis, resulting in a cohort of 101 dogs, consisting of 69
pedigree dogs (representing 32 different pedigrees) and 32 non-pedigree dogs (Table 4.2).
Although some regions could not be amplified or sequenced despite multiple attempts,
43 dogs were successfully sequenced across all 12 exons of P2RX4 (Table 4.2). On
average, 85% of exons were successfully sequenced from all 101 dogs, with the highest
region of sequence coverage in exons 2 and 12 (95% of dogs successfully sequenced) and
the lowest region of sequence coverage in exon 1 (62%) (Table 4.2).

130

A query of the Ensembl Genome Browser (https://www.ensembl.org/), the EMBL-EBI
European Variation Archive (EVA; https://www.ebi.ac.uk/eva/) and the iDOG Dog
Genome SNP (https://bigd.big.ac.cn/idog/) databases (last accessed April 2020) revealed
three reported missense variants; one in exon 1 of P2RX4 (no rsID, 26C>A, A9D; EVA
database), one in exon 7 (no rsID, 691C>T, R231C; EVA database) and one in exon 10
(rs852294963, 1033C>G, L345V; Ensembl). However, sequencing of the P2RX4 gene in
our cohort did not reveal any of these three reported missense variants, nor were any novel
missense variants identified (Table 4.2, Table 4.3). Combined, this data suggests that the
P2RX4 gene is highly conserved between dogs.

4.2.2. Two synonymous P2RX4 variants, Thr266Thr and Cys5Cys, were identified
amongst our cohort
At least six synonymous variants are reported on the Ensembl, EVA and iDOG databases,
however of these, only one variant (798C>T, Thr266Thr; rs852444127) was identified in
our cohort. This rs852444127 variant was observed in heterozygosity in two Labrador
Retrievers and one Beagle (Table 4.2, Table 4.3). Despite the observation of this variant
in two Labrador Retrievers, it was not observed in another five dogs of Labrador pedigree,
nor in three other dogs of Beagle pedigree. In exon 1 of canine P2RX4, a previously
unreported base pair change (15C>T) resulting in a synonymous cysteine at position five
(Cys5Cys; no rsID) was observed in heterozygosity in five pedigree dogs and three nonpedigree dogs, four of which were of Maltese pedigree (Table 4.2, Table 4.3). The other
four dogs in which this variant was observed included one Bull Terrier cross, one
Dachshund (miniature), one Golden retriever and one Staffordshire Bull Terrier (Table
4.2). This variant was absent in two other Maltese, whilst exon 1 could not be amplified
in a further four Maltese (Table 4.2). Although sample size for this pedigree was small,
the distribution of this variant between dogs of Maltese and non-Maltese pedigree was
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analysed. Both the allele frequency (0.33 and 0.04) and prevalence (66% and 7%) of this
variant were significantly different between dogs of Maltese and non-Maltese pedigree,
respectively (Table 4.4). This data suggests that the previously unreported Cys5Cys
variant may be commonly observed in, but not limited to, dogs of Maltese pedigree.
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Table 4.2. Distribution of P2RX4 gene variants in a random sample of 101 dogs.
Exon
Breed

Pedigree

Sexa

1

2

3

4

5

6

7

8

9

10

11

12

Alaskan Malamute

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Alaskan Malamute

Yes

M

WT

WT

WT

WT

Alaskan Malamute and Siberian Husky cross

No

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

American Staffordshire Terrier

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

American Staffordshire Terrier

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

American Staffordshire Terrier

Yes

F

WT

WT

WT

WT

WT

WT

WT

American Staffordshire Terrier

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Australian Bulldog

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Australian Bulldog

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Australian Bulldog

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Australian Cattle Dog (red)

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Australian Cattle Dog and Kelpie cross

No

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Basenji

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Basenji

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Beagle

Yes

M

WT

WT

WT

WT

WT

WT

WT

T266T

WT

WT

WT

WT

Beagle

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Beagle

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Border Collie

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Border Collie

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Border Collie

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Border Collie and Australian Cattle Dog cross

No

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT
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Exon
Breed

Pedigree

Sexa

British Bulldog

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Bull Arab

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Bull Terrier

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Bull Terrier

Yes

NR

WT

WT

WT

WT

Bull Terrier (miniature)

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Bull Terrier cross

No

M

C5C

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Bullmastiff cross

No

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Cattle Dog and Staffordshire Terrier/Pitbull Terrier cross

No

F

WT

WT

WT

Cavalier King Charles spaniel

Yes

M

WT

WT

WT

Cavalier King Charles spaniel and cocker spaniel cross

No

M

WT

WT

WT

WT

Chihuahua and Dachshund (miniature) cross

No

M

WT

WT

WT

Cocker Spaniel

Yes

F

WT

WT

WT

Cocker Spaniel

Yes

M

WT

WT

WT

Cocker Spaniel

Yes

NR

WT

WT

WT

WT

Corgi cross

No

F

WT

WT

WT

WT

Dachshund (miniature)

Yes

F

WT

WT

WT

WT

Dachshund (miniature)

Yes

F

WT

WT

WT

WT

Dachshund (miniature)

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Dalmatian and Pitbull Terrier cross

No

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Fox Terrier (miniature)

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Fox Terrier (miniature)

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

German Shepherd

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

1

2

3

4

5

6

7

8

9

10

11

12

WT

C5C

WT

WT

WT

WT
WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT
WT

WT

WT

WT

WT

WT

WT

WT
WT
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Exon
Breed

Pedigree

Sexa

German Shepherd

Yes

M

WT

WT

WT

WT

German Shepherd Cross

No

F

WT

WT

WT

WT

German Shorthaired Pointer

Yes

F

WT

WT

WT

WT

Golden Retriever

Yes

F

C5C

WT

Golden Retriever

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Golden Retriever

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Golden Retriever and Labrador Retriever cross

No

M

WT

WT

WT

WT

WT

WT

WT

Great Dane cross Irish Wolfhound

No

NR

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Hungarian Vizsla

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Jack Russell Terrier

Yes

F

WT

WT

WT

WT

WT

WT

WT

Jack Russell Terrier cross

No

F

WT

WT

WT

WT

WT

WT

WT

Jack Russell Terrier cross

No

M

WT

WT

WT

WT

Kelpie

Yes

M

WT

WT

WT

WT

WT

WT

WT

Labrador Retriever

Yes

F

WT

WT

WT

WT

WT

WT

WT

Labrador Retriever

Yes

F

WT

WT

WT

WT

Labrador Retriever

Yes

M

WT

WT

WT

WT

Labrador Retriever

Yes

F

WT

WT

WT

WT

Labrador Retriever

Yes

F

WT

Labrador Retriever

Yes

F

WT

Labrador Retriever

Yes

F

WT

Maltese

Yes

M

C5C

WT

WT

WT

Maltese

Yes

F

C5C

WT

WT

WT

1

2

3

4

5

6

7

8

9

10

11

12

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT
WT

WT
WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

T266T

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

T266T

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT
WT
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Exon
Breed

Pedigree

Sexa

Maltese

Yes

Maltese

1

2

3

4

5

F

WT

WT

WT

WT

Yes

M

WT

WT

WT

Maltese cross

No

M

C5C

WT

WT

WT

Maltese cross

No

F

WT

WT

Maltese cross

No

M

Maltese Shih Tzu

No

M

Maltese Shih Tzu

No

M

Maltese Shih Tzu

No

M

Mastiff and American Staffordshire Terrier cross

No

M

Newfoundland

Yes

Pitbull Terrier

WT

WT

WT

C5C

WT

WT

WT

WT

WT

6

7

8

9

10

11

12

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Pomeranian

Yes

F

WT

WT

WT

WT

Pug and Beagle cross

No

F

WT

WT

WT

Pug and Pomeranian cross

No

M

WT

WT

WT

Rhodesian Ridgeback

Yes

F

WT

WT

WT

WT

Rhodesian Ridgeback and Australian Cattle Dog cross

No

M

WT

WT

WT

WT

WT

Rottweiler

Yes

F

WT

WT

WT

WT

Schnauzer

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Schnauzer (miniature) and Bulldog cross

No

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Shar Pei

Yes

M

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Siberian Husky

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Staffordshire Bull Terrier

Yes

M

C5C

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT
WT

WT

WT

WT

WT

WT

WT

WT
WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT
WT
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Exon
Breed

Pedigree

Sexa

Staffordshire Bull Terrier

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Staffordshire Bull Terrier

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Staffordshire Bull Terrier

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Staffordshire Bull Terrier

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Staffordshire Bull Terrier

Yes

NR

WT

WT

WT

WT

WT

WT

WT

WT

WT

Staffordshire Bull Terrier

Yes

M

WT

WT

WT

WT

Staffordshire Bull Terrier

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Staffordshire Bull Terrier

Yes

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Staffordshire Bull Terrier cross

No

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Staffordshire Bull Terrier cross

No

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Staffordshire Bull Terrier cross

No

F

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

Staffordshire Bull Terrier cross

No

F

WT

WT

WT

WT

WT

WT

WT

WT

Unknown

No

F

WT

Unknown

No

NR

aSex:

F, female; FN, neutered female; M, male; MN, neutered male.
Empty fields indicate sex unknown or exons not sequenced.
For each mix pedigree dog (cross), the dominant breed phenotype is listed first.

1

2

3

4

5

6

7

8

9

10

11

12

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT

WT
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Table 4.3. Distribution of canine P2RX4 exon variants in our cohort of dog samples.
Genotype (n of dogs)
Variant

a

Amino acid

Dogs

Reference

Heterozygous

Allele

Prevalence

change

(n)

sequence

variantb

frequency

63

63

0

ND

ND

90

90

0

ND

ND

82

82

0

ND

ND

Reported missense variantsc
gcC>gcA (26)

A9D

Cgt>Tgt (691)

R231C

Ctc>Gtc (1033)

L345V

d

Reported synonymous variantse
aaT>aaC (426)

N142N

92

92

0

ND

ND

ggC>ggT (753)

G251G

88

88

0

ND

ND

tcT>tcC (1023)

S341S

82

82

0

ND

ND

Ttg>Ctg (1027)

L343L

82

82

0

ND

ND

gaG>gaA (1128)

E376E

82

82

0

ND

ND

Observed variantsf
tgC>tgT (15)

C5C

63

55

8

0.063

12.7%

acC>acT (798)

T266T

88

85

3

0.017

3.4%

Abbreviation: ND, not detected.
aParentheses indicate cDNA position.
bOnly heterozygous variants were observed in this cohort.
cMissense variants reported previously in either ENSEMBL, EVA or iDOG databases but not observed in this study.
drs85229496 (all other variants do not have rsIDs assigned)
eSynonymous variants reported previously in either ENSEMBL, EVA or iDOG databases but not observed in this
study.
fVariants that were observed at least once in our cohort.

Table 4.4. Prevalence and allele frequency Cys5Cys variant in dogs of Maltese pedigree.
Genotype (n of dogs)
Pedigree

Dogs (n)
b

Maltese

6

Non-Maltese

57

aOnly

Reference

Heterozygous

sequence

varianta

Allele
frequency

2

4

66%

0.33d

53

4

7%

0.04

heterozygous variants were observed in this cohort
two Maltese, one Maltese cross and one Maltese Shih Tzu.
cP = 0.0016 compared to non-Maltese.
dP = 0.0028 compared to non-Maltese.
All statistical comparisons by Fisher’s Exact test.
bIncludes

Prevalence
c
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4.3.

Discussion

This chapter has demonstrated that the coding sequence of P2RX4 is highly conserved
amongst 101 dogs, reporting no missense variants within this cohort. The lack of genetic
variation in canine P2RX4 contrasts that of canine P2RX7 (Chapter 3; Spildrejorde,
Bartlett, et al., 2014) which encodes at least four characterised missense variants across
just four of its exons. The difference between canine P2RX4 and P2RX7 parallels the
differences in frequencies of missense variants between human P2RX4 (Stokes et al.,
2011) and P2RX7 (Stokes et al., 2010). Since the publication of the canine genome
(Lindblad-Toh et al., 2005), few missense P2RX4 variants have been reported in
databases collating canine genome-wide sequencing data (Ensembl, EVA, iDOG) and
none so far have been validated by publication or characterised in functional studies.
Nonetheless, the reduced polymorphic variation in canine P2RX4 compared to human
P2RX4 is consistent with current observations of genome-wide loss in genetic variation
due to domestication and selective breeding (Ostrander et al., 2017). Currently, there are
around 400 recognised domestic pedigrees worldwide (Ostrander et al., 2017). With such
a diverse range of pedigrees worldwide, there is potential for regional or pedigree bias
within the present study, with dogs of Labrador, Staffordshire and Maltese pedigree
collectively forming over one third of the total cohort. Just over one quarter of the
pedigrees in this cohort are represented by a single sample and as such, the identification
of P2RX4 variants may have been precluded, particularly if they exhibit a very low minor
allele frequency or are more commonly associated with particular pedigrees.
This chapter identified a previously unreported synonymous variant (Cys5Cys) in exon 1
of canine P2RX4, which appeared to be associated with dogs of Maltese pedigree.
However, this region was notably difficult to amplify, requiring excessive optimisation
with multiple sets of primers before a sufficiently pure amplicon was obtained. This was

139

likely a result of sequence variability in the 5’ untranslated region (UTR) of canine P2RX4
(results not shown) preventing primer recognition during amplification and sequencing.
Despite successfully sequencing exon 1 in more than half of the canine samples, the
sequence identity of exon 1 in many samples remains unknown. Given this, it is difficult
to make strong associations about the distribution of this Cys5Cys variant in dogs due to
the reduced sample size. Additionally, the relatively high prevalence of this variant within
this cohort (>10%) and the lack of any reported Cys5Cys variant in a recently published
whole genome study of 582 dogs (Jagannathan et al., 2019) or other canine genome-wide
sequencing studies (Auton et al., 2013; Lindblad-Toh et al., 2005) suggests that the
incidence of this variant may be overrepresented in this cohort. However, it is also noted
that dogs of Maltese pedigree, in which this variant was more commonly observed, were
not represented in these studies. Therefore, it remains unclear whether the Cys5Cys
variant is truly associated with dogs of Maltese pedigree as suggested here and thus
requires sequencing of additional dogs for validation.
This study also demonstrated the presence of the Thr266Thr variant in three dogs, two of
which were Labrador Retrievers and one Beagle. Although the small sample size makes
it difficult to make associations between variant distribution and breeds or breed-specific
traits, this Thr266Thr variant has been reported in a number of different dog breeds in a
study of 582 dogs (Jagannathan et al., 2019). Of the 12 dogs (from 218 dogs with
sequence coverage across this region) in which this study reports the Thr266Thr variant,
four dogs were homozygous for this mutation including three Doberman Pinschers, and
a further eight dogs were heterozygous for this variant including one Labrador Retriever,
one Beagle and one Landseer (Jagannathan et al., 2019). Although this variant seems to
be distributed across a range of different dog breeds, it may be that this variant is
associated with particular breeds or clades, such as the Labrador Retriever, Beagle or
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Doberman Pinscher, however further sequencing of these breeds would be required to
make associations regarding the distribution of this variant in dogs. While the effect of
synonymous variations on receptor function is often assumed to be minimal, synonymous
mutations can influence a range of biologically relevant changes (Zeng & Bromberg,
2019). Thus, the Cys5Cys and Thr266Thr P2RX4 variants reported in dogs in this study
may have important effects on the expression or function of the P2X4 receptor, although
this is yet to be determined.
The presence of P2RX4 genetic variants or complete ablation of the P2RX4 gene have
been associated with a range of disorders common in ageing populations such as
neuroinflammation, chronic pain, age-related macular degeneration, cardiovascular
disease and neurodegeneration (Gu et al., 2013; Stokes et al., 2011; Su et al., 2019; Tsuda
et al., 2009; Verma et al., 2017). Given the persistence of similar diseases in canine
populations (Awano et al., 2009; Moon et al., 2015; Sandor & Kubinyi, 2019), combined
with the high level of conservation of the canine P2RX4 gene, the P2X4 receptor is
emerging as a highly druggable target for treatment of canine disease. This may also
impart benefits for modelling mechanisms of human disease, as dogs have been wellestablished as natural models of human ageing and disease (Sandor & Kubinyi, 2019).
Despite this, data regarding the expression of P2X4 receptors in canine tissues is still
limited (Delorey et al., 2012; Lee et al., 2005). Thus, to elucidate the involvement of
P2X4 receptors in canine disease, receptor expression patterns should be identified in
canine tissues similar to those where P2X4 receptors are found in humans, such as blood
vessels, brain, gut, lungs and immune cells (Burnstock & Knight, 2004).
In conclusion, this chapter demonstrates that the P2RX4 receptor is well conserved
amongst dogs, identifying only two synonymous variants, Cys5Cys and Thr266Thr, and
no other missense variants in a cohort of 101 dogs. As a result of this high level of
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conservation, this study has highlighted the potential for targeting the P2X4 receptor for
therapeutic treatment in dogs and suggests that the canine P2X4 receptor may aid in
modelling mechanisms of human disease.
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Chapter 5: Pharmacological characterisation of canine and
human P2X4 receptors
5.1.

Introduction

The P2X4 receptor, which forms a homo-trimeric, adenosine-5’-triphosphate
(ATP)-gated Ca2+ channel, was originally cloned from rat brain cDNA (Bo et al., 1995;
Soto et al., 1996) and later, cloned from human brain tissue (Garcia-Guzman et al., 1997).
Since then, the rodent and human P2X4 receptors have been extensively characterised
through heterologous expression in cell models (Bianchi et al., 1999; Jones et al., 2000),
as well as identified and studied in a range of cells including monocytes, macrophages,
T cells, endothelial cells and glial cells (Antonioli et al., 2019; Di Virgilio & Vuerich,
2015; Stokes & Surprenant, 2009; Trang et al., 2009; Trang & Salter, 2012; Tsuda et al.,
2010; Yamamoto et al., 2000). P2X4 receptors from bovine, Xenopus and zebrafish have
also been structurally and functionally characterised (Ase et al., 2019; Hattori & Gouaux,
2012; Kawate et al., 2009) and have provided a foundation for understanding the
mechanisms of targeting P2X4 receptors with novel compounds, including antagonists
(Werner et al., 2019), antibodies (Bergmann et al., 2019; Williams et al., 2019) and
positive modulators (Dhuna et al., 2019). Despite this, studies have yet to clone or
characterise P2X4 receptors from dogs.
Elucidation of P2X4 receptor expression, structure and function has led to suggestions
that P2X4 receptors are an attractive therapeutic target for the treatment of a number of
major health issues in ageing human populations, including chronic pain and
inflammation (Bernier et al., 2018), nerve injury (Su et al., 2019), demyelinating diseases
such as multiple sclerosis (Di Virgilio & Sarti, 2018; Domercq & Matute, 2019;
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Sadovnick et al., 2017; Zabala et al., 2018) and cardiovascular disease (Stokes et al.,
2011; Yamamoto et al., 2006). Similar health issues commonly arise in dogs (BlackburnMunro, 2004; Grubb, 2010a, 2010b), however despite evidence suggesting that functional
P2X4 receptors may be expressed in dogs (Bezprozvanny & Ehrlich, 1993; Delorey et
al., 2012; Lee et al., 2005; Mészáros & Volpe, 1991), to date, there have been no studies
characterising the canine P2X4 receptor. Given the recent advances in the understanding
of P2X4 receptors (Stokes et al., 2017), this chapter aimed to heterologously express the
canine P2X4 receptor in mammalian cells and characterise the expression, sub-cellular
localisation and function using antibodies, agonists, modulators and antagonists, and
directly compare this with the human P2X4 receptor.

5.2.

Results

5.2.1. Expression and localisation of canine and human P2X4 receptors in HEK293
cells
To determine if the canine P2X4 receptor could be heterologously expressed in a
mammalian cell line, HEK293 cells, a cell line commonly used for studying
heterologously expressed P2X receptors (Jiang & Roger, 2020), were transfected with
canine or human P2X4-EmGFP, with EmGFP alone or mock transfected and analysed by
western blotting and confocal microscopy. Expression of a predicted 80 kDa EmGFPbound P2X4 band was observed in lysates from HEK293 cells transfected with canine or
human P2X4 receptors following incubation with an anti-P2X4 receptor antibody (Figure
5.1). In contrast, no P2X4 receptor expression was observed in lysates from HEK293 cells
that were transfected with the EmGFP expression vector alone or mock transfected,
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despite equal protein loading as indicated by similar expression of actin (Figure 5.1).

Figure 5.1. Expression of canine and human P2X4 receptors in HEK293 whole-cell lysates.
HEK293 cells, transfected with canine or human P2X4-EmGFP, EmGFP plasmid DNA alone
(EmGFP) or mock transfected (mock), were analysed by western blotting using an anti-P2X4
receptor antibody (top panel) and anti-actin antibody (bottom panel) prior to imaging. Results are
representative of three independent experiments.

Previous studies have revealed that human and rodent P2X4 receptors localise to
lysosomes (Huang et al., 2014; Stokes & Surprenant, 2009). To observe the localisation
of the canine P2X4 receptor, HEK293 cells were transfected with canine or human
P2X4-EmGFP and analysed by confocal microscopy. HEK293 cells transfected with
canine or human P2X4 receptors revealed distinct vesicular localisation that was similar
between the two orthologues as visualised by the EmGFP-tagged P2X4 receptor
(Figure 5.2). These vesicular canine and human P2X4-EmGFP compartments colocalised
with lysosomal-associated membrane protein 1 (LAMP1)-immunoreactive lysosomes
(Figure 5.2) (Pearson’s coefficient = 0.765 and 0.819, respectively). In contrast, HEK293
cells transfected with the EmGFP expression construct alone had no distinct vesicular
localisation of EmGFP, but rather were retained primarily within the nuclei (Figure 5.2).
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Figure 5.2. Expression and localisation of canine and human P2X4 receptors in HEK293
cells. HEK293 cells, transfected with canine or human P2X4-EmGFP or pEmGFP alone, were
fixed, permeabilised and stained with anti-LAMP1 primary antibody and anti-mouse-PE
secondary antibody to label lysosomes. Cells were imaged by confocal microscopy and
co-localisation analysed by ImageJ. Images are representative results of three independent
experiments. Scale bar = 20 µm.

5.2.2. ATP, ADP and BzATP induce concentration-dependent Ca2+ responses in
HEK293 cells transfected with canine or human P2X4 receptors
To determine if canine and human P2X4-EmGFP expression constructs were functional
when expressed in HEK293 cells, the permeability properties of the P2X4 receptor Ca2+
channels were used to measure changes in intracellular Ca2+ bound to the ratiometric
fluorescent dye, Fura-2, following application of extracellular ligands. Incubation of
HEK293 cells, transfected with canine or human P2X4 receptors, with ATP, ADP or
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BzATP induced rapid Ca2+ responses which peaked within 10-30 s of application of
nucleotide. This peak phase was followed by a slowly declining, sustained phase (Figure
5.3A-C). No response was observed upon addition of extracellular Ca2+ solution (ECS)
alone (Figure 5.3D). ATP was the most potent agonist of the canine P2X4 receptor (pEC50
6.13 ± 0.05) in HEK293 cells, evoking a concentration-dependent Ca2+ response with
maximal activity at 10 µM (Figure 5.3E). Likewise, ATP produced a similar response in
HEK293 cells expressing the human P2X4 receptor (Figure 5.3F; pEC50 6.48 ± 0.04).
ADP induced a less potent concentration-dependent response in HEK293 cells expressing
canine or human P2X4 receptors (Figure 5.3E and Figure 5.3F; pEC50 4.50 ± 0.09 and
4.87 ± 0.03, respectively), with maximal response occurring near 100 µM. BzATP
induced ATP-like Ca2+ responses in HEK293 cells expressing the human P2X4 receptor
(pEC50 4.13 ± 0.29), although with a greatly reduced potency compared to ATP and ADP
(Figure 5.3F). In contrast, BzATP had very little effect on Ca2+ response in HEK293 cells
expressing the canine P2X4 receptor (Figure 5.3E; pEC50 < 3).

5.2.3. ATP and ADP but not BzATP induce Ca2+ responses in HEK293 cells lacking
heterologously expressed P2X4 receptors
Previous studies indicate the expression of P2Y receptors in HEK293 cells, which have
the capability to mobilise Ca2+ in response to extracellular nucleotides (Fischer et al.,
2005; Schachter et al., 1997). Therefore, to determine if the nucleotides used above could
induce Ca2+ responses in the absence of P2X4 receptors, HEK293 cells were transfected
with the EmGFP vector alone or mock transfected and changes in intracellular Ca2+ were
measured using the Fura-2 Ca2+ response assay. ATP and ADP, but not BzATP, induced
Ca2+ responses in HEK293 cells that were mock transfected or transfected with the
EmGFP expression vector alone (Figure 5.4A-C). No response was observed upon
addition of ECS alone (Figure 5.4D). These responses were smaller than those observed
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in P2X4 receptor-transfected cells and had a decay phase response that returned to
baseline levels faster (Figure 5.4) than HEK293 cells transfected with canine or human
P2X4 receptors (Figure 5.3).

Figure 5.3. Ca2+ response agonist profile of HEK293 cells transfected with canine or human
P2X4 receptors. (A-F) HEK293 cells, transfected with canine or human P2X4-EmGFP, were
loaded with Fura-2 and incubated in absence or presence of each nucleotide (as indicated). (A-C)
Ca2+ traces (ΔF340/380) for each nucleotide at indicated maximal concentration or (D) ECS
vehicle control. (E-F) Nucleotide-induced peak ΔCa2+ response presented as percent of maximum
response to 10 µM ATP with data fit to the Hill equation to produce concentration-response
curves. (A-F) Data shown are mean ± SEM from five independent experiments.
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Figure 5.4. Ca2+ traces of HEK293 cells lacking heterologously expressed P2X4 receptors in
response to extracellular nucleotides. (A-D) HEK293 cells, transfected with the EmGFP
expression vector or mock transfected, were loaded with Fura-2 and incubated in absence or
presence of each nucleotide (as indicated). (A-C) Ca2+ traces (ΔF340/380) for each nucleotide at
indicated maximal concentration or (D) ECS vehicle control. (A-D) Data shown are mean ± SEM
from three independent experiments.

5.2.4. Endogenous P2Y1 and P2Y2 receptors play a role in nucleotide-induced Ca2+
mobilisation in HEK293 cells
To determine if endogenous P2Y1 or P2Y2 receptors mediate Ca2+ mobilisation in
HEK293 cells, nucleotide-induced changes in intracellular Ca2+ were measured in
absence or presence of the selective P2Y1 receptor antagonist, MRS2179 (Boyer et al.,
1998), or the selective P2Y2 receptor antagonist, AR-C118925 (Kemp et al., 2004;
Rafehi, Burbiel, et al., 2017). MRS2179 reduced ATP- and ADP-induced Ca2+ responses
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by 28.5 ± 7.3% (Figure 5.5A) and 42 ± 14.7% (Figure 5.5B), respectively. AR-C118925
inhibited ATP- and uridine-5’-triphosphate (UTP)-induced Ca2+ responses by
64.7 ± 8.3% (Figure 5.5C) and 90.5 ±14.7% (Figure 5.5D), respectively. Collectively,
these results confirm that P2Y1 and P2Y2 receptors play a role in Ca2+ mobilisation in
HEK293 cells, which may confound Ca2+ recordings in transfected HEK293 cells.

Figure 5.5. Nucleotide-induced peak Ca2+ responses in HEK293 cells in absence or presence
of P2Y1 or P2Y2 receptor antagonists. (A-D) Non-transfected HEK293 cells were loaded with
Fura-2 and pre-incubated in absence or presence of (A, B) 20 µM MRS2179 or (C, D) 10 µM
AR-C118925 for 5 min at 37°C. Cells were then exposed to (A, C) 10 µM ATP, (B) 30 µM ADP
or (D) 10 µM UTP and Fura-2 fluorescence was recorded. (A-D) Data shown are mean agonistinduced peak Ca2+ response (ΔF340/380) ± SEM from three independent experiments.
*P < 0.05 compared to nucleotide alone using a parametric Student’s t-test.

5.2.5. ATP induces concentration-dependent inward currents in HEK293 cells
transfected with canine or human P2X4 receptors
While both P2X and P2Y receptors are responsible for Ca2+ mobilisation following
activation, only P2X receptors directly mediate inward currents upon activation
(Nörenberg et al., 2010; Tolhurst et al., 2005). Therefore, to further study ATP responses
in canine and human P2X4 receptors in HEK293 cells, whole-cell inward currents were
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measured using a planar automated patch clamp (APC) electrophysiology system
(Milligan & Jiang, 2020). Robust inward currents were induced with a charge density of
21 ± 7 and 34 ± 16 pC/pF at 100 µM ATP in HEK293 cells transfected with the canine
(Figure 5.6A) or human P2X4 receptor (Figure 5.6B), respectively. In contrast, no ATPinduced currents were observed with up to 300 µM ATP in cells transfected with the
EmGFP vector alone (Figure 5.6C). Consistent with Ca2+ response data described above
(Figure 5.3E, F), ATP demonstrated similar potency at canine (pEC50 5.02 ± 0.11) and
human P2X4 receptors (pEC50 5.17 ± 0.10) when expressed in HEK293 cells (Figure
5.6D).

Figure 5.6. ATP-induced inward currents in HEK293 cells transfected with canine or
human P2X4 receptors. (A-D) Inward currents from HEK293 cells transfected with canine or
human P2X4-EmGFP, or EmGFP vector alone were measured by automated whole-cell patch
clamp electrophysiology. (A-C) Representative current traces in absence (0 µM; external
recording solution) or presence of ATP following ~1 s exposure (as indicated by black bar). (D)
ATP-induced normalised inward current presented as percent of maximum response to 1 mM
ATP, with data fit to the Hill equation to produce concentration-response curves. (A-D) Data
shown are mean ± SEM from eight (canine P2X4), six (human P2X4) or five (EmGFP)
independent experiments.
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5.2.6. Expression of canine and human P2X4 receptors in 1321N1 human
astrocytoma cells
Collectively, the above data suggests that the use of HEK293 cells as an expression
system for studying P2X4 receptor-mediated Ca2+ responses could be confounded by the
presence of endogenously expressed P2Y1 and P2Y2 receptors. As such, a 1321N1 human
astrocytoma cell line was utilised for studying Ca2+ responses from heterologously
expressed canine and human P2X4 receptors, as they have previously been shown to lack
functional P2 receptors (Bianchi et al., 1999). To first determine if these cells could
effectively express these P2X4 receptor expression constructs, 1321N1 cells were
transfected with canine or human P2X4-EmGFP, EmGFP vector alone, or mock
transfected, and the cells were analysed by western blotting and confocal microscopy.
Expression of a predicted 80 kDa EmGFP-bound P2X4 band was observed in lysates
from 1321N1 cells transfected with canine or human P2X4 receptors, following
incubation with an anti-P2X4 receptor antibody (Figure 5.7). In contrast, no P2X4
receptor expression was observed in cell lysates from 1321N1 cells that were transfected
with the EmGFP expression vector alone or mock transfected, despite equal protein
loading observed with actin (Figure 5.7).

Figure 5.7. Expression of canine and human P2X4 receptors in 1321N1 cells. 1321N1 cells,
transfected with canine or human P2X4-EmGFP, EmGFP plasmid DNA alone (EmGFP) or mock
transfected (Mock), were analysed by western blotting using an anti-P2X4 receptor antibody
(top panel) and anti-actin antibody (bottom panel) prior to imaging. Data representative of three
independent experiments.
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Consistent with expression and localisation in transfected HEK293 cells (Figure 5.2),
1321N1 cells transfected with canine and human P2X4-EmGFP, but not EmGFP vector
alone, revealed distinct vesicular subcellular localisation as determined by EmGFP
fluorescence (Figure 5.8, Appendix Figure A5.1). These vesicular compartments were
immunoreactive to LAMP1, consistent with the lysosomal sub-localisation revealed in
transfected HEK293 cells (Pearson’s coefficient = 0.735 and 0.610, respectively).

Figure 5.8. Expression and localisation of canine and human P2X4 receptors in 1321N1 cells.
1321N1 human astrocytoma cells, transfected with canine or human P2X4-EmGFP or pEmGFP
alone, were fixed, permeabilised and stained with anti-LAMP1 primary antibody and
PE-conjugated anti-mouse secondary antibody to label lysosomes. Cells were imaged by confocal
microscopy and co-localisation analysed by ImageJ. Images are representative results of three
independent experiments. Scale bar = 20 µm.

153

5.2.7. ATP, ADP and BzATP induce concentration-dependent Ca2+ responses in
1321N1 cells transfected with canine or human P2X4 receptors
The above data determined that canine and human P2X4 receptors could be
heterologously expressed in 1321N1 cells, with a similar pattern of expression to that
observed in HEK293 cells (Figure 5.1 and Figure 5.2). To determine and compare canine
and human P2X4 receptor activity, agonist-induced Ca2+ responses were recorded in
1321N1 cells transfected with canine or human P2X4-EmGFP, or EmGFP vector alone.
Consistent with observations in HEK293 cells (Figure 5.3), incubation of 1321N1 cells
transfected canine or human P2X4-EmGFP with ATP, ADP or BzATP induced rapid
Ca2+ responses which peaked within 10-30 s of application of nucleotide and were
followed by a slowly declining, sustained phase (Figure 5.9A-C). Minimal responses
were observed upon addition of ECS vehicle alone (Figure 5.9D).
ATP was the most potent agonist of the canine P2X4 receptor in 1321N1 cells
(pEC50 6.59 ± 0.13), evoking a concentration-dependent Ca2+ response with maximal
activity at 10 µM (Figure 5.9E). Likewise, ATP produced a similar response in 1321N1
cells expressing the human P2X4 receptor (Figure 5.9F; pEC50 6.72 ± 0.06). ADP induced
a less potent concentration-dependent response in 1321N1 cells expressing canine or
human P2X4 receptors, with maximal response occurring near 100 µM (Figure 5.9E, F;
pEC50 5.02 ± 0.14 and 5.20 ± 0.15, respectively). Consistent with observations in
HEK293 cells, BzATP induced ATP-like Ca2+ responses in 1321N1 cells transfected with
the human P2X4 receptor, with reduced potency compared to ATP (Figure 5.9F;
pEC50 4.72 ± 0.18). BzATP however, had very little effect on the Ca2+ response in
1321N1 cells expressing the canine P2X4 receptor (Figure 5.9E; pEC50 3.60 ± 0.13).
Addition of nucleotides to 1321N1 cells transfected with EmGFP vector alone induced
minimal Ca2+ responses (Figure 5.9A-C), which were similar to those observed in absence
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of nucleotide for P2X4 receptors and EmGFP vector transfected cells (Figure 5.9A-D).

Figure 5.9. Ca2+ response agonist profile in 1321N1 cells transfected with canine or human
P2X4 receptors. (A-F) 1321N1 cells, transfected with canine or human P2X4-EmGFP, or
EmGFP vector alone, were loaded with Fura-2 and incubated in absence or presence of each
nucleotide (as indicated). (A-C) Ca2+ traces (ΔF340/380) for each nucleotide at indicated maximal
concentration or (D) ECS vehicle control. (E-F) Nucleotide-induced peak ΔCa2+ response are
presented as percent of maximum response to 10 µM ATP with data fit to the Hill equation to
produce concentration-response curves. (A-F) Data shown are mean ± SEM from five
independent experiments.
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5.2.8. ADP-induced Ca2+ responses in 1321N1 cells transfected with canine or
human P2X4 receptors are a result of ATP contaminants in ADP stocks
The above results (Figure 5.3 and Figure 5.9) suggest that ADP is an agonist of canine
and human P2X4 receptors, however previous characterisation of the human P2X4
receptor determined that ADP concentrations up to 100 µM ADP failed to induce a
significant response (Garcia-Guzman et al., 1997). Studies have demonstrated that
commercial ADP stocks may contain small contaminating amounts of ATP, therefore
ADP (and ATP as control) was pre-treated with hexokinase to remove contaminating
ATP as previously described (Micklewright et al., 2018). Hexokinase-treatment of ADP
significantly reduced Ca2+ responses in 1321N1 cells transfected with canine or human
P2X4 receptors (Figure 5.10A, B). Therefore, despite previously observing ADP-induced
Ca2+ responses in both HEK293 and 1321N1 cells transfected with canine and human
P2X4 receptors, this data confirms that ADP is not an agonist of human P2X4 and
furthermore, demonstrates that the canine P2X4 receptor is also not activated by ADP.

5.2.9. Ivermectin positively modulates ATP-induced Ca2+ responses in 1321N1 cells
transfected with canine or human P2X4 receptors
The positive modulation of human P2X4 receptor activity by ivermectin is well
established (Layhadi et al., 2018; Priel & Silberberg, 2004; Samways et al., 2012). To
determine whether ivermectin can positively modulate canine P2X4 receptor activity,
1321N1 cells transfected with canine or human P2X4 receptors were incubated in the
absence or presence of 3 µM ivermectin, then activated with increasing concentrations of
ATP and agonist-induced Ca2+ responses were measured. Pre-incubation with ivermectin
resulted in increased peak and sustained Ca2+ responses in 1321N1 cells transfected with
canine (Figure 5.11A, B) or human P2X4 receptors (Figure 5.11D, E) compared to ATP
in absence of ivermectin (0.1% dimethyl sulfoxide (DMSO)). Significant peak Ca2+
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Figure 5.10. Ca2+ response profile of hexokinase-treated ADP in 1321N1 cells transfected
with canine or human P2X4 receptors. (A, B) 1321N1 cells, transfected with canine or human
P2X4-EmGFP, were loaded with Fura-2 and incubated in absence or presence nucleotide. ADP
and ATP were pre-incubated with hexokinase (Hex; 4.5 U.mL-1) for 1 hr at 37°C prior to addition.
Nucleotide-induced peak ΔCa2+ response are presented as percent of maximum response to 10
µM with data fit to the Hill equation to produce concentration-response curves. Data shown are
mean ± SEM from five independent experiments. *P < 0.05 compared to ADP in absence of
hexokinase using a two-way ANOVA with Bonferroni post hoc test.

potentiation was observed at 0.1 µM and 0.3 µM ATP for both canine (Figure 5.11C) and
human P2X4 receptors (Figure 5.11F). Ivermectin treatment also potentiated peak Ca2+
responses (but failed to reach significance) at concentrations of 1 µM ATP and higher in
1321N1 cells expressing canine or human P2X4 receptors (Figure 5.11C, F). Collectively,
ivermectin demonstrated a significant 2.9-fold decrease in EC50 of ATP for the canine
P2X4 receptor (Table 5.1; ivermectin pEC50 6.98 ± 0.05 vs. DMSO pEC50 6.52 ± 0.12)
and a significant 1.7-fold decrease in the EC50 of ATP for the human P2X4 receptor
(ivermectin pEC50 6.91 ± 0.13 vs. DMSO pEC50 6.69 ± 0.07).
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Figure 5.11. Positive modulation of ATP-induced Ca2+ responses by ivermectin in 1321N1
cells transfected with canine or human P2X4 receptors. (A-F) 1321N1 cells, transfected with
canine or human P2X4-EmGFP, were loaded with Fura-2 and pre-incubated in the absence
(0.1% DMSO in ECS) or presence of 3 µM ivermectin for 20 min. Cells were incubated in the
absence or presence of increasing concentrations of ATP. Ca2+ traces of indicated concentrations
of ATP in (A, D) absence or (B, E) presence of ivermectin. (C, F) ATP-induced ΔCa2+ responses
presented as percent of maximum response to 10 µM ATP in absence of ivermectin, with data fit
to the Hill equation to produce concentration-response curves. (A-F) Data are mean ± SEM from
five independent experiments. *P < 0.05 compared to respective ATP concentration in absence
of ivermectin using a two-way ANOVA with Bonferroni post hoc test.

5.2.10. Ivermectin positively modulates ATP-induced inward currents on the canine
P2X4 receptor in HEK293 cells
To further demonstrate that ivermectin positively modulates canine P2X4 receptor
activity, ATP-induced inward currents were recorded in HEK293 cells transfected with
the canine P2X4 receptor. Preliminary data indicated that HEK293 cells produced more
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consistent and larger currents compared to 1321N1 cells (results not shown), most likely
due to percent transfection efficiency. Therefore, HEK293 cells were used to study the
effect of ivermectin on P2X4 receptor-mediated currents. Pre-incubation of 1 µM
ivermectin with HEK293 cells transfected with the canine P2X4 receptor evoked
increased peak inward currents with markedly reduced desensitisation kinetics compared
to those in absence of ivermectin (Figure 5.12A, B). This resulted in significant 2.0- to
2.5-fold increases in charge density compared cells transfected with the canine P2X4
receptor in the absence of ivermectin (P < 0.05, Student’s t-test). Together, this data and
that above suggest that ivermectin positively modulates canine P2X4 receptor activity
through both inward currents and Ca2+ mobilisation and further supports previous
findings that ivermectin positively modulates human P2X4 receptor activity (Priel &
Silberberg, 2004; Stokes & Surprenant, 2009).

Figure 5.12. Positive modulation of ATP-induced inward currents by ivermectin in HEK293
cells transfected with the canine P2X4 receptor. (A, B) Inward currents from HEK293 cells
transfected with canine P2X4-EmGFP were measured by automated whole-cell patch clamp
electrophysiology. HEK293 cells were resuspended in standard external solution and bathed in
(A) absence (vehicle; 0.1% DMSO) or (B) presence of 1 µM ivermectin for 10 min prior to
recording current. Recordings were taken in absence (0 µM; external recording solution) or
presence of ATP following ~1 s exposure, in the absence or presence of ivermectin (as indicated
by black bars). Data are representative traces from five independent experiments. Data in (A) are
the full 5 s scale traces presented in Figure 5.6A for comparison of current amplitude and
desensitisation in absence of ivermectin.
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5.2.11. Non-selective antagonists of P2X4 receptors, duloxetine, paroxetine and
TNP-ATP inhibit ATP-induced Ca2+ responses in 1321N1 cells transfected with
canine or human P2X4 receptors
To determine if ATP-induced Ca2+ responses mediated by the canine P2X4 receptor could
be inhibited non-selective antagonists of human or rodent P2X4 receptors; duloxetine
(Yamashita et al., 2016), paroxetine (Nagata et al., 2009) or TNP-ATP (Balazs et al.,
2013), 1321N1 cells transfected with canine or human P2X4 receptors were pre-incubated
with each antagonist then incubated with ATP. Duloxetine demonstrated similar
concentration-dependent inhibition of ATP-induced Ca2+ responses in 1321N1 cells
transfected with canine or human P2X4 receptors (Figure 5.13A-C; pIC50 4.82 ± 0.20 and
4.77 ± 0.18, respectively). Paroxetine demonstrated concentration-dependent inhibition
of ATP-induced Ca2+ responses (Figure 5.13D-F; pIC50 4.88 ± 0.13 and 4.11 ± 0.20,
respectively) which was significantly more potent at the canine P2X4 receptor compared
to the human P2X4 receptor (Table 5.1). Meanwhile, TNP-ATP demonstrated similar
concentration-dependent inhibition of ATP-induced Ca2+ responses in 1321N1 cells
transfected with canine or human P2X4 receptors (Figure 5.13G-I; pIC50 5.09 ± 0.27 and
5.36 ± 0.24, respectively), although somewhat greater potency compared to duloxetine
and paroxetine (Figure 5.13C, F, I, Table 5.1).
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Figure 5.13. ATP-induced Ca2+ response profile of non-selective P2X receptor antagonists
in 1321N1 cells transfected with canine or human P2X4 receptors. (A-I) 1321N1 cells,
transfected with canine or human P2X4-EmGFP, were loaded with Fura-2 and incubated in
absence (ECS alone or 1% DMSO in ECS) or presence of increasing concentrations of (A-C)
duloxetine, (D-F) paroxetine or (G-I) TNP-ATP for 20 min and then exposed to 0.75 µM ATP
(approximate to the EC80 of ATP). Representative ΔCa2+ traces in absence or presence of
antagonists at (A, D, G) canine and (B, E, H) human P2X4 receptors. (C, F, I) ATP-induced ΔCa2+
responses are presented as percent of maximum response to 10 µM ATP in the absence of
antagonists, with data fit to the Hill equation to produce concentration-response curves. Data
points indicate the mean ± SEM from five independent experiments.
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5.2.12. Selective antagonists of P2X4 receptors, BX430 and 5-BDBD inhibit ATPinduced Ca2+ responses in 1321N1 cells transfected with canine or human P2X4
receptors
Despite demonstrating pharmacological blockade of canine P2X4 receptor Ca2+
responses, the previously described antagonists do not demonstrate selectivity for the
P2X4 receptor over other targets (Stokes et al., 2017). Therefore, to determine if a
selective P2X4 receptor antagonist could block canine P2X4 receptor activity, 1321N1
cells transfected with canine or human P2X4 receptors were pre-incubated with the
selective P2X4 receptor antagonists, BX430 (Ase et al., 2015) or 5-BDBD (Balazs et al.,
2013), then incubated with ATP. Both BX430 (Figure 5.14A-C) and 5-BDBD
(Figure 5.14D-F) demonstrated concentration-dependent inhibition of canine and human
P2X4 receptors. Notably, 5-BDBD displayed similar efficacy against both species
(Figure 5.14C; pIC50 5.24 ± 0.24 and 5.28 ± 0.36, respectively). In contrast, BX430 was
significantly more potent against the human P2X4 receptor compared to the canine P2X4
receptor (Figure 5.14F; pIC50 5.71 ± 0.08 and pIC50 5.11 ± 0.06, respectively) and was
more effective against the human P2X4 receptor, with maximal inhibition of ~80% (at
10 µM BX430) compared to ~50% maximal inhibition (at 100 µM BX430) against the
canine P2X4 receptor (Figure 5.14F, Table 5.1).
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Figure 5.14. ATP-induced Ca2+ response profile of selective P2X4 antagonists in 1321N1
cells transfected with canine or human P2X4 receptors. (A-F) 1321N1 cells, transfected with
canine or human P2X4-EmGFP, were loaded with Fura-2 and incubated in absence (1% DMSO
in ECS) or presence of increasing concentrations of (A-C) BX430 or (D-F) 5-BDBD for
20 min and then exposed to 0.75 µM ATP (approximate to the EC80 of ATP). Representative
ΔCa2+ traces in absence or presence of antagonists at (A, D) canine and (B, E) human P2X4
receptors. (C, F) ATP-induced ΔCa2+ responses are presented as percent of maximum response to
10 µM ATP in the absence of antagonists, with data fit to the Hill equation to produce
concentration-response curves. Data points indicate the mean ± SEM from five independent
experiments.

5.2.13. The P2X4 antagonist 5-BDBD displays a competitive mode of inhibition in
1321N1 cells transfected with canine or human P2X4 receptors
The above data suggests that the selective P2X4 receptor antagonist, 5-BDBD, can inhibit
the canine P2X4 receptor with similar potency and effectiveness compared to the human
P2X4 receptor, making it a strong candidate for future studies of uncharacterised P2X4
receptor orthologues. Therefore, to further assess the mechanism of inhibition of
5-BDBD, 1321N1 cells transfected with canine or human P2X4 receptors were
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pre-incubated with 30 µM 5-BDBD and then with maximal concentrations of the P2X4
receptor agonists, ATP and BzATP. Despite inhibiting ATP-induced Ca2+ responses at
the approximate EC80 of ATP (0.75 µM ATP, Figure 5.14F), 30 µM 5-BDBD failed to
reduce canine or human P2X4 receptor-mediated Ca2+ responses at a saturating
concentration of 10 µM ATP (Figure 5.15A). In contrast, pre-incubation of 1321N1 cells
transfected with canine or human P2X4 receptors with 30 µM 5-BDBD resulted in a
significant reduction (81 ± 8% and 48 ± 7% reduction, respectively) in Ca2+ response
evoked by 300 µM BzATP (Figure 5.15B). Together this data suggests that 5-BDBD is a
more potent inhibitor of P2X4 receptors at sub-saturating concentrations of ATP, for both
canine and human P2X4 receptors, which is consistent with a competitive mode of
inhibition. However, BzATP at 300µM was effectively blocked by 5-BDBD and likely
requires much higher concentrations (>300 µM) to provide binding site saturation.

Figure 5.15. Inhibitory effect of 5-BDBD at maximal P2X4 receptor agonist concentrations
in 1321N1 cells transfected with canine or human P2X4 receptors. (A, B) 1321N1 cells,
transfected with canine or human P2X4-EmGFP, were loaded with Fura-2, pre-incubated in the
absence (0.3% DMSO in ECS) or presence of 30 µM 5-BDBD for 20 min and then incubated
with maximal or near maximal concentrations of (A) ATP or (B) BzATP, respectively. Data were
plotted as a percentage of the maximal response to 10 µM ATP in the absence of antagonist. Data
are presented as the mean ± SEM from six independent experiments. *P < 0.05 compared to
nucleotide alone using a parametric Student’s t-test.

164

Table 5.1. Pharmacological activity of compounds mediating changes in intracellular Ca2+
in 1321N1 cells expressing canine or human P2X4 receptors.
Canine P2X4
pEC50 or pIC50
Agonists (pEC50)a
ATP
BzATP
ADPb
Modulators (pEC50)c
Ivermectin
ATP
Antagonists (pIC50)d
BX430
5-BDBD
Duloxetine
Paroxetine
TNP-ATP

Hill
coefficient

Human P2X4
pEC50 or pIC50

Hill
coefficient

6.59 ± 0.13
3.44 ± 0.13e f (41%)
N.R (<10%)

1.89
1.72
-

6.72 ± 0.06
5.04 ± 0.26f (92%)
N.R. (<10%)

1.59
1.68
-

6.98 ± 0.05f (111%)
6.52 ± 0.12

1.60
2.09

6.91 ± 0.13f (137%)
6.69 ± 0.07

1.85
1.66

5.11 ± 0.06e (43%)
5.24 ± 0.24 (53%)
4.82 ± 0.20 (13%)
4.88 ± 0.13e (28%)
5.09 ± 0.27 (18%)

1.65
0.89
1.00
0.76
1.00

5.71 ± 0.08 (29%)
5.28 ± 0.36 (54%)
4.77 ± 0.18 (13%)
4.11 ± 0.20 (37%)
5.36 ± 0.24 (8%)

1.29
0.99
1.00
0.84
1.00

Abbreviations; N.R., negligible response (pEC50 not calculated).
aValues in parentheses indicate the percent of maximum response compared to 10 µM ATP.
bADP in the presence of hexokinase to remove contaminating ATP.
cpEC of ATP in the absence or presence of 3 µM ivermectin; values in parentheses indicate the percent of response
50
compared to 10 µM ATP.
dpIC of antagonists calculated using the approximate pEC of ATP (0.75 µM); values in parentheses indicate the
50
80
percent of response in the presence of 100 µM antagonist compared to maximum ATP in absence of antagonist.
eP < 0.05 compared to the pEC/IC of respective compound at human P2X4 receptor (Student’s t-test).
50
fP < 0.05 compared to ATP alone for corresponding P2X4 receptor (Mann-Whitney U test for agonists and
ivermectin, Student’s t-test for antagonists). Data are mean ± SEM from five independent experiments.

5.3.

Discussion

This chapter described the expression and pharmacology of the canine P2X4 receptor,
which until now had remained uncharacterised. The data presented in this chapter
indirectly supports the expression of a functional P2X4 receptor in dogs and demonstrates
pharmacological similarities to the human P2X4 receptor in vitro through both
electrophysiological recordings and Ca2+ response assays. These functional similarities
are further supported by similarities in lysosomal sub-cellular localisation. Notable
differences between canine and human P2X4 receptors were observed however, including
reduced sensitivity to BzATP, and the selective P2X4 receptor antagonist BX430, for the
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canine P2X4 receptor, observations of which have been reported for rodent P2X4
receptors (Abdelrahman et al., 2017; Ase et al., 2019).
Consistent with previous reports on other mammalian P2X4 receptor orthologues (Ase et
al., 2019; Garcia-Guzman et al., 1997; Jones et al., 2000; Soto et al., 1996), ATP was an
agonist of the canine P2X4 receptor, with EC50 values similar to those previously
published for the human P2X4 receptor (Jones et al., 2000; Layhadi et al., 2018). Given
the high sequence similarity to the human P2X4 receptor (~90%) and complete
conservation of amino acid residues involved in ATP-binding across the P2X4 receptor
orthologues that have been cloned and characterised to date (Chataigneau et al., 2013;
Jiang, Rassendren, et al., 2000; Roberts et al., 2008), the response to ATP was not
unexpected. BzATP was identified as a partial agonist of the canine P2X4 receptor,
although with greatly reduced sensitivity compared to the human P2X4 receptor. This
reduced sensitivity to BzATP at the canine P2X4 receptor is in agreement with previous
reports of BzATP at the rat P2X4 receptor, where the EC50 was >100 µM (Abdelrahman
et al., 2017). In addition, this chapter confirms data from previous studies reporting
BzATP as a partial agonist of the human P2X4 receptor (Abdelrahman et al., 2017;
Bianchi et al., 1999; He et al., 2003). Although the reasons for these differences in BzATP
sensitivity were not further explored in-depth in this chapter, they may likely be attributed
to variations in BzATP-sensitive amino acids (Browne et al., 2010; Pasqualetto et al.,
2018; Tvrdonova et al., 2014). This could lead to a shift in equilibrium of open and closed
channel conformations in the BzATP-bound state, as previously observed with α,βmethylene ATP bound to the zebrafish P2X4 receptor (Minato et al., 2016).
ADP was originally determined to have no activity at the human P2X4 receptor (GarciaGuzman et al., 1997), however there have been conflicting reports since reporting partial
agonistic responses (Bianchi et al., 1999; Carpenter et al., 1999; He et al., 2003). ATP
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contamination of commercially available ADP stocks has been suggested to contribute to
discrepancies in agonist-induced responses of P2X receptors (Mahaut-Smith et al., 2000).
As such, using hexokinase to remove any contaminating ATP, this chapter explored
whether ATP contamination contributed to the observed ADP-induced responses at
canine and human P2X4 receptors. Accordingly, it was determined that ADP is not an
agonist of the canine P2X4 receptor as originally reported for the human P2X4 receptor
(Garcia-Guzman et al., 1997). This result was only explored in 1321N1 cells and not in
HEK293 cells, as it has been demonstrated that HEK293 cells express ADP-responsive
P2Y1 receptors (Fischer et al., 2005; Schachter et al., 1997) which would result in
ADP-induced responses through P2Y1-activated Ca2+ mobilisation. This however,
supports data presented in this chapter that ADP-induced Ca2+ responses in HEK293 cells
were only partially reduced by the P2Y1-selective inhibitor, MRS2179, suggesting
contamination by ATP likely triggered P2Y2-mediated Ca2+ mobilisation, preventing
complete inhibition by MRS2179.
It is reported here that ivermectin is a positive modulator of the canine P2X4 receptor.
Significant increases in the efficacy of ATP-induced Ca2+ responses at canine and human
P2X4 receptors were observed in 1321N1 cells. Furthermore, treatment with ivermectin
increased peak inward currents and reduced desensitisation kinetics in HEK293 cells
transfected with the canine P2X4 receptor. This data is consistent with previous reports
that ivermectin positively modulates human P2X4 receptor responses (Layhadi et al.,
2018; Priel & Silberberg, 2004; Samways et al., 2012) and is supported by conservation
of amino acid residues in P2X4 receptors from both species involved in the recognition
and binding of ivermectin (Jelinkova et al., 2006; Popova et al., 2013).
This chapter demonstrates that three non-selective P2X4 receptor-targeting compounds,
duloxetine, paroxetine and TNP-ATP, can inhibit the canine P2X4 receptor. Duloxetine
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and paroxetine are clinically prescribed anti-depressants which have also been reported
to alleviate chronic neuropathic pain in rats (Iyengar et al., 2004; Zarei et al., 2014) and
humans (Patetsos & Horjales-Araujo, 2016; Sindrup et al., 2005). Inhibition of the P2X4
receptor by duloxetine and paroxetine has only come to light in recent years (Nagata et
al., 2009; Yamashita et al., 2016) and continued research regarding their mechanism of
P2X4 receptor antagonism have been limited. Consistent with these previous studies
however, both compounds effectively blocked ATP-induced Ca2+ responses at canine and
human P2X4 receptors, although at relatively high concentrations (>100 µM). It is
understood that paroxetine can cause Ca2+ release from intracellular stores (Fang et al.,
2011; Pan et al., 2010) and this may contribute to desensitisation of P2X4
receptor-mediated Ca2+ flux, however given the lack of selectivity of paroxetine for P2X4
receptors, this was not further examined in this chapter.
Results from this chapter reveal that two known selective inhibitors of human or rodent
P2X4 receptors, BX430 and 5-BDBD, can also inhibit the canine P2X4 receptor. The
phenylurea BX430 demonstrated moderately potent inhibition of the canine P2X4
receptor, although had a four-fold greater IC50 compared to the human P2X4 receptor.
This difference in BX430 efficacy is consistent with previously reported species-selective
differences, where potent inhibition of ATP-induced responses were observed at human
and bovine P2X4 receptors, moderate inhibition observed at zebrafish and Xenopus P2X4
receptors and no inhibition observed at mouse or rat P2X4 receptors (Ase et al., 2015;
Ase et al., 2019). Variation in the ability of BX430 to bind and inhibit the P2X4 receptor
has been attributed to a single amino acid residue (Ile312 human numbering) which forms
a docking site with Asp88 and Tyr300 and appears to play a crucial role in dictating
sensitivity to BX430. However, all three amino acid residues are conserved in the canine
P2X4 receptor indicating that other amino acid residues may also contribute to the
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reduced sensitivity of this receptor to BX430.
In contrast, the benzodiazepine derivative 5-BDBD inhibited canine and human P2X4
receptors with similar potency but limited effectiveness compared to the other inhibitors.
This is consistent with previous reports of moderately potent inhibition of human or
rodent P2X4 receptors by 5-BDBD (Abdelrahman et al., 2017; Ase et al., 2015; Balazs et
al., 2013; Coddou et al., 2019). Furthermore, data from this chapter suggests that the
mechanism of inhibition of 5-BDBD at the P2X4 receptor is of a competitive nature,
consistent with previous reports of allosteric inhibitors which demonstrate competitive
binding properties at the human P2X4 receptor (Abdelrahman et al., 2017; Balazs et al.,
2013). Nonetheless, it is evident that BX430 and 5-BDBD lack potency and efficacy, and
given the strong associations arising between the P2X4 receptor and disease, this
highlights the urgency to identify more potent, selective P2X4 receptor antagonists.
Finally, it is reported here that heterologously expressed canine P2X4 receptor localised
to intracellular compartments of 1321N1 and HEK293 cells, which closely mimicked that
observed for the human P2X4 receptor. Consistent with studies on the sub-cellular
localisation of human and rodent P2X4 receptors (Huang et al., 2014; Stokes &
Surprenant, 2009), the canine P2X4 receptor co-localised with LAMP1-labelled
lysosomes. The presence of the canine P2X4 receptor within the endo-lysosomal pathway
is further supported by the conservation of di-leucine (L22I23) and tyrosine-based
(Y372xxV and Y378xxGL) endo-lysosomal targeting motifs (Qureshi et al., 2007).
In conclusion, this chapter demonstrates that a functional canine P2X4 receptor can be
heterologously expressed in mammalian cell lines with similar patterns of expression to
the human P2X4 receptor. The canine P2X4 receptor demonstrated similarities to the
human P2X4 receptor in response to ATP, ivermectin and antagonists such as 5-BDBD,
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TNP-ATP and duloxetine. Notable pharmacological differences were observed however,
between canine and human P2X4 receptors for BzATP and BX430. This chapter supports
evidence that the canine P2X4 receptor may play a role in mediating cellular responses
similar to that in humans and may therefore be important in diseases such as chronic pain,
inflammation and neurodegeneration. This chapter highlights the need to further develop,
identify and characterise more potent, effective and selective P2X4 receptor compounds
for research and clinical applications.
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Chapter 6: Characterisation of P2 receptor signalling
pathways in the DH82 canine macrophage cell line
6.1.

Introduction

DH82 cells are a canine macrophage cell line isolated from a 10 year old Golden Retriever
with malignant histiocytosis (Wellman et al., 1988). This cell line has demonstrated
macrophage-like physiology, with studies demonstrating the expression of macrophage
markers such as CD11c and CD18 (Heinrich et al., 2015), and the secretion of tumour
necrosis factor (TNF)-α and IL-6 similar to that observed in lipopolysaccharide (LPS)stimulated canine monocytes (Barnes et al., 2000). Recent developments have
demonstrated that DH82 cells can also be differentiated towards M1 (via LPS and
interferon γ stimulation) or M2a macrophage subtypes (via IL-4 and IL-13 stimulation)
(Herrmann et al., 2018), making DH82 cells a suitable in vitro model of canine
macrophages.
Purinergic receptors, such as P2X4, P2X7 and P2Y2 receptors, are commonly expressed
on human and rodent macrophages (Higgins et al., 2014; Layhadi & Fountain, 2019;
Layhadi et al., 2018; Stokes & Surprenant, 2007) where they have been demonstrated to
modulate signalling pathways that control chronic pain and inflammation in mice
(Chessell et al., 2005; Ulmann et al., 2010). While direct evidence of P2 receptors in
DH82 cells is yet to be published, it has been demonstrated that treatment of
LPS-stimulated DH82 cells with ATP, the primary endogenous agonist of canine P2X4
and P2X7 receptors (Chapter 4; Roman et al., 2009), results in reduced TNF-α and IL-6
expression (Fujimoto et al., 2012). Furthermore, infection of DH82 cells with canine
distemper virus has been shown to modulate inflammatory signalling pathways common
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to P2X7 receptor-mediated signalling (Zheng et al., 2020), suggesting a possible role for
endogenous purinergic signalling in this canine macrophage cell line.
The use of human and mouse cell lines with pro-monocytic or macrophage-like
physiology, such as U937, THP-1 or RAW264.7 cells, has allowed for the study of
endogenous P2 receptors (Ase et al., 2015; Honore et al., 2009; Humphreys et al., 1998;
Layhadi & Fountain, 2017; Micklewright et al., 2018; Muzzachi et al., 2013; Tu et al.,
2017; Zhang, Hao, et al., 2019). Therefore, this chapter aimed to determine the functional
expression of P2 receptors in DH82 canine macrophages and pharmacologically
characterise their P2 receptor-mediated Ca2+ signalling pathways.

6.2.

Results

6.2.1. DH82 cells express messenger RNA for multiple P2 receptors
DH82 cells are a potential model for studying endogenous purinergic signalling in canine
macrophages (Fujimoto et al., 2012) but have not been studied further in this context since
this report. To establish the P2 receptor messenger RNA (mRNA) expression profile for
DH82 cells, RNA was isolated from cells and complimentary DNA (cDNA) was obtained
by reverse transcription polymerase chain reaction (RT-PCR). Primers designed to canine
P2X1-7 receptors and canine P2Y1, 2, 4, 6, 11-14 (obtained from the Ensembl CanFam3.1
database https://asia.ensembl.org/Canis_familiaris/Info/Index) were used to amplify
canine P2 receptor cDNA by RT-PCR. P2X4 receptor mRNA was most abundantly
detected in DH82 cells, with relative levels comparable to GAPDH mRNA (Figure 6.1A,
B). Other P2X receptor mRNAs, including P2X1 and P2X7 receptors were detected,
although to a much lesser degree than the P2X4 receptor (Figure 6.1A, B). Additionally,
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mRNA from a number of P2Y receptor subtypes were also detected, including P2Y1,
P2Y2, P2Y6, and P2Y11 receptors, however, similar to P2X1 and P2X7 receptors, these
were expressed at a greatly reduced level compared to P2X4 receptors (Figure 6.1A, C).
Amplicons were also compared to a β-actin housekeeping gene with similar results
(results not shown).

Figure 6.1. mRNA expression of P2X and P2Y receptors in DH82 cells. (A-C) RNA was
isolated from DH82 cells and cDNA was synthesised and amplified using primer pairs designed
to each respective P2RX or P2RY genes, with GAPDH as a positive control. Amplification in
absence of cDNA (control) was conducted for each primer pair to ensure specificity of primers.
Amplicons were visualised by agarose gel electrophoresis using GelRed and the GelDoc XR+
imaging system. Amplicon sizes (in base pairs) are listed in Table 2.6. (B, C) Semi-quantification
of (B) P2X and (C) P2Y receptor amplicons relative to GAPDH. (A) Representative images and
(B,C) data shown (mean ± SEM) from three independent experiments.
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6.2.2. ATP and UTP induce concentration-dependent Ca2+ responses in DH82 cells,
while ADP and BzATP induce partial responses
To determine the agonist profile of functional P2 receptors in DH82 cells, nucleotides
known to activate P2 receptors from dogs, humans or rodents (Alexander et al., 2019;
Jacobson et al., 2020) were utilised to measure changes in intracellular Ca2+. Incubation
with ATP or UTP induced robust Ca2+ responses which peaked within 15 s of application
of nucleotide (Figure 6.2A, B). This peak was followed by a decay phase that declined
significantly faster compared to ATP-induced Ca2+ responses from heterologously
expressed canine P2X4 receptors observed in the previous chapter (Figure 5.3A, Figure
5.8A, Appendix Figure A6.1). These responses eventually returned to baseline
approximately 70-80 s after peak nucleotide-induced ΔF340/380 was observed (Figure
6.2A, B). ADP and BzATP induced smaller Ca2+ responses compared to ATP and UTP
(Figure 6.2C, D). UDP and 2MeSADP were unable to induce Ca2+ responses up to 30 µM
and 100 µM, respectively (Figure 6.2E, F). Decay time, calculated as the time constant
(τ), was similar for ATP and UTP (τ = 56.9 ± 4.8 s and 56.7 ± 5.9 s, respectively), however
BzATP (τ = 102.3 ± 17.9 s) had a significantly longer decay time compared to ATP (P <
0.05), UTP (P < 0.05) or ADP (τ = 23.8 ± 0.4 s; P < 0.001), while UDP and 2MeSADP
did not respond and as such, decay time could not be calculated (Figure 6.2G).
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Figure 6.2. Nucleotide-induced Ca2+ response profiles in DH82 cells. (A-I) DH82 cells in
extracellular Ca2+ solution (ECS) were loaded with Fura-2, incubated in the absence (basal) or
presence of each nucleotide (as indicated) and Fura-2 fluorescence was recorded. Ca2+ traces
(ΔF340/380) for (A) 100 µM ATP (n=6), (B) 30 µM UTP (n=3), (C) 100 µM ADP (preincubated
with 4.5 U. mL-1 hexokinase for 1 hr at 37°C) (n=3), (D) 300 µM BzATP (n=3), (E) 30 µM UDP
(n=3) and (F) 100 µM 2MesADP (n=3). (G) One phase decay time (τ) calculated from the peak
of each Ca2+ trace, ND = no data. (H) Peak nucleotide-induced Ca2+ responses and (I) net Ca2+
movement were fit to the Hill equation to produce concentration-response curves (n values
correspond to respective individual traces above). (A-I) Data shown are mean ± SEM from three
to six independent experiments as indicated for each nucleotide. (G) *P < 0.05 and ***P < 0.001
between nucleotides as indicated analysed using a one-way ANOVA with Bonferroni post hoc
test.
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As Ca2+ responses were observed with a number of nucleotides, including those known
to activate mammalian ionotropic P2X (ATP, BzATP) and metabotropic P2Y receptors
(ATP, UTP, ADP), nucleotide-induced peak ΔF340/380 Ca2+ responses (Figure 6.2H)
and net Ca2+ movement (Figure 6.2I; calculated as area under the curve [AUC]) were both
used for constructing concentration-response curves where appropriate throughout this
chapter. This demonstrates potential differences in Ca2+ response phenotype (fast decay
vs slower sustained decay) to account for the possibility of co-expression of both P2X
and P2Y receptor subtypes in DH82 cells. Nucleotides induced concentration-dependent
Ca2+ responses with the rank order of potency of UTP > ATP >> ADP ≈ BzATP, with
UDP and 2MesADP being unresponsive (Figure 6.2H, I; Table 6.1). There were no
significant differences between the EC50 values calculated for net Ca2+ movement and
peak Ca2+ response for any nucleotide (Table 6.1).

Table 6.1. Nucleotide-induced changes in intracellular Ca2+ in DH82 cells.
Net Ca2+ movement (AUC)
Nucleotide

ATP
UTP
a

ADP

BzATP
UDP

Peak Ca2+ response

pEC50

Hill
coefficient

pEC50

Hill
coefficient

5.92 ± 0.09 (100%)

1.43

5.88 ± 0.05 (100%)

0.99

6.26 ± 0.12 (69.1%)

1.71

6.16 ± 0.09 (65.9%)

1.02

4.07 ± 0.21 (19.9%)b

1.00

4.03 ± 0.30 (26.4%)b

1.47

< 4.00 (20.5%)
NR (<10%)

c

2.66
-

< 4.00 (12.1%)
NR (<10%)

c

2.26
-

2MeSADP
NR (<10%)
NR (<10%)
Abbreviations: AUC, area under the curve; NR, negligible response (pEC50 not calculated).
a
ADP in the presence of hexokinase to remove contaminating ATP.
b
P < 0.05 compared to the respective pEC50 of ATP and UTP.
c
P < 0.01 compared to the respective pEC50 of ATP and UTP.
Data are mean ± SEM from three to six independent experiments (as per Figure 6.2). Values in
parentheses indicate the percent of each maximum agonist response compared to 100 µM ATP. All
statistical comparisons by one-way ANOVA.
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6.2.3. The non-selective P2X receptor antagonist, TNP-ATP, reduces net Ca2+
movement in DH82 cells
The above data demonstrated that DH82 cells express mRNA of a number of P2X
receptors (Figure 6.1), while agonists of these receptors induced Ca2+ responses (Figure
6.2). To determine if P2X receptors were mediating these Ca2+ responses, DH82 cells
were preincubated with the non-selective P2X receptor antagonist, TNP-ATP (Virginio
et al., 1998), then activated with ATP. Preincubation with 50 µM TNP-ATP partially
reduced Ca2+ responses mediated by 10 µM ATP, however, little to no effect was
observed at 1 µM or 100 µM ATP (Figure 6.3A-C). This was supported by a significant

Figure 6.3. ATP-induced Ca2+ responses in DH82 cells in the absence or presence of TNPATP. (A-F) DH82 cells in ECS were loaded with Fura-2 and preincubated in the absence (ATP
alone) or presence of 50 µM TNP-ATP (in ECS) for 5 min. Cells were then exposed to increasing
concentrations of ATP and Fura-2 fluorescence was recorded. ATP-induced (D) peak Ca2+
response and (E) net Ca2+ movement were fit to the Hill equation to produce concentrationresponse curves. (F) One phase decay time (τ) calculated from the peak of each Ca2+ trace in AC. (A-F) Data shown are mean ± SEM from four independent experiments. (D-F)

**

P < 0.01

compared to respective concentration of ATP alone analysed using a two-way ANOVA with
Bonferroni post hoc test.

177

reduction in net Ca2+ movement at 10 µM ATP, but not at other ATP concentrations
(Figure 6.3E; two-way ANOVA with Bonferroni post hoc test). Notably, no significant
change in peak Ca2+ response or decay time was observed (Figure 6.3D, F; two-way
ANOVA with Bonferroni post hoc test). Overall, preincubation with TNP-ATP resulted
in a non-significant shift in the EC50 of ATP compared to cells in absence of TNP-ATP
for peak Ca2+ response (Figure 6.3D; pEC50 5.38 ± 0.08 vs 5.57 ± 0.13, respectively;
P = 0.133 Student’s t test) and a significant shift for net Ca2+ movement (Figure 6.3E;
pEC50 5.04 ± 0.14 vs 5.69 ± 0.13, respectively; P = 0.007 Student’s t test).

6.2.4. The non-selective P2X receptor antagonist, paroxetine, reduces net Ca2+
movement in DH82 cells
Next, DH82 cells were preincubated with a non-selective P2X receptor antagonist,
paroxetine, which has been shown to inhibit P2X4 receptors (Chapter 5; Abdelrahman et
al., 2017; Nagata et al., 2009) and P2X7 receptors (Dao-Ung et al., 2015; Wang et al.,
2016). Preincubation with 100 µM paroxetine reduced Ca2+ responses mediated by ATP
concentrations of 10 µM or greater (Figure 6.4A-C). Similar to TNP-ATP, paroxetine did
not significantly reduce peak Ca2+ responses (Figure 6.4D; two-way ANOVA with
Bonferroni post hoc test) however did significantly reduce net Ca2+ movement and decay
kinetics (Figure 6.4E, F; two-way ANOVA with Bonferroni post hoc test). Overall,
preincubation with paroxetine did not significantly shift the EC50 of ATP compared to
cells in absence of paroxetine for peak Ca2+ response (Figure 6.4D; pEC50 5.55 ± 0.31 vs
5.51 ± 0.48, respectively; P = 0.479 Student’s t test) or net Ca2+ movement (Figure 6.4E;
pEC50 5.27 ± 0.35 vs 5.4 ± 0.28, respectively; P = 0.387 Student’s t test). Collectively,
this data combined with that above (Figure 6.3) suggests that DH82 cells express
functional P2X receptors.
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Figure 6.4. ATP-induced Ca2+ responses in DH82 cells in the absence or presence of
paroxetine. (A-F) DH82 cells in ECS were loaded with Fura-2 and preincubated in the absence
(ATP alone) or presence of 100 µM paroxetine (0.3% DMSO) for 5 min. Cells were then exposed
to increasing concentrations of ATP and Fura-2 fluorescence was recorded. ATP-induced (D)
peak Ca2+ response and (E) net Ca2+ movement were fit to the Hill equation to produce
concentration-response curves. (F) One phase decay time (τ) calculated from the peak of each
Ca2+ trace in A-C. (A-F) Data shown are mean ± SEM from four independent experiments. (D-F)
*

P < 0.05,

**

P < 0.01 and

***

P < 0.001 compared to respective concentration of ATP alone

analysed using a two-way ANOVA with Bonferroni post hoc test.

6.2.5. The P2X1/P2X7 receptor antagonist, MRS2159, potentiates ATP-induced
Ca2+ responses in DH82 cells
The above non-selective P2X receptor antagonist data (Figure 6.3 and 6.4) combined with
mRNA expression of P2X1, P2X4 and P2X7 receptors (Figure 6.1) suggests that DH82
cells express functional P2X receptors. As such, selective P2X receptor antagonists were
then utilised to identify the functional P2X receptor subtype/s in DH82 cells. First, the
potent and selective antagonist of P2X1/P2X7 receptors, MRS2159 (Donnelly-Roberts,
Namovic, Han, et al., 2009; Sophocleous et al., 2015), was preincubated with cells prior
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to activation with increasing concentrations of ATP. Preincubation with 0.3 µM
MRS2159 potentiated Ca2+ responses in DH82 cells evoked by up to 10 µM ATP, but not
other ATP concentrations (Figure 6.5A-C). Significant increases in ATP-induced peak
Ca2+ response and net Ca2+ movement were observed in the presence of MRS2159 (Figure
6.5D, E; two-way ANOVA with Bonferroni post hoc test). Additionally, incubation with

Figure 6.5. ATP-induced Ca2+ responses in DH82 cells in the absence or presence of
MRS2159. (A-F) DH82 cells in ECS were loaded with Fura-2 and preincubated in the absence
(ATP alone) or presence of 0.3 µM MRS2159 (in ECS) for 20 min. Cells were then exposed to
increasing concentrations of ATP and Fura-2 fluorescence was recorded. ATP-induced (D) peak
Ca2+ response and (E) net Ca2+ movement were fit to the Hill equation to produce concentrationresponse curves. (F) One phase decay time (τ) calculated from the peak of each Ca2+ trace in AC. (A-F) Data shown are mean ± SEM from four independent experiments. (D-F) *P < 0.05, **P
< 0.01 and ***P < 0.001 compared to respective concentration of ATP alone analysed using a twoway ANOVA with Bonferroni post hoc test.

MRS2159 resulted in a significant shift in the EC50 compared to cells in absence of
MRS2159 for ATP-induced peak Ca2+ response (Figure 6.5E; pEC50 5.84 ± 0.20 vs
5.25 ± 0.23, respectively; P = 0.027 Student’s t test) and net Ca2+ movement (Figure 6.5F;
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pEC50 5.94 ± 0.21 vs 5.10 ± 0.13, respectively; P = 0.007 Student’s t test). However, no
significant differences in decay kinetics between cells incubated in absence or presence
of MRS2159 were observed (Figure 6.5F; two-way ANOVA with Bonferroni post hoc
test). Together this data indicates that the P2X1/P2X7 antagonist, MRS2159, positively
modulates, rather than inhibits, ATP-induced Ca2+ response in DH82 cells.

6.2.6. The selective P2X4 receptor antagonist, 5-BDBD, partially reduces ATPinduced Ca2+ responses in DH82 cells
Next, DH82 cells were preincubated with the selective P2X4 receptor antagonist,
5-BDBD (Balazs et al., 2013), which was demonstrated in the previous chapter to inhibit
canine P2X4 receptors (Figure 5.14). Cells were then incubated with increasing
concentrations of ATP and Ca2+ responses were determined. Preincubation with 30 µM
5-BDBD appeared to minimally reduce the Ca2+ response mediated by ATP
(Figure 6.6A-C). However, there was no significant difference in the EC50 for cells in the
absence or presence of 5-BDBD for ATP-induced peak Ca2+ response (Figure 6.6D;
pEC50 5.87 ± 0.12 vs 5.82 ± 0.10, respectively; P = 0.372 Student’s t-test) or net Ca2+
movement (Figure 6.6E; pEC50 5.73 ± 0.18 vs 5.64 ± 0.14, respectively; P = 0.358
Student’s t-test), although a trend towards decreased net Ca2+ movement was observed at
10 µM ATP (Figure 6.6E; two-way ANOVA with Bonferroni post hoc test). Of note,
there was a significant reduction in decay kinetics at 10 µM ATP for cells incubated in
presence of 5-BDBD compared to those in absence of the antagonist (Figure 6.6F; twoway ANOVA with Bonferroni post hoc test).
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Figure 6.6. ATP-induced Ca2+ responses in DH82 cells in the absence or presence of
5-BDBD. (A-F) DH82 cells in ECS were loaded with Fura-2 and preincubated in the absence
(ATP alone) or presence of 30 µM 5-BDBD (0.3% DMSO) for 5 min. Cells were then exposed
to increasing concentrations of ATP and Fura-2 fluorescence was recorded. ATP-induced (D)
peak Ca2+ response and (E) net Ca2+ movement were fit to the Hill equation to produce
concentration-response curves. (F) One phase decay time (τ) calculated from the peak of each
Ca2+ trace in A-C. (A-F) Data shown are mean ± SEM from five independent experiments. (D-F)
*

P < 0.05 compared to respective concentration of ATP alone analysed using a two-way ANOVA

with Bonferroni post hoc test.

6.2.7. The P2X4 receptor positive allosteric modulator, ivermectin, potentiates
ATP-induced Ca2+ responses in DH82 cells
The above data suggests that DH82 cells may express functional P2X4 receptors (Figure
6.6). However, as demonstrated in the previous chapter (Chapter 5, Figure 5.14) the
limited potency and efficacy of 5-BDBD at canine P2X4 receptors may impede the study
of these receptors in a mixed model of canine purinergic signalling. Therefore, to further
investigate if DH82 cells express functional P2X4 receptors, ivermectin, which has been
demonstrated to effectively potentiate Ca2+ responses mediated by canine P2X4 receptors
(Chapter 5, Figure 5.11), was preincubated with cells prior to activation with increasing
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concentrations of ATP. Preincubation with 3 µM ivermectin potentiated ATP-induced
Ca2+ responses in DH82 cells (Figure 6.7A-C), with significant increases in ATP-induced
net Ca2+ movement and peak Ca2+ response observed in the presence of ivermectin

Figure 6.7. ATP-induced Ca2+ responses in DH82 cells in the absence or presence of
ivermectin. (A-F) DH82 cells in ECS were loaded with Fura-2 and preincubated in the absence
(ATP alone) or presence of 3 µM ivermectin (IVM; 0.1% DMSO) for 20 min. Cells were then
exposed to increasing concentrations of ATP and Fura-2 fluorescence was recorded. (ATPinduced (D) peak Ca2+ response and (E) net Ca2+ movement were fit to the Hill equation to
produce concentration-response curves. (F) One phase decay time (τ) calculated from the peak of
each Ca2+ trace in A-C. (A-F) Data shown are mean ± SEM from four independent experiments.
(D-F) ***P < 0.001 compared to respective concentration of ATP alone analysed using a two-way
ANOVA with Bonferroni post hoc test.

compared to cells in absence of ivermectin at ATP concentrations upwards of 10 µM
(Figure 6.7D, E; two-way ANOVA with Bonferroni post hoc test). However, similar to
5-BDBD, there was no significant difference in the EC50 in the absence or presence of
ivermectin for ATP-induced peak Ca2+ response (Figure 6.7D; pEC50 5.76 ± 0.19 vs 5.37
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± 0.35; P = 0.372 Student’s t test) or net Ca2+ movement (Figure 6.7E; pEC50 5.62 ± 0.01
vs 5.57 ± 0.12, respectively; P = 0.358 Student’s t test). Additionally, there were no
significant differences in decay kinetics between cells incubated in absence or presence
of ivermectin (Figure 6.7F; two-way ANOVA with Bonferroni post hoc test).
Collectively this data (Figure 6.6 and Figure 6.7) suggests that DH82 cells express
functional P2X4 receptors.

6.2.8. ATP and UTP induce Ca2+ influx and store-operated Ca2+ entry in DH82 cells
The above data suggests that DH82 cells may express low levels of functional P2X4
receptors. Despite this, P2X receptor antagonists were unable to completely inhibit
ATP-induced Ca2+ responses, indicating the potential for a non-ionotropic mechanism of
nucleotide-induced Ca2+ responses in DH82 cells. Gq/11-coupled P2Y receptors, which are
activated by nucleotides such as ATP and UTP, can mediate release of Ca2+ from
intracellular stores (Abbracchio et al., 2006). To determine if the observed Ca2+ responses
in DH82 cells were occurring through P2Y receptor-mediated intracellular Ca2+
mobilisation, nucleotide-induced changes in intracellular Ca2+ were measured in the
presence of extracellular or intracellular Ca2+ chelators. Compared to cells in the presence
of extracellular Ca2+ (Figure 6.8A, E), cells incubated with EGTA demonstrated partially
reduced ATP- and UTP-induced Ca2+ responses (Figure 6.8B, F). This was supported by
significant reductions in decay time (Figure 6.8I) and net Ca2+ movement (Figure 6.8J,
K) for both ATP- and UTP-mediated responses. In contrast, preincubation with the cellpermeant Ca2+ chelator, BAPTA-AM, near completely reduced ATP- and UTP-induced
Ca2+ responses (Figure 6.8C, G) and net Ca2+ movement (Figure 6.8J, K) in DH82 cells.
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Figure 6.8. Ca2+ mobilisation in the absence or presence of extracellular and/or intracellular
Ca2+. (A-K) DH82 cells in (A, E) ECS or (B-D, F-H) Ca2+-free solution were loaded with Fura-2
and preincubated in the (A, E) absence (ECS control) or presence of (B, F) 2 mM EGTA for 30 s
or (C, G) 15 µM BAPTA-AM for 30 min. (D, H) Cells were preincubated with 1 µM thapsigargin
(TG) for 30 min prior to application of 2 mM EGTA. (A-K) Cells were then exposed to (A-D)
100 µM ATP or (E-H) 30 µM UTP and Fura-2 fluorescence was recorded. (I) One phase decay
time (τ) calculated from the peak of each Ca2+ trace in A, B, E and F. (J, K) Net Ca2+ movement
from each trace in A-H. (A-K) Data shown are mean ± SEM from four independent experiments.
P < 0.05, **P < 0.01 and ***P < 0.001 compared to respective ECS control; †P < 0.05 and ††P <

*

0.01 compared to EGTA; #P < 0.05 compared to BAPTA-AM analysed using a (I) Student’s ttest or (J, K) one-way ANOVA with Bonferroni post hoc test.
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To further determine the mechanism by which Ca2+ was released into the cytosol
following exposure to nucleotides, DH82 cells were preincubated with thapsigargin to
inhibit SERCA pumps (Thastrup et al., 1990). Treatment with thapsigargin alone resulted
in a significant increase in cytosolic Ca2+ (Appendix Figure A6.2) which completely
inhibited ATP- and UTP-induced Ca2+ responses (Figure 6.8D, H, J, K). Collectively,
these results demonstrate that both extracellular and intracellular sources of Ca2+ are
involved in nucleotide-induced Ca2+ signalling mechanisms in DH82 cells, suggesting a
functional role for both P2X and P2Y receptor subtypes in these cells.

6.2.9. The non-selective P2 receptor antagonist Suramin reduces ATP- and UTPinduced Ca2+ responses in DH82 cells
The above data provides evidence of ATP- and UTP-induced Ca2+ responses and
intracellular Ca2+ mobilisation in DH82 cells (Figure 6.2 and Figure 6.8). Consistent with
the above data, the canine P2Y2 receptor from Madin-Darby canine kidney (MDCK) cells
has been demonstrated to respond to both ATP and UTP with similar potency (Zambon
et al., 2000), suggesting the presence of functional P2Y2 receptors in DH82 cells. To
determine if nucleotide-induced Ca2+ mobilisation was mediated by P2Y receptors, DH82
cells were preincubated with increasing concentrations of the non-selective P2 receptor
antagonist, suramin (Kempson et al., 2008). Cells were then incubated with ATP or UTP
at their respective EC80 (3 µM or 1 µM, respectively) to determine the optimal
concentration for P2Y receptor inhibition. Ca2+ responses evoked by 3 µM ATP were
inhibited by 1 mM suramin, however lower concentrations of suramin (<100 µM) had
little-to-no inhibitory effect (Figure 6.9A). In contrast, Ca2+ responses evoked by 1 µM
UTP were inhibited by 100 µM and 1 mM, but not 10 µM suramin or less (Figure 6.9B).
Significant differences were observed between ATP- and UTP-induced responses in the
presence of 100 µM suramin (Figure 6.9C, D; two-way ANOVA with Bonferroni post

186

hoc test). This resulted in a significant shift in the IC50 of suramin between ATP- and

Figure 6.9. ATP- and UTP-induced Ca2+ responses in DH82 cells in the absence or presence
of suramin. (A-D) DH82 cells in ECS were loaded with Fura-2 and preincubated in the absence
(ECS vehicle) or presence of increasing concentrations of suramin (in ECS) for 30 min. Cells
were then exposed to (A) 3 µM ATP or (B) 1 µM UTP (respective EC80 values) and Fura-2
fluorescence was recorded. Nucleotide-induced (C) peak Ca2+ response and (D) net Ca2+
movement were normalised to 3 µM ATP or 1 µM UTP alone and expressed as a percentage of
the response in absence of inhibitor (% of control). Data were then to fit data to the Hill equation
to produce concentration-response curves and calculate the IC50. (A-D) Data shown are mean ±
SEM from three independent experiments. (C, D) *P < 0.05 and

***

P < 0.001 compared to

respective concentration of suramin with UTP analysed using a two-way ANOVA with
Bonferroni post hoc test.
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UTP-induced peak Ca2+ response (Figure 6.9C; pIC50 3.02 ± 0.06 and 3.70 ± 0.05,
respectively; P < 0.001 Student’s t test) and net Ca2+ movement (Figure 6.9D; pIC50 3.03
± 0.12 and 3.54 ± 0.14, respectively; P = 0.025 Student’s t test).

6.2.10. The selective P2Y2 receptor antagonist, AR-C118925, inhibits ATP and UTPinduced Ca2+ responses in DH82 cells
To investigate further which P2Y receptor subtypes may be involved in nucleotideinduced Ca2+ mobilisation in DH82 cells, cells were preincubated with increasing
concentrations of the selective P2Y2 receptor antagonist, AR-C118925 (Rafehi, Burbiel,
et al., 2017), then incubated with P2Y2 receptor agonists, ATP or UTP at their respective
EC80 concentrations. Ca2+ responses evoked by 3 µM ATP were only partially inhibited
by AR-C118925 at concentrations of 1 µM or greater (Figure 6.10A). In contrast, Ca2+
responses evoked by 1 µM UTP were near completely inhibited by AR-C118925 at
concentrations of 10 µM or greater (Figure 6.10B). Significant differences were observed
between ATP- and UTP-induced net Ca2+ movement, but not peak Ca2+ response, in the
presence of 100 µM AR-C118925 (Figure 6.10C, D; two-way ANOVA with Bonferroni
post hoc test). This resulted in a significant difference between the IC50 of AR-C118925
in response to activation by ATP and UTP calculated using peak Ca2+ responses
(Figure 6.10C; pIC50 6.18 ± 0.16 and 6.61 ± 0.09, respectively; P = 0.033 Student’s t test),
but not net Ca2+ movement (Figure 6.10D; pIC50 6.67 ± 0.19 and 6.87 ± 0.12, respectively;
P = 0.198 Student’s t test). Together this data demonstrates that the selective P2Y2
receptor antagonist, AR-C118925, can inhibit nucleotide-induced Ca2+ mobilisation in
DH82 cells, suggesting that DH82 cells express functional P2Y2 receptors.
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Figure 6.10. ATP- and UTP-induced Ca2+ responses in DH82 cells in the absence or presence
of AR-C118925. (A-D) DH82 cells in ECS were loaded with Fura-2 and preincubated in the
absence or presence of increasing concentrations of AR-C118925 (AR-C; 0.3% DMSO) for 30
min. Cells were then exposed to (A) 3 µM ATP or (B) 1 µM UTP (respective EC80 values) and
Fura-2 fluorescence was recorded. Nucleotide-induced (C) peak Ca2+ response and (D) net Ca2+
movement were normalised to 3 µM ATP or 1 µM UTP alone and expressed as the percent of
control in absence of inhibitor. Data were then to fit data to the Hill equation to produce
concentration-response curves and calculate the IC50. (A-D) Data shown are mean ± SEM from
four independent experiments. (C, D) **P < 0.01 compared to respective concentration of suramin
with UTP analysed using a two-way ANOVA with Bonferroni post hoc test.
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6.2.11. Combined blockade of P2X4 and P2Y2 receptors with 5-BDBD and ARC118925 completely inhibits nucleotide-induced Ca2+ movement in DH82 cells
The above data suggests that P2X4 and P2Y2 receptors mediate nucleotide-induced Ca2+
responses in DH82 cells. To determine whether combined blockade can impair
nucleotide-induced Ca2+ responses in DH82 cells, cells were preincubated together with
5-BDBD and AR-C118925, then incubated with ATP or UTP. Consistent with above data
(Figure 6.6), preincubation with 5-BDBD had minimal effect on peak Ca2+ response
(Figure 6.11A, B), but did reduce ATP-induced net Ca2+ movement by 38.5 ± 9.9%
(Figure 6.11A, C). In contrast, 5-BDBD had minimal inhibitory effect on UTP-induced
Ca2+ responses (9.6 ± 6.2% reduction; Figure 6.11B, D). Consistent with above data
(Figure 6.10), AR-C118925 reduced ATP-induced responses (Figure 6.11A, C; 71.1 ±
18.8% inhibition) and near completely inhibited UTP-induced Ca2+ responses (Figure
6.11B, D; 83.2 ± 8.3% inhibition), with notable levels of net Ca2+ movement still observed
upon activation with ATP, but not UTP (Figure 6.11A and B, respectively). Preincubation
with 5-BDBD and AR-C118925 together resulted in near complete inhibition of ATPinduced (Figure 6.11A, C; 89.8 ± 3.8% inhibition) and UTP-induced Ca2+ responses
(Figure 6.11B, D; 93.9 ± 1.7% inhibition).
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Figure 6.11. Combined blockade of ATP- and UTP-induced Ca2+ responses in DH82 cells
with 5-BDBD and AR-C118925. (A-D) DH82 cells in ECS were loaded with Fura-2 and
preincubated in the absence or presence of 30 µM 5-BDBD (0.3% DMSO) and 10 µM
AR-C118925 (AR-C; 0.03% DMSO) for 30 min. Cells were then exposed to (A) 3 µM ATP or
(B) 1 µM UTP (respective ~EC80 values) and Fura-2 fluorescence was recorded.
(C) ATP-induced and (D) UTP-induced net Ca2+ movement were calculated as area under the
curve from (A) and (B), respectively. (A-D) Data shown are mean ± SEM from four independent
experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 compared to respective nucleotide alone; ††P
< 0.01 and †††P < 0.001 compared to respective nucleotide + 5-BDBD analysed using a one-way
ANOVA with Bonferroni post hoc test.
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6.2.12. Expression and localisation of P2X4 and P2Y2 on DH82 cells by confocal
microscopy and western blotting
To confirm the above data that DH82 cells express P2X4 and P2Y2 receptors, DH82 cells
and MDCK cells, which express P2Y2 receptors (Post et al., 1998; Zambon et al., 2000),
and human 1321N1 cells, which are devoid of these P2 receptors (Bianchi et al., 1999;
Moore et al., 2001), were immunolabelled with anti-P2X4 or anti-P2Y2 receptor
antibodies and analysed by western blotting and confocal microscopy. Immunoblotting
with anti-P2X4 and anti-P2Y2 receptor antibodies revealed the expression of 50 kDa and
45kDa bands, respectively, in both DH82 and MDCK cells corresponding to the predicted
molecular weight of the P2X4 and P2Y2 receptors, respectively (Figure 6.12). In contrast,
negligible P2X4 or P2Y2 receptor expression was observed in 1321N1 cells, despite equal
loading as indicated by similar expression of actin (Figure 6.12).

Figure 6.12. Expression of P2X4 and P2Y2 receptors in DH82 whole-cell lysates. DH82,
MDCK and 1321N1 cell lysates were analysed by western blotting using an anti-P2X4 receptor
antibody (top panel), anti-P2Y2 receptor antibody (middle panel) or anti-actin antibody (bottom
panel) prior to imaging. Results are representative of three independent experiments.
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Confocal microscopy revealed the presence of both P2X4 and P2Y2 receptors in fixed
and permeabilised DH82 cells (Figure 6.13A, B). Notably, the expression of P2X4
receptors was relatively low and largely intracellular (Figure 6.13A, Appendix Figure
A6.4) consistent with data from the previous chapter demonstrating colocalization of the
canine P2X4 receptor with lysosomal compartments (Chapter 5, Figure 5.2 and Figure
5.8). Meanwhile, the expression of P2Y2 receptors on DH82 cells was relatively high and
predominantly localised to the cell surface (Figure 6.13B, Appendix Figure
A6.3,Appendix Figure A6.4), consistent with its reported expression at the apical
membrane of MDCK cells (Qi et al., 2005; Wolff et al., 2005).

Figure 6.13. Expression and localisation of P2X4 and P2Y2 receptors in DH82 cells. DH82
cells were fixed, permeabilised and stained with (A) anti-P2X4 receptor or (B) anti-P2Y2 receptor
primary antibodies, followed by Alexa Fluor594-conjugated anti-goat or anti-rabbit secondary
antibodies, respectively. Cells were imaged by confocal microscopy. Images are representative
results of three separate experiments. Scale bar = 20 µm.
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6.2.13. P2Y2 receptor-mediated Ca2+ mobilisation is coupled to the phospholipaseC/ inositol 1,4,5-trisphosphate signal transduction pathway
Collectively, the above data (Figures 6.1-6.13) reveal that the P2Y2 receptor is the
predominant P2 receptor in DH82 cells. The P2Y2 receptor is a Gq-coupled receptor found
in human and rodent macrophages (Higgins et al., 2014; Layhadi & Fountain, 2019) that
can activate PLC and IP3 receptors (Stokes & Surprenant, 2007); a process which results
in the release of endoplasmic reticulum Ca2+ stores (Bowler et al., 2003). Therefore, to
examine the mechanism by which P2Y2 receptor-mediated intracellular Ca2+ mobilisation
occurs in DH82 canine macrophages, cells were preincubated with antagonists of PLC
(U-73122) and IP3 receptors (2-aminoethoxydiphenyl borate; 2-APB), as well as an
antagonist of P2Y2 receptors (AR-C118925) as a control, and nucleotide-induced Ca2+
mobilisation was recorded. Measurements were made in Ca2+ free buffer, where CaCl2
was substituted for 2 mM EGTA, to ensure only intracellular Ca2+ mobilisation was
measured.
Consistent with previous observations, AR-C118925 near completely inhibited
intracellular Ca2+ mobilisation in DH82 cells evoked by either 10 µM ATP (Figure 6.14A;
90.5 ± 3.3% inhibition) or 10 µM UTP (Figure 6.14B; 87.3 ± 7.4% inhibition). Similarly,
preincubation of DH82 cells with 75 µM 2-APB, resulted in near-complete inhibition of
intracellular Ca2+ mobilisation evoked by either 10 µM ATP (Figure 6.14A; 90.7 ± 4.4%
inhibition) or 10 µM UTP (Figure 6.14B; 91.2 ± 3.1% inhibition). In contrast,
preincubation with 5 µM U-73122 only partially reduced intracellular Ca2+ mobilisation
evoked by 10 µM ATP (Figure 6.14A; 64.9 ± 5.9% inhibition) or 10 µM UTP (Figure
6.14B; 55.5 ± 8.7% inhibition). Combination of two or three of these antagonists
completely impaired ATP- and UTP-induced Ca2+ responses (Figure 6.14A, B). Thus,
preincubation with AR-C118925, 2-APB, U-73122 or any combination of these
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antagonists resulted in a statistically significant reduction (P < 0.001, one-way ANOVA)
of intracellular Ca2+ mobilisation compared to that evoked by ATP alone (Figure 6.14A)
or UTP alone (Figure 6.14B). Together, this data demonstrates that intracellular Ca2+
signalling mediated by P2Y2 receptors in DH82 cells is coupled to the PLC and IP3
receptor signal transduction pathway.

Figure 6.14. Nucleotide-induced Ca2+ mobilisation in DH82 cells depleted of extracellular
Ca2+ in the absence or presence of AR-C118925, U-73122 and 2-APB. DH82 cells were loaded
with Fura-2 and preincubated in Ca2+-free solution containing 2 mM EGTA in the absence or
presence of 10 µM AR-C118925 (AR-C; 0.03% DMSO), 5 µM U-73122 (0.05% DMSO) or
75 µM 2-APB (0.15% DMSO) for 5 min. Cells were then exposed to (A) 10 µM ATP or
(B) 10 µM UTP and Fura-2 fluorescence was recorded. (A, B) Data shown are mean ± SEM from
five independent experiments. **P < 0.01 and

***

P < 0.001 compared to respective nucleotide

alone, analysed using a one-way ANOVA with Bonferroni post hoc test.

6.3.

Discussion

This chapter aimed to characterise the expression and function of endogenous P2
receptors in the DH82 canine macrophage cell line. The data presented here demonstrated
that DH82 cells express functional P2X4 and P2Y2 receptors, where they mediate Ca2+
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influx and intracellular Ca2+ mobilisation, respectively. This was supported by
pharmacological data demonstrating that agonists, modulators or antagonists of P2X4 or
P2Y2 receptors could differentially modulate these Ca2+ responses in DH82 cells. The
presence of these two receptors was confirmed at the mRNA and protein levels. P2Y2
receptor activation was coupled with downstream PLC and IP3 receptors to signal
intracellular Ca2+ mobilisation from the endoplasmic reticulum, a well-characterised
pathway involved in human and rodent metabotropic signalling (Erb & Weisman, 2012).
The agonist profile of ATP on DH82 cells demonstrated pharmacological similarities to
the canine P2X4 receptor determined in Chapter 5, as well as studies on the P2X4 receptor
in human macrophage cells (Layhadi & Fountain, 2017). Consistent with data on cells
heterologously expressing canine P2X4 receptors (Chapter 5), BzATP also induced Ca2+
responses in DH82 cells with a significantly lower potency compared to ATP, supporting
a role for P2X4 receptors in the observed Ca2+ responses in these cells. Additionally, the
increased decay kinetics of Ca2+ responses evoked by BzATP compared to ATP may
suggest that P2X4 receptors are involved in ATP-induced Ca2+ responses in DH82 cells.
The data presented in this chapter demonstrates that the positive allosteric modulator of
P2X4 receptors, ivermectin (Priel & Silberberg, 2004), can increase ATP-induced Ca2+
responses in DH82 cells. This resulted in an increase in the efficacy of ATP to evoke Ca2+
responses in DH82 cells that was similar to that observed with heterologously expressed
canine P2X4 receptors (Chapter 5). Taken together with the agonist profile data, this
chapter supports the expression of functional P2X4 receptors in DH82 cells. Ivermectin
has also been shown to positively modulate human P2X7 receptors (Norenberg et al.,
2012), however the limited Ca2+ response to BzATP, a potent canine P2X7 receptor
agonist (Roman et al., 2009; Sluyter, Shemon, Hughes, et al., 2007), suggests a lack of
functional P2X7 receptors. Furthermore, the P2X1/P2X7 receptor antagonist MRS2159
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(Donnelly-Roberts, Namovic, Han, et al., 2009; Sophocleous et al., 2015) demonstrated
no inhibitory effect, but rather potentiated the ATP-induced Ca2+ response, further
suggesting that DH82 cells lack functional P2X7 receptors. Of note, another P2X1
receptor antagonist, Ro0437626, potentiated, rather than inhibited ATP-induced Ca2+
responses in monocyte-derived macrophages (Layhadi et al., 2018). MRS2159 can also
inhibit most P2 receptors at higher concentrations (10 µM), with only P2X4 and P2Y2
receptors remaining relatively unresponsive (Donnelly-Roberts, Namovic, Han, et al.,
2009), indirectly supporting the presence of P2X4 and P2Y2 receptors in DH82 cells.
This chapter demonstrates that the non-selective P2X receptor antagonists TNP-ATP and
paroxetine, which are now known to target the canine P2X4 receptor (Chapter 5), can
partially inhibit ATP-induced net Ca2+ movement in DH82 cells. However, as
demonstrated in Chapter 5, while effective at higher concentrations, these antagonists are
not particularly potent or selective inhibitors of canine P2X4 receptors, and in some cases
may mediate increases in intracellular Ca2+ response on their own (Fang et al., 2011; Pan
et al., 2010). As such, it is difficult to draw conclusions on the expression of functional
P2X4 receptors in DH82 cells using these antagonists. Regardless, the selective P2X4
receptor antagonist 5-BDBD (Balazs et al., 2013) demonstrated partial reduction of ATPinduced net Ca2+ movement in DH82 cells, which may be attributed to the low expression
of P2X4 receptors observed by confocal microscopy or the previously observed weak
inhibitory effect of 5-BDBD at canine P2X4 receptors, or a combination of these two
factors. Nonetheless, this data supports the presence of functional P2X4 receptors in
DH82 cells where they play a limited role in nucleotide-induced Ca2+ movement.
Consistent with previous reports of P2 receptors on human and rodent macrophages
(Bowler et al., 2003; Higgins et al., 2014; Layhadi & Fountain, 2019; Layhadi et al., 2018;
Stokes & Surprenant, 2007, 2009), both ATP and UTP induced robust Ca2+ responses
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with

similar EC50

values in

DH82

cells.

Additionally, these

ATP-

and

UTP-induced Ca2+ responses differed in the absence or presence of extracellular or
intracellular Ca2+, consistent with the known activation of Gq/11-coupled P2Y receptors,
including P2Y1, P2Y2, P2Y4 (in rodents), P2Y6 and P2Y11 receptors (von Kugelgen,
2019). Of these P2Y receptors, canine P2Y1, P2Y2 and P2Y11 receptors have previously
been cloned from MDCK cells and characterised (Post et al., 1998; Qi et al., 2001;
Zambon et al., 2000). Much like human P2Y2 receptors (Schachter et al., 1997), canine
P2Y2 receptors have previously demonstrated both ATP- and UTP-induced responses,
consistent with the nucleotide-induced responses presented in this chapter (Zambon et al.,
2000). Additionally, the agonist profile of BzATP in DH82 cells demonstrates similarities
to that observed with human P2Y2 receptors, where BzATP is ineffective at
concentrations below 100 µM (Humphreys et al., 1998; Katzur et al., 1999). In contrast,
canine P2Y11 receptors have been shown to have markedly different nucleotide responses
between humans and dogs, with ATP being a potent agonist of human, but not canine
P2Y11 receptors, and ADP and its analogue 2MeSADP being potent agonists of canine,
but not human P2Y11 receptors (Qi et al., 2001). In DH82 cells, ADP-induced Ca2+
responses were significantly lower than ATP-induced responses, while no Ca2+ responses
were observed with 2MeSADP. BzATP is also a full agonist of human P2Y11 receptors
(Communi et al., 1999), further suggesting that DH82 cells do not express functional
P2Y11 receptors.
ADP and 2MeSADP have been reported as potent agonists of the canine P2Y 1 receptor
(Hughes et al., 2003). Although significantly less than that observed with ATP or UTP,
ADP induced a small Ca2+ response in DH82 cells, which could suggest that DH82 cells
express low amounts of functional P2Y1 receptors. However, the lack of response to
2MeSADP suggests that P2Y1 receptors are unlikely to be responsible for P2Y
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receptor-mediated Ca2+ mobilisation in DH82 cells. Thus, the observed Ca2+ responses in
DH82 cells are likely primarily induced by P2Y2 receptor activation, as demonstrated by
previous studies on canine P2Y2 receptors cloned from MDCK cells, which revealed ADP
as a partial, low-potency agonist (Jan et al., 1998; Zambon et al., 2000). No Ca2+ response
was observed in the presence of the P2Y6 receptor agonist, UDP (Communi, Parmentier,
et al., 1996; Nicholas et al., 1996), suggesting that DH82 cells likely do not express
functional P2Y6 receptors.
Data from this chapter revealed that the non-selective P2Y receptor antagonist, suramin,
could inhibit ATP- and UTP-induced Ca2+ responses in DH82 cells. Despite its lack of
potency and selectivity, suramin remains a valuable tool in characterising P2Y receptor
responses, as it is considered a low-potency antagonist of P2Y2 receptors, but is relatively
insensitive to P2Y4 receptors (Charlton et al., 1996a; Wildman et al., 2003). Given that
ATP and UTP are equipotent agonists of P2Y2 and P2Y4 receptors (von Kügelgen, 2006),
the data presented here suggests that DH82 cells express functional P2Y2, but not P2Y4
receptors. The expression of functional P2Y2 data was further supported by potent
inhibition of ATP and UTP-induced Ca2+ responses using the selective P2Y2 receptor
antagonist, AR-C118925 (Rafehi, Burbiel, et al., 2017). Although studies have yet to
determine if AR-C118925 is selective for canine P2Y2 receptors, it has been demonstrated
that this compound displays high selectivity for human and rodent P2Y2 receptors over
other P2 receptors (Rafehi, Burbiel, et al., 2017).
ATP- and UTP-mediated Ca2+ responses in DH82 cells were also inhibited by antagonists
of PLC and IP3 receptors, U-73122 and 2-APB, respectively. This was consistent with
previous studies that have shown that P2Y2 receptors from MDCK cells couple to
Gq/11 protein-coupled signalling pathways (Insel et al., 2001; Post et al., 1998; Zambon et
al., 2000). Despite observing near complete inhibition of Ca2+ mobilisation with 2-APB,
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only partial inhibition was observed with U-73122, although higher concentrations (>10
µM) have been shown to completely block P2Y2 receptor-mediated Ca2+ responses (Liu
et al., 2018). Of note, inhibition of ATP-induced Ca2+ responses by P2Y receptor
antagonists was approximately two-fold less than that observed with UTP, suggesting that
ATP remained active at other receptors involved in mediating changes in intracellular
Ca2+, such as P2X4 receptors, which are relatively insensitive to suramin (Jones et al.,
2000). In support of this, ATP- and UTP-induced Ca2+ responses were completely
inhibited by dual inhibition with 5-BDBD and AR-C118925, supporting a role for both
P2X4 and P2Y2 receptors in DH82 cells.
Pro-monocytic and macrophage-like cell lines have recently proven useful models for
studying endogenous purinergic signalling via P2X4 and P2Y2 receptors (Layhadi &
Fountain, 2017; Stokes & Surprenant, 2007, 2009). However, studies have demonstrated
that macrophage cell lines, such as human THP-1 and U-937 cells, can be differentiated
through cytokine stimulation, towards a more specialised phenotype whereby expression
of P2 receptors, such as P2X4 and P2X7 receptors, are upregulated (Gadeock et al., 2010;
Layhadi & Fountain, 2017; Muzzachi et al., 2013). Although the lack of expression of
P2X7 receptors in DH82 cells was unexpected given the expression of these receptors in
canine monocytes (Jalilian, Peranec, et al., 2012; Stevenson et al., 2009) and other rodent
or human macrophage cell lines, such as RAW264.7 and THP-1 cells (Gadeock et al.,
2010; Hu et al., 1998), these cell lines often require cytokine stimulation to promote
upregulation of these receptors. During the course of this study, a study was published
that demonstrated that DH82 canine macrophage cells could be differentiated towards the
M1 or M2a subtype through cytokine stimulation (Herrmann et al., 2018). However, data
reported throughout this chapter utilised unstimulated DH82 cells and thus it remains to
be determined if differentiation influences P2 receptor expression or function. Future
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studies should determine the P2 receptor expression and activity on cytokine-stimulated
DH82 cells, as well as make direct comparisons with native canine macrophages to
further determine their suitability as a canine macrophage cell line.
In conclusion, this chapter demonstrates for the first time, that DH82 canine macrophages
express functional P2X4 and P2Y2 receptors. This chapter indirectly supports evidence
that P2X4 and P2Y2 receptors play roles in Ca2+ signalling events in canine macrophages
in vivo, similar to that observed in human macrophages, where they have known roles in
signalling chronic pain and inflammation. DH82 cells provide the first canine
macrophage cell line for the study of endogenous P2X4 and P2Y2 receptors. Thus, these
cells may aid in the development and preclinical screening of novel or uncharacterised
P2 receptor agonists, antagonists and modulators of these receptors for potential use in
the treatment of canine diseases.
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Chapter 7: The role of P2Y1 and P2Y12 receptors in platelet
activation and aggregation in dogs and cats
7.1.

Introduction

Thrombosis and haemostasis are complex and serious health concerns not only in humans
(Koupenova et al., 2017), but in companion animals such as dogs and cats (de Laforcade,
2012). A key factor in thrombotic events is the regulation of platelets in circulating blood,
which play a major role in inflammatory and immune-mediated cardiovascular disease
(Aksu et al., 2012; Cortese et al., 2020; Ghoshal & Bhattacharyya, 2014). Current
treatments for thrombotic events in humans include selective inhibitors of the platelet
P2Y12 receptor, such as ticagrelor, cangrelor, clopidogrel and prasugrel (von Kugelgen,
2017), which are among the most commonly prescribed group of drugs in humans
(Erlinge, 2011). In contrast, treatments for thrombotic events in companion animals have
primarily been limited to heparin and aspirin (Smith, 2012). Preliminary studies have
demonstrated the therapeutic potential of P2Y12 inhibitors in dogs (Bjorkman et al., 2013;
Huang et al., 2000; Mellett et al., 2011; Ravnefjord et al., 2012; van Giezen et al., 2012;
van Giezen et al., 2009; Wang et al., 2010) and cats (Borgeat et al., 2014; Ho et al., 2017;
Hogan et al., 2004), suggesting an important role for the P2Y12 receptor in the activation
and aggregation of platelets in companion animals such as dogs and cats.
Platelets in rodents and humans express at least eight P2Y receptors, including the P2Y1
and P2Y12 receptors, which form Gq and Gi protein-coupled receptors, respectively (von
Kügelgen & Harden, 2011). The platelet P2Y1 and P2Y12 receptors, which are activated
most

potently

by

ADP

and

its

synthetic

analogue

2MeSADP, together play an important role in platelet activation and aggregation (Hechler
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& Gachet, 2015). Activation of the P2Y1 receptor in humans and rodents mediates Ca2+
mobilisation from intracellular stores, leading to a change in platelet shape and initiation
of platelet aggregation (Hechler, Léon, et al., 1998; Jin et al., 1998; Savi et al., 1998).
Meanwhile, activation of the P2Y12 receptor in humans and rodents inhibits adenylyl
cyclase, causing a decrease in cAMP production which subsequently amplifies and
sustains the platelet aggregation response mediated by the P2Y1 receptor (Daniel et al.,
1998; Hechler, Eckly, et al., 1998). The expression and function of P2Y1 and P2Y12
receptors in platelets of dogs and cats is limited to identification of the genes coding these
receptors (Lindblad-Toh et al., 2005; Pontius et al., 2007), as well as the observed
pharmacological effects of P2Y12 inhibitors during in vivo or ex vivo studies on platelet
activation and aggregation in these companion animals (Luis Fuentes, 2012; van Giezen
& Humphries, 2005).
Despite known differences in ADP-induced platelet activation between dogs or cats with
other species, such as humans or rodents (Nylander et al., 2006; Soslau et al., 1993), direct
evidence for the expression and role of the platelet P2Y1 and P2Y12 receptors in
companion animals is absent. Given the important therapeutic potential of targeting
platelet P2Y receptors for veterinary medicine, the characterisation of P2Y receptors on
platelets from dogs and cats remains an important area of investigation. Therefore, this
chapter aimed to establish a high throughput 384-well plate assay to analyse platelet
aggregation from small volumes of blood (< 5 mL) and investigate P2Y1 and P2Y12
receptor expression and function on dog platelets in comparison to human platelets. Given
the lack of knowledge in the field, this chapter also studied P2Y1 and P2Y12 receptors on
cat platelets as a second companion animal to compare to dog platelets which were
collected and transported in a similar manner.
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7.2.

Results

7.2.1. Differential centrifugation of whole blood from dogs, cats and humans yields
relatively pure CD61+ platelets in platelet rich plasma (PRP)
CD61 (also known as integrin 3β/glycoprotein IIIa) is a platelet membrane glycoprotein
that has been used for flow cytometric identification of platelets in dogs (Wills et al.,
2006), cats (Cremer et al., 2018) and humans (Hagberg & Lyberg, 2000). To determine
if isolation of PRP from whole blood of dogs, cats and humans produced relatively pure
platelet samples, PRP were labelled with an APC-conjugated isotype control or APCconjugated

anti-CD61

antibody

and

analysed

by

flow

cytometry

(Figure 7.1A-E). The anti-CD61 antibody is known to cross react with dog, cat and human
CD61 (Cremer et al., 2018; Hagberg & Lyberg, 2000; Wills et al., 2006). Platelet subsets
were gated by forward scatter (FSC) and side scatter (SSC) from whole blood (Figure
7.1A) and these gates were used to identify platelets in PRP (Figure 7.1B). This analysis
revealed that dog, cat and human PRP routinely contained >96% anti-CD61+ platelets
(Figure 7.1C-E).

7.2.2. ADP and 2MeSADP induce aggregation of dog, cat and human platelets in a
concentration-dependent manner
The P2Y1 and P2Y12 receptor agonists ADP and 2MeSADP, have been shown to activate
and aggregate platelets from dogs, cats and humans using LTA assays (Chaudhary &
Kim, 2019; Li et al., 2016; Soslau et al., 1993). However, ethical limits on blood
collection volumes for smaller animals such as dogs and cats can hinder traditional LTA
assays requiring larger sample volumes. Therefore, a 384-well plate aggregation assay
was designed (Figure 7.2), based on a 96-well plate assay from a previous study
(Lordkipanidze et al., 2014), to allow for analysis of platelet activation and aggregation
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in vitro using small sample volumes. PRP and PPP were aggregated in the absence or
presence of P2Y receptor agonists and platelet aggregation were quantified by measuring
absorbance at 595 nm (A595; Figure 7.2A). Percent aggregation in PRP were calculated
using the A595 of PRP relative to the A595 of PPP (Figure 7.2B).

Figure 7.1. Flow cytometric analysis of dog, cat and human platelets prior in PRP. (A-E)
The percentage of platelets in PRP isolated from whole blood of dogs, cats and humans (n =3
each) were determined by flow cytometry. (A, B) Forward scatter area (FSC-A) and side scatter
area (SSC-A) were used to identify and subsequently analyse platelets from (A) whole blood and
(B) PRP isolated from dog (top panels), cat (middle panels) or human (bottom panels) whole
blood. Platelets were labelled with (C, E; black histogram) isotype control or (D, E; blue
histogram) anti-CD61 antibody to examine the percentage of
representative of three independent experiments.

platelets in PRP. Data are
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Figure 7.2. Workflow detailing platelet isolation from whole blood, aggregation using a
384-well plate light transmission aggregometry (LTA) assay and data analysis. (A) Whole
blood taken from healthy dogs, cats or humans were centrifuged at 200 x g for 20 min and the top
layer (1-1.5 mL) of containing PRP was collected. The remaining volume (1.5-2 mL) was
centrifuged again at 1000 x g for 10 min to collect the PPP. Platelet counts were conducted using
a haemocytometer to ensure counts were between 2-4x108 platelets.mL-1, then PRP and PPP (15
µL) were transferred into wells of 0.75% gelatin-coated 384 well plates. Agonists in Tyrode’s
buffer were added and plates were incubated for 45 min at 37°C, comprising 60 x 10-s orbital
shaking cycles (700 rpm). Absorbance at 595 nm (A595) was measured before each shaking cycle,
where A595 corresponded inversely with platelet aggregation. In some experiments, samples were
preincubated in absence or presence of antagonists (in Tyrode’s buffer) prior to aggregation (as
indicated). (B) Platelet aggregation in each well containing PRP was calculated at each time point
by subtracting the A595 measured at each time point (PRPt) from the maximum A595 of that PRP
sample (max PRP A595) measured across the entire 45 min in that well. This was divided by the
minimum A595 of the PPP sample (Min PPP A595) subtracted from the max PRP A595 and expressed
as a percentage, as described in Chapter 2.11.5. Agonist-induced (basal subtracted) responses at
10 min (unless otherwise indicated) were used to plot concentration-response curves and calculate
the half maximal effective (EC50) or inhibitory (IC50) concentrations.

206

To characterise and compare platelet P2Y receptor agonist profiles, PRP and PPP isolated
from dogs, cats and humans were incubated in the absence or presence of increasing
concentrations of ADP or 2MeSADP and platelet aggregation was determined using the
384-well plate LTA assay. Incubation with up to 30 µM ADP, or up to 300 nM
2MeSADP, induced platelet aggregation in dogs (Figure 7.3A, B), cats (Figure 7.3D, E)
and humans (Figure 7.3G, H). Platelet aggregation was monitored over a 45 min period,
reaching near maximal levels of aggregation in dogs and humans within
10-15 min (Figure 7.3A,B, G, H). In contrast, cat platelets reached near maximal levels
of aggregation after 5 min (Figure 7.3G, H). Aggregation in absence of ADP or
2MeSADP at assay endpoint was low for both cat (27% and 32%, respectively)
(Figure 7.3D, E) and human platelets (32% and 38%, respectively) (Figure 7.3G, H), but
was notably higher for dog platelets (80% and 77%, respectively) (Figure 7.3A, B), with
platelet aggregation continuing to increase at a steady rate over 45 min.
Consistent with previous studies on human P2Y receptors (Takasaki et al., 2001),
2MeSADP was significantly more potent than ADP in mediating platelet aggregation in
dog (Figure 7.3C; pEC50 8.50 ± 0.26 vs 6.05 ± 0.26, P < 0.001), cat (Figure 7.3F; pEC50
8.24 ± 0.16 vs 6.06 ± 0.16, P < 0.001) and human (Figure 7.3I; pEC50 8.02 ± 0.20 vs 6.02
± 0.09, P < 0.001) platelets (Table 7.1). Despite notable differences in aggregation
kinetics between dog, cat and human platelets (Figure 7.3A, B, D, E, G, H), there were
no significant differences between the EC50 of ADP or 2MeSADP between any species
(Table 7.1). Notably, there were large differences between the Hill coefficient of the three
species, with cat platelets demonstrating a Hill coefficient approximately 3-fold greater
than that observed with dog or human platelets (Table 7.1).
Platelet aggregates (from Figure 7.3) were observed at the completion of the aggregation
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assay in PRP incubated in the presence of ADP or 2MeSADP for dogs, cats and humans
(Figure 7.4). Fewer platelet aggregates were observed in PRP incubated in absence of
nucleotides (basal) compared with PRP incubated in the presence of nucleotides for dogs,
cats and humans (Figure 7.4). Taken together, this data reveals that the modified 384-well
plate LTA assay can be used to emulate platelet aggregation in dogs, cats and humans.

Figure 7.3. ADP and 2MeSADP-induced platelet aggregation in dogs, cats and humans. (AI) PRP and PPP isolated from (A-C) dog, (D-F) cat or (G-I) human whole blood (n = 3 per species)
were incubated in the absence (in an equal volume of Tyrode’s buffer, vehicle) or presence of
increasing concentrations ADP or 2MeSADP and platelet aggregation was measured as described
in Figure 7.2. (C, F, I) Agonist-induced percent of aggregation was calculated for each PRP
sample relative to the aggregation in PPP after 10 min of aggregation and data were fit to the Hill
equation to produce concentration-response curves. (A-I) Data shown for each species are mean
± SEM from three independent experiments.
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Table 7.1. Pharmacological activity of nucleotides mediating aggregation of dog, cat and
human platelets.
Dog
Nucleotide

Hill
coefficient

pEC50
ADP
2MeSADP

6.05 ± 0.26
8.50 ± 0.20

Cat

1.48 ± 0.36
a

0.97 ± 0.15

Hill
coefficient

pEC50
6.06 ± 0.16
8.24 ± 0.16

Human

4.95 ± 1.31
a

3.00 ± 1.79

Hill
coefficient

pEC50
6.02 ± 0.09
8.02 ± 0.20

1.67 ± 0.53
a

1.23 ± 0.22

Abbreviations; pEC50, negative logarithm of the half-maximal effective concentration of agonist.
a
P < 0.001 compared to the pEC50 of ADP in respective species platelets (Student’s t-test).

Figure 7.4. Morphology of dog, cat and human platelets post-aggregation by bright field
microscopy. PRP isolated from dog, cat or human whole blood was incubated at 37°C with
shaking over 45 min (as per Figure 7.2A) in the absence (basal) or presence of 3 µM ADP or 30
nM 2MeSADP then imaged using a Lionheart FX automated live cell imager. Images were taken
at 20x magnification. Scale bar is 100 µm. Images are representative of platelet aggregation
observed throughout this chapter.

7.2.3. Expression of P2Y1 and P2Y12 in dog, cat and human platelets
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The above data (Figure 7.3 and Figure 7.4) demonstrates that ADP and 2MeSADP can
induce platelet aggregation in PRP from dogs, cats and humans, which is consistent with
the activation of recombinant human P2Y1 or P2Y12 receptors (Takasaki et al., 2001). To
determine if dog, cat and human platelets expressed P2Y1 or P2Y12 receptors, platelet
lysates from PRP were immunolabelled with anti-P2Y1 receptor or anti-P2Y12 receptor
antibodies (Table 2.4) and analysed by western blotting. Incubation with an anti-P2Y1
antibody revealed strong expression of a 50 kDa in dog and cat platelets (Figure 7.5A),
which is just larger than the predicted molecular weight of P2Y1 (42 kDa). Despite equal
loading observed by similar expression of actin, only a very faint band was observed at
this position for human platelets using the same length exposure (Figure 7.5A). In
contrast, incubation with an anti-P2Y12 antibody revealed strong expression of 40 kDa
and 75 kDa bands in human platelets, faint expression of these bands in cat platelets, and
only a 37 kDa band observed in dog platelets (Figure 7.5B). These bands are consistent
with the predicted (39 kDa) and previously reported apparent molecular weights of P2Y12
receptors on human platelets (Mundell et al., 2018). Together this data suggests that dog,
cat and human platelets express P2Y1 and P2Y12 receptors, although to varying degrees.

Figure 7.5. Expression of P2Y1 and P2Y12 in dog, cat and human platelet lysates. Platelet
lysates from dog, cat or human PRP were analysed by western blotting using an (A) anti-P2Y1
receptor (top panel), (B) anti-P2Y12 (top panel) and (A, B) anti-actin (bottom panels) antibody
prior to imaging. Arrows indicate (A) P2Y1 or (B) P2Y12 bands. Results are representative of three
independent experiments.

210

7.2.4. Ticagrelor inhibits ADP- and 2MeSADP-induced platelet aggregation in dog,
cat and human platelets
Ticagrelor is a selective P2Y12 antagonist that has well established inhibitory effects on
nucleotide-induced platelet aggregation in humans (von Kugelgen, 2017). To investigate
and compare the effect of ticagrelor on platelets of dogs, cats and humans, PRP were
preincubated with increasing concentrations of ticagrelor then incubated in absence or
presence of P2Y12 agonists at the appropriate EC80 for each species. Ticagrelor inhibited
ADP- and 2MeSADP-induced platelet aggregation in dogs (Figure7.6A-C), cats
(Figure7.6D-F) and humans (Figure7.6G-I), with maximal inhibition observed between
1-3 µM for dog and cat platelets, and between 3-10 µM for human platelets. There were
no significant differences in the potency of ticagrelor in response to activation by ADP
between dog (pIC50 6.04 ± 0.09), cat (pIC50 6.31 ± 0.04) and human (pIC50 6.46 ± 0.29)
platelets. In contrast, the potency of ticagrelor in response to activation by 2MeSADP
differed significantly between dog (pIC50 6.54 ± 0.05), cat (pIC50 6.31 ± 0.01) and human
(pIC50 6.00 ± 0.04) platelets (Table 7.2). Additionally, there was a significant difference
in the potency of ticagrelor in response to activation by ADP compared to 2MeSADP for
dog, but not for either cat or human platelets (Table 7.2). Notably, cat platelets
demonstrated higher Hill coefficients in the presence of ticagrelor for both ADP- and
2MeSADP-induced responses compared to both canine and human platelets (Table 7.2).
Ticagrelor is known to competitively and reversibly bind to the human P2Y12 receptor
(Hoffmann et al., 2014). To further investigate and compare the effect of ticagrelor on
platelets of dogs, cats and humans, PRP were preincubated in absence or presence of three
different concentrations of ticagrelor (as indicated), then incubated with increasing
concentrations of ADP or 2MeSADP. Ticagrelor demonstrated a similar pattern of
inhibition of ADP-induced aggregation in dog, cat and human platelets, although with
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seemingly greater efficacy on cat platelets (Figure 7.7A, C, E). Additionally, ticagrelor
demonstrated a similar pattern of inhibition of 2MeSADP-induced aggregation of dog
and cat platelets, which was greater than the inhibition induced by ticagrelor in human
platelets (Figure 7.7B, D, F). Collectively this data reveals that ticagrelor can inhibit
ADP- and 2MeSADP-induced aggregation of dog, cat and human platelets, with some
differing effectiveness between species.

Figure 7.6. ADP and 2MeSADP-induced platelet aggregation in dogs, cats and humans in
the absence or presence of ticagrelor. (A-I) PRP and PPP isolated from (A-C) dog, (D-F) cat or
(G-I) human whole blood (n = 3 per species) were preincubated in the absence (0 nM basal; 0.1%
DMSO in Tyrode’s buffer, vehicle) or presence of increasing concentrations ticagrelor for 15 min
then incubated in absence (0 nM basal) or presence of (A, D, G) 3 µM ADP, (B, E) 10 nM
2MeSADP or (H) 30 nM 2MeSADP (EC80 determined for each species) and platelet aggregation
was measured as described in Figure 7.2. (C, F, I) Agonist-induced percent of aggregation was
calculated for each PRP sample relative to the aggregation in PPP after 10 min of aggregation and
then normalised to the percent aggregation in absence of ticagrelor (control; agonist alone). Data
were fit to the Hill equation to produce concentration-response curves. (A-I) Data shown for each
species are mean ± SEM from three independent experiments.
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Table 7.2. Pharmacological activity of ticagrelor in response to ADP- and 2MeSADPinduced aggregation of dog, cat and human platelets.
Dog
Nucleotide

Hill
coefficient

pIC50
ADPa
2MeSADP

6.04 ± 0.09
b

6.54 ± 0.05

Cat

1.99 ± 0.62
c

1.02 ± 0.31

Hill
coefficient

pIC50
6.31 ± 0.04
6.31 ± 0.01

Human

2.80 ± 0.29
d

3.59 ± 0.09

Hill
coefficient

pIC50
6.46 ± 0.29
6.00 ± 0.04

0.70 ± 0.13
ef

1.69 ± 0.95

Abbreviations; pIC50, negative logarithm of the half-maximal inhibitory concentration of antagonist.
a
3 µM ADP (EC80 of ADP for dog, cat and human platelets).
b
10 nM 2MeSADP (EC80 of 2MeSADP for dog and cat platelets) or 30 nM 2MeSADP (EC80 of
2MeSADP for human platelets).
c
P = 0.008 compared to the IC50 of ticagrelor with ADP on dog platelets (Student’s t-test).
d
P = 0.018 compared to the IC50 of ticagrelor with 2MeSADP on dog platelets (one-way ANOVA with
Bonferroni’s post-test).
e
P < 0.001 compared to the IC50 of ticagrelor with 2MeSADP on dog platelets (one-way ANOVA with
Bonferroni’s post-test).
f
P = 0.004 compared to the IC50 of ticagrelor with 2MeSADP on cat platelets (one-way ANOVA with
Bonferroni’s post-test).

7.2.5. MRS2179 partially inhibits ADP- and 2MeSADP-induced platelet activation
in dog, cat and human platelets
MRS2179 is a selective P2Y1 antagonist that has known inhibitory effects on nucleotideinduced platelet aggregation in humans (Baurand et al., 2001). To further investigate and
compare the effect of MRS2179 on platelets of dogs, cats and humans, PRP were
preincubated in absence or presence of three different concentrations of MRS2179 (as
indicated), then incubated with increasing concentrations of ADP or 2MeSADP.
Preincubation with MRS2179 partially inhibited ADP- and 2MeSADP-induced platelet
aggregation in dogs (Figure 7.8A-C), cats (Figure 7.8D-F) and humans (Figure 7.8G-I),
with maximal inhibition observed near 30 µM for dog platelets and near 10 µM for cat
and human platelets. There were no significant differences in the potency of MRS2179
in response to activation by ADP between dog (pIC50 5.34 ± 0.12), cat (pIC50 5.34 ± 0.24)
and human (pIC50 5.51 ± 0.17) platelets.
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Figure 7.7. ADP and 2MeSADP concentration-response curves for platelet aggregation in
dogs, cats and humans in the absence or presence of ticagrelor. (A-F) PRP and PPP isolated
from (A, B) dog, (C, D) cat or (E, F) human whole blood (n = 3 per species) were preincubated
in the absence (0 nM basal; 0.1% DMSO in Tyrode’s buffer, vehicle) or presence of increasing
concentrations ticagrelor for 15 min, then incubated in absence (0 nM basal) or presence of
(A, C, E) ADP or (B, D, F) 2MeSADP (as indicated) and platelet aggregation was measured as
described in Figure 7.2. (A-F) Agonist-induced percent of aggregation was calculated for each
PRP sample relative to the aggregation in PPP after 10 min of aggregation and then normalised
to the percent aggregation in absence of ticagrelor at the maximum agonist concentration
(control). Data were fit to the Hill equation to produce concentration-response curves. (A-F) Data
shown for each species are mean ± SEM from three independent experiments.

In contrast, there was a significant difference in the potency of MRS2179 in response to
activation by 2MeSADP between dog (pIC50 5.35 ± 0.11) and human (pIC50 6.21 ± 0.20),
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but not cat (pIC50 5.77 ± 0.09) platelets (Table 7.3). There were no significant differences
in the potency of MRS2179 in response to activation by ADP compared to 2MeSADP for
any species. Of note, MRS2179 appeared to be a more effective inhibitor of ADP-induced
aggregation in dog platelets compared to cat and human platelets (Figure 7.8), however
large variations in the Hill coefficient were observed for dog and cat platelets activated
by 2MeSADP and ADP, respectively (Table 7.3).

Figure 7.8. ADP and 2MeSADP-induced platelet aggregation in dogs, cats and humans in
the absence or presence of MRS2179. (A-I) PRP and PPP isolated from (A-C) dog, (D-F) cat
or (G-I) human whole blood (n = 3 per species) were preincubated in the absence (0 nM basal;
Tyrode’s buffer, vehicle) or presence of increasing concentrations MRS2179 for 15 min then
incubated in absence (0 nM basal) or presence of (A, D, G) 3 µM ADP, (B, E) 10 nM 2MeSADP
or (H) 30 nM 2MeSADP (EC80 determined for each species) and platelet aggregation was
measured as described in Figure 7.2. (C, F, I) Agonist-induced percent of aggregation was
calculated for each PRP sample relative to the aggregation in PPP after 10 min of aggregation and
then normalised to the percent aggregation in absence of MRS2179 (control; agonist alone). Data
were fit to the Hill equation to produce concentration-response curves. (A-I) Data shown for each
species are mean ± SEM from three independent experiments.

215

MRS2179 is known to competitively and reversibly bind to the human P2Y1 receptor
(Boyer et al., 1998) and has been shown to partially displace radiolabelled 2MeSADP in
washed human platelets (Baurand et al., 2001). To further investigate and compare the
effect of MRS2179 on platelets of dogs, cats and humans, PRP and PPP were
preincubated with three different concentrations of MRS2179 (as indicated), then
incubated with increasing concentrations of ADP or 2MeSADP. Preincubation with
increasing concentrations of MRS2179 resulted in a right-shifted ADP-induced
concentration response curve for dog platelets (Figure 7.9A), which was not observed for
cat (Figure 7.9C) and human (Figure 7.9E) platelets. In contrast, preincubation with
increasing concentrations of MRS2179 revealed a similar pattern of inhibition of
2MeSADP-induced aggregation of dog (Figure 7.9B), cat (Figure 7.9D) and human
platelets (Figure 7.9F). Collectively this data reveals that MRS2179 can inhibit platelet
aggregation in dogs with greater efficacy than in cats or humans, suggesting an increased
importance for P2Y1 receptors in ADP-induced platelet aggregation in dogs.

Table 7.3. Pharmacological activity of MRS2179 in response to ADP- and 2MeSADPinduced aggregation of dog, cat and human platelets.
Dog
Nucleotide
pIC50

Cat
Hill
coefficient

pIC50

Human
Hill
coefficient

pIC50

Hill
coefficient

ADPa

5.34 ± 0.12

1.63 ± 0.36

5.34 ± 0.24

0.12 ± 2.11

5.51 ± 0.17

1.58 ± 0.37

2MeSADPb

5.35 ± 0.11

3.29 ± 1.01

5.77 ± 0.09

1.82 ± 0.55

6.21 ± 0.20

1.43 ± 0.43c

Abbreviations; pIC50, negative logarithm of the half-maximal inhibitory concentration of antagonist.
a
3 µM ADP (EC80 of ADP for dog, cat and human platelets).
b
10 nM 2MeSADP (EC80 of 2MeSADP for dog and cat platelets) or 30 nM 2MeSADP (EC80 of
2MeSADP for human platelets).
c
P = 0.008 compared to the IC50 of MRS2179 with 2MeSADP on dog platelets (one-way ANOVA with
Bonferroni’s post-test).
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Figure 7.9. ADP and 2MeSADP concentration-response curves for platelet aggregation in
dogs, cats and humans in the presence or absence of MRS2179. (A-F) PRP and PPP isolated
from (A, B) dog, (C, D) cat or (E, F) human whole blood (n = 3 per species) were preincubated
in the absence (0 nM basal; Tyrode’s buffer, vehicle) or presence of increasing concentrations
MRS2179 for 15 min, then incubated in absence (0 nM basal) or presence of (A, C, E) ADP or
(B, D, F) 2MeSADP (as indicated) and platelet aggregation was measured as described in Figure
7.2. (A-F) Agonist-induced percent of aggregation was calculated for each PRP sample relative
to the aggregation in PPP after 10 min of aggregation and then normalised to the percent
aggregation in absence of MRS2179 at the maximum agonist concentration (control). Data were
fit to the Hill equation to produce concentration-response curves. (A-F) Data shown for each
species are mean ± SEM from three independent experiments.
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7.2.6. Platelet aggregation in absence of ADP or 2MeSADP in dogs is greater and
more variable than in cats and humans
The data in this chapter demonstrated that ADP and 2MeSADP can induce aggregation
of platelets through activation of P2Y1 and P2Y12 receptors, using a high throughput ex
vivo platelet aggregation assay. However, aggregation in the absence of P2Y receptor
agonists throughout this chapter was notably higher in dog platelets compared to cat or
human platelets (Figure 7.3, Figure7.6 and Figure 7.8). Therefore, to further investigate
platelet aggregation between the three species, percent aggregation data at the endpoint
(45 min) of assays above (Figure 7.3, Figure7.6 and Figure 7.8), as well as after 10 min
of aggregation, was pooled and compared for platelets in absence or presence of their
respective EC80 for ADP or 2MeSADP (in absence of any antagonist). At assay endpoint,
aggregation of dog, cat and human platelets were all significantly greater in the presence
of ADP compared to their respective counterparts in absence of ADP (Figure 7.10A).
Percent aggregation of platelets in the presence of ADP was significantly greater in dogs
and cats compared to humans (Figure 7.10A). However, precent aggregation of platelets
in the absence of ADP was significantly greater in dogs compared to cats and humans,
with platelet aggregation in absence of ADP up to 2-fold greater in dogs compared to cats
and humans (Figure 7.10A). Similar results were obtained between platelets from the
three species incubated in absence or presence of 2MeSADP (Figure 7.10B).
Additionally, similar trends in variation of platelet aggregation were observed between
platelets from all three species incubated in absence or presence of ADP (Figure 7.10C)
or 2MeSADP (Figure 7.10D) for 10 min. However, this variation was much less than that
observed after 45 min (Figure 7.10A, B) and likely falls within the expected variation
commonly observed between species due to slight differences in receptor expression or
binding site affinity. Collectively, this data reveals increased percent aggregation and
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variation in dog, but not cat or human platelets when aggregated ex vivo using this 384well plate LTA assay in absence of nucleotide agonists.

Figure 7.10. Variation in ADP- and 2MeSADP-induced platelet aggregation between dogs,
cat and humans. (A-D) Percent aggregation data in the absence (basal) or presence of (A, C) 3
µM ADP, or (B, D) 10 nM (dog and cat) or 30 nM (human) 2MeSADP were pooled from Figures
7.3, 7.6 and 7.8. Data were compared at (A, B) assay endpoint and (C, D) after 10 min of
aggregation (used throughout to plot concentration-response curves) using a one-way ANOVA
with Bonferroni post hoc test; ***P < 0.001 compared to respective species basal,
compared to respective dog basal,

†††

P < 0.001

P < 0.001 compared to dog ADP or 2MeSADP, ‡P < 0.05

###

and ‡‡‡P < 0.001 compared to cat ADP or 2MeSADP using a one-way ANOVA with Bonferroni
post hoc test (A, B) Data shown for each species are mean percent of platelet aggregation relative
to PPP ± SEM from nine independent experiments.
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7.3.

Discussion

This chapter aimed to examine the expression and pharmacology of the P2Y1 and P2Y12
receptors on dog platelets and compare this to cat and human platelets. The data presented
in this chapter demonstrates that dogs and cats express functional P2Y 1 and P2Y12
receptors, which differ in expression to these receptors in human platelets. This was
evidenced by pharmacological data demonstrating that the P2Y1 and P2Y12 receptor
agonists, ADP and 2MeSADP, could induce platelet aggregation, while the selective
antagonists of either P2Y1 or P2Y12 receptors could inhibit platelet aggregation in dogs
and cats, with similar potency when directly compared to human platelets.
Consistent with the activation of the cloned human P2Y1 and P2Y12 receptors (Hollopeter
et al., 2001; Waldo & Harden, 2004), both ADP and 2MeSADP were full agonists of dog
and cat platelets, with respective agonist potencies similar to that observed with human
platelets. In addition, 2MeSADP was significantly more potent than ADP on dog, cat and
human platelets, consistent with what is reported for human P2Y1 and P2Y12 receptors
(von Kugelgen, 2019). Agonist-induced aggregation curves observed in human platelets
throughout this chapter were also comparable with previous studies utilising similar
plate-based LTA assays (Lordkipanidze et al., 2014; Martins Lima et al., 2018). Use of
such assays for dog and cat platelet aggregation are yet to be reported, despite the use of
other LTA assays to assess platelets from these companion animals (Gant et al., 2020).
Notably, cat platelets demonstrated greater Hill coefficients for both ADP- and
2MeSADP-induced concentration-response curves, suggesting greater cooperativity in
ligand-receptor binding on cat compared to dog and human platelets (Weiss, 1997). This
may also contribute to the increased response kinetics observed in cat compared to dog
and human platelets.
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The data presented in this chapter demonstrates that the selective P2Y12 inhibitor
ticagrelor (Husted & Van Giezen, 2009) can inhibit ADP- and 2MeSADP-induced
aggregation of dog and cat platelets, with similar potency and effectiveness to that
observed in human platelets. This data is consistent with preclinical studies demonstrating
that ticagrelor maintains its anti-platelet effects in dogs in vivo (Ravnefjord et al., 2012;
van Giezen et al., 2012). Moreover, to the best of my knowledge, this data demonstrates
for the first time the effect of ticagrelor on nucleotide-induced ex vivo aggregation of cat
platelets. This data supports the blockade of cat platelet aggregation in vivo by a second
P2Y12 receptor antagonist, clopidogrel (Hogan et al., 2015)
This chapter demonstrates partial inhibition of dog, cat and human platelet aggregation
by the selective P2Y1 receptor antagonist, MRS2179. This data is consistent with that
observed in human platelets (Baurand et al., 2001) and is in support of data published
during the course of the current study that demonstrated that MRS2179 inhibits
2MeSADP-induced aggregation of dog platelets (Chaudhary & Kim, 2019). This
functional data was supported by an increased expression of P2Y1 compared to P2Y12
receptors in dogs compared to humans and may suggest an increased importance or
potential uncharacterised role for P2Y1 receptors in dog or cat platelets.
Of note, throughout this chapter, the spontaneous aggregation of dog platelets in absence
of nucleotide agonists was significantly greater and more variable than that observed for
cat or human platelets. The exact reason for this remains unclear, however variations in
canine platelet concentrations may be a contributing factor. Canine PRP volumes and
platelet counts following isolation were much more variable than cat or human PRP
volumes and platelet counts (results not shown) with a number of dogs recruited for this
study returning platelet counts <1.5x108 platelets.mL-1 (and could not be included for
analysis, results not shown). This variation may also be a result of a number of other
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factors including age, sex, breed and neutering status, which are known to have an impact
on platelet concentrations in dogs (Lawrence et al., 2013). Another explanation for the
variation in dog platelet concentrations may include abnormalities in platelet size as a
result of macrothrombocytopaenia (Hayakawa et al., 2016; Pedersen et al., 2002; Santoro
et al., 2007) or differences in ATP/ADP ectonucleotidase (CD39/CD73) expression
(Caiazzo et al., 2020) which are also known to have an impact on platelet function.
Variations in dog platelet function may also arise from genetic variants, such as that
identified in a family of Greater Swiss Mountain dogs which results in a deletion of serine
173 from the second loop of the extracellular domain (Boudreaux & Martin, 2011; Flores
et al., 2017). This deletion has been shown to impair ADP-induced platelet function and
has been associated with post-operative haemorrhage in these dogs (Flores et al., 2017).
However, none of the dogs in this study presented with any known bleeding disorders.
There are a limited number of studies reporting variations in dog platelet aggregation.
Spontaneous platelet aggregation was previously observed in dogs in absence of agonists
after long term (> 20 min) aggregation assays (Marschner et al., 2012), which could be
linked to the use of non-sodium citrate anticoagulants (Mani et al., 2011) or
concentrations of sodium citrate different from that used in the current study (Morales et
al., 2007). Consistent with our observations, high biological variability in platelet
function has been reported within and between platelet samples from healthy dogs studied
over four weeks (Blois et al., 2015). Other studies have analysed ex vivo aggregation of
dog platelets under different conditions using a range of both laboratory and point-of-care
methods, including LTA, whole blood impedance aggregometry (Multiplate analyser),
platelet function analysers (PFA-100/200) or Plateletworks platelet function screen,
(Bjorkman et al., 2013; Bryant et al., 2008; Chaudhary & Kim, 2019; Kalbantner et al.,
2010; Niitsu et al., 2008; Post et al., 2008; Ravnefjord et al., 2012; Saati et al., 2018;
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Soslau et al., 1993; Wang et al., 2010). However, most of these studies do not comment
on platelet function in absence of P2Y12 agonists or over a longer period of activation as
reported in this chapter. In addition, it should be noted that variability in the Hill
coefficient of agonists and antagonists was particularly notable between platelets from
dogs, cats and humans. This variability suggests a need for further studies with larger
sample numbers to validate the findings in this thesis.
The LTA assay is considered the gold standard for platelet function testing
(Lordkipanidze et al., 2007), however traditional aggregometers are limited by the
requirement for larger sample volumes and low sample throughput (Sun et al., 2019). The
lack of a reliable platelet function test with a low volume, high throughput method has
potentially limited the ability to study the pharmacology of novel compounds using ex
vivo aggregation of platelets from mice, dogs and other small mammals. Several studies
have successfully applied the principle of LTA to multi-well plates for assessing human
platelet aggregation (Armstrong et al., 2009; Chan et al., 2011; Lordkipanidze et al., 2014;
Martins Lima et al., 2018), providing a viable method for testing platelet function using
high-throughput methods and low sample volumes in a laboratory setting. Consistent with
these studies, the data presented in this chapter has demonstrated that this high throughput
384-well plate LTA assay can be used to measure aggregation of platelets from small
volumes of dog, cat and human PRP. However, notable variability exists amongst platelet
function tests in clinical and laboratory settings worldwide (Cattaneo et al., 2009;
Lordkipanidze et al., 2007; Paniccia et al., 2015; Renda et al., 2010) and as such, it
remains to be determined how the assay used throughout this chapter compares with other
platelet function tests. This chapter was limited in terms of sample size, with each
experimental condition only determined using three different donors per species. Further
research analysing platelet aggregation in dogs would benefit from incorporating a greater
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sample of dogs and utilising a panel of different platelet function tests, as has recently
been suggested (Zwart et al., 2019).
This chapter demonstrated the expression of P2Y1 and P2Y12 receptors on dog, cat and
human platelets using anti-P2Y1 and anti-P2Y12 antibodies. In contrast, the expression of
P2Y1 receptors was greater in dog and cat platelets compared to human platelets, with the
opposite observed for the P2Y12 receptor. While differences in expression may contribute
to variation in platelet aggregation between species, differences in expression could also
be attributed to lack of cross-reactivity of these antibodies between species. Despite this
however, the recognition epitopes of the dog P2Y1 receptor, as well as dog and cat P2Y12
receptors differ from the respective human receptors by only one amino acid. Of note, the
anti-P2Y12 antibody detected bands at 37-40 kDa and 75 kDa, corresponding to the
reported monomeric and dimeric species of human P2Y12 (Mundell et al., 2018), while
only the monomeric species was observed for P2Y1. Furthermore, despite a focus on the
role of P2Y receptors on dog platelets, this chapter did not explore other platelet
purinergic receptors, such as the P2X1 and P2Y14 receptors (Dovlatova et al., 2008; Vial
et al., 1997), with the former known to have a role in human platelet Ca2+ responses, shape
change and amplification of P2Y-mediated aggregation (Jones et al., 2014). The role of
the platelet P2Y14 receptor, which is activated by uridine-5’diphosphate (UDP)-glucose,
remains unclear, although may be involved in neutrophil recruitment (Amison et al.,
2017). Other receptors with known roles in platelet function in humans and mice, such as
the ATP/ADPases CD39 and CD73 (Chaurasia et al., 2020; Covarrubias et al., 2016;
Marcus et al., 2001), may also play an increasingly important role in canine platelet
aggregation and thrombosis.
In conclusion, this chapter provides direct evidence of P2Y1 and P2Y12 receptor
expression on dog and cat platelets and has compared this to human platelets. Dog and
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cat platelets were aggregated by known human P2Y1 and P2Y12 receptor agonists, ADP
and 2MeSADP, and platelet aggregation could be inhibited by the selective P2Y12
receptor antagonist ticagrelor. The selective P2Y1 receptor antagonist MRS2179 also
inhibited platelet aggregation in dogs with greater efficacy compared to cat and human
platelets. Together this chapter emphasises the potential for targeting platelet P2Y
receptors in companion animals using currently available P2Y1 or P2Y12 inhibitors for
the treatment of thrombosis or haemostasis.
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Chapter 8: General discussion and conclusions
8.1.

Introduction

Purinergic signalling describes the cell signalling pathways which encompass a family of
receptors, namely the P1 adenosine receptors, and the P2X and P2Y nucleotide receptors
(Burnstock & Knight, 2004; Fredholm et al., 2000). Over the last three decades since P2
receptors were first cloned and characterised, our understanding of the roles that these
receptors play in mediating mammalian physiology and pathophysiology has increased
exponentially (Burnstock, 2016a; Burnstock & Boeynaems, 2014; Burnstock & Pelleg,
2015; Burnstock & Ralevic, 2014). This has made these receptors highly attractive for
therapeutic targeting. Notably, a number of P2 receptors, including P2Y1, P2Y2, P2Y12,
P2X4 and P2X7, amongst others, have demonstrated roles in chronic inflammatory or
neuropathic pain (Bernier et al., 2018; Zhang & Li, 2019). These disorders remain highly
problematic and constantly evolving areas of both human and veterinary medicine
(Garland, 2014; Grubb, 2010a; Walsh, 2016).
In humans, the P2Y1 and P2Y12 receptors also play important roles in mediating the
activation and aggregation of platelets during thrombotic events, such as ischemic stroke
(Daniel et al., 1998; Hechler, Léon, et al., 1998; Jin et al., 1998; Savi et al., 1998). In dogs
however, the expression of functional platelet P2Y receptors in had not been directly
reported prior to this thesis, and functional data on P2Y receptor activation on dog
platelets has relied on models of canine thrombosis (Ravnefjord et al., 2012; van Giezen
et al., 2012), as well as data on human P2Y1 and P2Y12 receptors (Hollopeter et al., 2001;
Léon et al., 1997). A number of canine P2Y receptors, including the P2Y1, P2Y2 and
P2Y11 receptor, have been described through cloning from Madin-Darby canine kidney
(MDCK) cells (Hughes et al., 2003; Zambon et al., 2001; Zambon et al., 2000). However,
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characterisation of the roles of canine P2Y receptors since these reports have been limited.
In contrast, the canine P2X7 receptor has been relatively well characterised, both by our
group and by others (Sluyter, 2017). However, prior to this thesis, there was limited
understanding of the genetics, expression and function of all other canine P2X receptors,
such as the canine P2X4 receptor.

8.2.

Canine P2RX7 gene missense variants in dogs are associated with

brachycephalic traits or specific breeds of dog
Data reported in Chapter 3 expanded on a previous study by our group that identified and
functionally characterised four canine P2RX7 gene missense variants in a cohort of 65
dogs (Spildrejorde, Bartlett, et al., 2014). Combining data from the 65 dogs reported in
the previous study (Spildrejorde, Bartlett, et al., 2014), with a further 69 dogs in the
current study, this thesis reports the prevalence of two previously reported (Lindblad-Toh
et al., 2005), commonly occurring canine P2RX7 missense variants, rs23314713
(Phe103Leu) and rs23315462 (Pro452Ser). Two others which were previously reported
(Spildrejorde, Bartlett, et al., 2014), but less frequently observed, rs851148233
(Arg270Cys) and rs850760787 (Arg365Gln), were also reported in Chapter 3. Analysis
of this data revealed that the rs23314713, but not the rs23315462 variant, was associated
with brachycephaly in dogs. Although canine brachycephaly is not considered a disorder
in itself, it is a prominent skeletal deformation that is common in modern domestic breeds,
such as the Bulldog and Staffordshire Bull Terrier (Asher et al., 2009; Bannasch et al.,
2010) and is commonly attributed to obstructive airway syndrome (Packer et al., 2015).
A study has revealed an association between the rs23314713 variant and an increased
susceptibility to glioma (Truve et al., 2016), a disease more frequently observed in
brachycephalic dogs (Hayes et al., 1975; Snyder et al., 2006; Song et al., 2013). This may
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suggest

that

brachycephalic

breeds

are

more

susceptible

to

glioma

than

non-brachycephalic breeds. However, this would require further investigation of
brachycephalic traits and the presence of the rs23315462 variant in dogs with and without
glioma before further associations could be made. It should be noted however, that
approximately half of the brachycephalic dogs sequenced for P2RX7 missense variants
were Staffordshire Bull Terriers, all of which were at least heterozygous for the
rs23315462 variant. Their overrepresentation in this study is likely a result of their
increased popularity amongst the Australian population (Teng et al., 2016). Given this, it
may be suggested that the rs23314713 variant is not associated with brachycephaly per
se, but rather with certain breeds of a given ancestry that commonly display
brachycephalic traits, such as the Staffordshire Bull Terrier.
The rs851148233 and rs850760787 variants were not assessed for association with
brachycephaly in this thesis due to their low prevalence in dogs. It was noted that the
rs851148233 and rs850760787 variants were associated with Cocker Spaniel and
Labrador Retriever breeds, respectively (Chapter 3). The rs851148233 has yet to be
reported in other studies, although few Cocker Spaniel samples have been analysed using
genome-wide sequencing studies to date (Jagannathan et al., 2019). Sequencing of
additional dogs, particularly of Cocker Spaniel pedigree, would further elucidate the
prevalence of this variant amongst the canine population. In contrast, the association of
the rs850760787 variant with dogs of Labrador Retriever pedigree reported in Chapter 3
is consistent with canine whole-genome sequencing studies which have also reported this
variant in at least three other Labrador Retrievers and a Landseer (Auton et al., 2013;
Jagannathan et al., 2019). Future studies should focus on assessing the prevalence of this
variant in Labrador Retrievers, which may reveal further associations with disorders
common to this breed, such as hip and elbow dysplasia (Edwards et al., 2018; Lavrijsen
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et al., 2014) or mast cell tumours (Hayward et al., 2016).
Although it is yet to be determined if P2RX7 gene variants are associated with other
diseases in dogs, studies have demonstrated roles for the canine P2X7 receptor in
inflammatory signalling processes, such as IL-1β release (Roman et al., 2009;
Spildrejorde, Curtis, et al., 2014), phosphatidylserine exposure and haemolysis of
erythrocytes (Faulks et al., 2016; Sluyter, Shemon, Hughes, et al., 2007). Given the roles
of these signalling processes in human disease (Burnstock, 2016b; Sluyter, 2015), it is
suggested that variants which alter canine P2X7 receptor function, such as the
rs23314713 (partial loss of function), rs850760787 (partial loss of function) and
rs851148233 variants (loss of function), may be implicated in canine inflammatory
disorders. This is supported by reports of human P2RX7 missense variants coding for loss
or gain of function P2X7 receptors that are associated with accelerated bone loss and risk
of fracture (Gartland et al., 2012; Jorgensen et al., 2012), reduced cardiovascular risk
(Gidlof et al., 2012), multiple sclerosis (Sadovnick et al., 2017) and reduced pain
signalling (Stokes et al., 2010).

8.3.

The canine P2RX4 gene is highly conserved amongst domestic dog

breeds and encodes a functional P2X4 receptor
Despite the prevalence of at least four missense mutations across just four of the 13 exons
of the canine P2RX7 gene (Chapter 3), data from this thesis reported no missense
mutations across the 12 exons of the canine P2RX4 gene in a study of 101 dogs
(Chapter 4). The contrast in frequency of canine P2RX4 and P2RX7 variants suggests that
the canine P2X4 receptor is highly conserved and may play a crucial role in canine
physiology. This data parallels that observed in humans, with a reduced frequency of
P2RX4 compared to P2RX7 missense variants (Stokes et al., 2010; Stokes et al., 2011). It
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could be considered that variants of the P2RX4 gene have been unintentionally selected
out of modern domestic dogs, consistent with reports of genome-wide loss of genetic
diversity due to domestication, selective breeding and subsequent population bottlenecks
(Ostrander et al., 2017).
Notably, genome-wide association studies have analysed samples from a number of grey
wolves and free-ranging canines indigenous to Asia, eastern Europe or North America,
however there were no reported P2RX4 missense variants in these canines (Auton et al.,
2013; Freedman et al., 2014; Jagannathan et al., 2019; Wang et al., 2013). This is despite
a number of canine P2RX7 missense variants reported amongst these samples. This
further supports suggestions that the P2RX4 gene may have been well conserved
throughout canine evolution and domestication. However, this suggestion is complicated
by sharp bottlenecks in wolf populations which occurred shortly after their divergence
from dogs, suggesting that genetic diversity amongst modern wolves may not accurately
represent that of their early ancestors (Freedman et al., 2014). Combining the canine
P2RX4

gene

sequencing

data

from

Chapter

4

with

that

reported

from

whole-genome sequencing studies, canine P2RX4 variant data has now been assessed in
over 700 dogs (Auton et al., 2013; Freedman et al., 2014; Jagannathan et al., 2019; Wang
et al., 2013). Given this, the canine P2RX4 gene appears to be highly conserved amongst
domestic and indigenous dogs, as well as grey wolves. Thus, it remains to be determined
if variants of this gene are associated with canine pathophysiology, but if so, they are
most likely to be rare or associated only with specific breeds.
Studies in humans have demonstrated that a P2RX4 loss of function variant, rs28360472
(Tyr315Cys), is associated with increased pulse pressure (Stokes et al., 2011) which is
supported by impaired vasculature dilation and increased blood pressure in P2X4
receptor-deficient mice (Yamamoto et al., 2006). Others have demonstrated that P2X4
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receptor-deficient mice display reduced hypersensitivity in models of inflammatory and
neuropathic chronic pain (Tsuda et al., 2009; Ulmann et al., 2008). In contrast,
potentiation of P2X4 receptor function in mice using ivermectin, a safe and commonly
used anti-parasitic in veterinary medicine, has demonstrated promising results for
neuroprotection and nerve remyelination (Zabala et al., 2018). To this end, both inhibition
and potentiation of P2X4 receptors have been highlighted as potential therapeutic
strategies for treating disease in humans (Stokes et al., 2017). However, this would require
careful development and testing of modulators of P2X4 receptor function (Stokes et al.,
2020), as well as a highly personalised medical approach such as that suggested for the
treatment of alcohol use disorders with ivermectin (Ch'Ng & Lawrence, 2018). Given the
unprecedented level of genetic conservation of canine P2RX4, the P2X4 receptor in dogs
may prove to be an appealing candidate for veterinary therapeutics, for post-operative
pain management, as well as treatment of cardiovascular or neurodegenerative diseases.
Until now however, evidence for functional canine P2X4 receptors was based on
functional characterisation of human and rodent P2X4 receptors (Bianchi et al., 1999;
Townsend-Nicholson et al., 1999) and molecular modelling from the published zebrafish
P2X4 crystal structure (Hassanzadeh-Ghassabeh et al., 2013; Kawate et al., 2009). Data
from Chapter 5 demonstrated that the canine P2RX4 gene encoded a functional
lysosomal-targeting receptor which formed an ATP-gated Ca2+ channel similar to that
observed with the human P2X4 receptor. Consistent with that previously reported for the
human P2X4 receptor (Stokes et al., 2017), canine P2X4 receptor responses were
potentiated by ivermectin and inhibited by 5-BDBD, paroxetine and duloxetine. A
number of differences were observed when compared to the human P2X4 receptor, such
as the limited effectiveness of BzATP and BX430 towards the canine P2X4 receptor
(Chapter 5). Future studies would benefit from structural modelling and functional
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characterisation of mutant canine P2X4 receptors, as has been conducted recently for a
number of other P2X4 receptor orthologues to identify important residues and domains
for docking of BX430 (Ase et al., 2019). This may provide further detail into the
mechanisms behind the binding of selective P2X4 receptor allosteric modulators and
antagonists.
Despite demonstrating heterologous expression and function of canine P2X4 receptors in
Chapter 5, the expression of P2X4 receptors in dogs still remains poorly understood.
Future studies should focus on studying the distribution and expression of P2X4 receptors
amongst a wide range of canine cells and tissues. This would allow further
characterisation of the function of canine P2X4 receptors in specific cells or tissues and
provide a platform for assessing the role of P2X4 receptors in canine physiology and
pathophysiology. Nonetheless, data from this thesis demonstrated low amounts of
expression of P2X4 receptors on DH82 canine macrophages. This expression correlated
with P2X4 receptor activation and inhibition as determined by Ca2+ flux assays
(Chapter 6) using ligands and antagonists which had previously been confirmed to target
canine the P2X4 receptor (Chapter 5). DH82 cells demonstrated a persistent Ca2+
response to ATP in the presence of selective and non-selective P2X receptor antagonists.
This suggested the presence of other non-ionotropic purinergic receptors, such as
Gq/11-coupled P2Y receptors (Abbracchio et al., 2006). Thus, further pharmacological
characterisation of DH82 canine macrophages was carried out to determine if this cell
line provided a suitable model for studying endogenous canine purinergic signalling. This
revealed the expression of a functional receptor which was sensitive to ATP,
UTP and thapsigargin, and could evoke Ca2+ responses in the absence of extracellular
Ca2+. This receptor was confirmed as the canine P2Y2 receptor through inhibition by
suramin, and for the first time, using the selective P2Y2 receptor antagonist AR-C118925
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(Chapter 6). P2Y2 receptors in DH82 cells were pharmacologically similar to the canine
P2Y2 receptor cloned from MDCK cells (Zambon et al., 2000). Thus, the data in this
thesis confirmed the presence of at least two P2 receptors, P2X4 and P2Y2, on DH82
canine macrophages, establishing this cell line as a useful model for studying endogenous
canine purinergic signalling and implicating a role for these receptors in canine
macrophage physiology.
Other studies have reported both P2X4 and P2Y2 receptors on macrophages and microglia
(Bowler et al., 2003; Kobayashi et al., 2006; Layhadi et al., 2018; Stokes & Surprenant,
2007, 2009), while both of these receptors are also implicated in chronic pain signalling
(Trang et al., 2009; Ulmann et al., 2008; Zhu et al., 2015). Despite this, co-stimulation of
P2X4 and P2Y2 receptors in macrophages and microglia, as well as their combined
contribution to chronic pain signalling pathways has not been directly studied. A recent
study has demonstrated the importance of the chemokine receptor type 2 (CCR2) and its
ligand CCL2, for the direct communication of monocyte-derived macrophages and
microglia for regulating inflammatory responses following nerve injury (Greenhalgh et
al., 2018). Moreover, P2Y2 activation on rat macrophages is known to stimulate the
synthesis and release of CCL2 (Stokes & Surprenant, 2007), which was independently
demonstrated to upregulate cell surface expression of microglial P2X4 receptors through
lysosomal exocytosis (Toyomitsu et al., 2012).
As such, I propose here a mechanism of P2Y2-P2X4 receptor co-signalling in
macrophages (and/or microglia) (Figure 8.1) which involves (1) the initial activation of
cell surface P2Y2 receptors following pain stimuli (e.g. inflammatory challenge or nerve
injury). (2) This stimulates PLC-mediated CCL2 secretion (Higgins et al., 2014; Stokes
& Surprenant, 2007) (3, 4) upregulating the expression and trafficking of P2X4 receptors
on ATP-rich lysosomes (inactive at pH <5) to the cell surface (Huang et al., 2014;
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Toyomitsu et al., 2012). (5) These cell surface P2X4 receptors are locally activated by
extracellular ATP, released through lysosomal exocytosis (Qureshi et al., 2007;
Sivaramakrishnan et al., 2012) and the subsequent P2Y2-P2X4-mediated increase in
intracellular Ca2+ results in (6) the synthesis and release of prostaglandin E2 from
macrophages (Ulmann et al., 2010) or brain-derived neurotrophic factor from microglia
(Trang et al., 2009), which heightens responses to chronic inflammatory or neuropathic
pain stimuli, respectively. Given the apparent co-expression of P2Y2 and P2X4 receptors
on DH82 macrophages, this cell line may provide a suitable model for studying chronic
pain signalling mechanisms of dogs in vitro. Future studies should focus on investigating
these pathways in DH82 cells. Of note, a recent study has reported the polarisation of
DH82 macrophages, as well as canine monocyte-derived macrophages, toward a
classically activated (M1) and alternatively activated (M2a) macrophage subtype
(Herrmann et al., 2018). The DH82 macrophages used throughout this thesis were
unstimulated and thus further study on the expression and function of P2 receptors on
activated DH82 macrophages remains of interest.

8.4.

Canine platelets express P2Y1 and P2Y12 receptors which together

play roles in mediating platelet aggregation
Data from this thesis provided direct evidence of P2Y1 and P2Y12 receptor expression on
platelets from dogs (Chapter 7), implicating a role for these receptors in canine platelet
aggregation and thrombosis. Until now, the expression of P2Y receptors on dog platelets
had not been directly reported. Notably, the expression of P2Y12 receptors on dog platelets
appears to be lower in comparison to P2Y1 receptors, a finding that was reciprocated with
cat platelets, but opposite to that of human platelets (Chapter 7). Future studies could
explore these species differences through radioligand binding, which has been used to
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demonstrate that human platelets contain ~150 P2Y1 receptor binding sites

Figure 8.1. Proposed mechanism for P2Y2-P2X4 receptor-mediated chronic pain signalling
in macrophages. (1) Chronic pain stimuli, such as an inflammatory challenge can result in an
increase in extracellular ATP, activating cell-surface P2Y2 receptors. (2) The activation of P2Y2
receptors induces the upregulation, and PLC-mediated secretion of CCL2, which in turn (3)
stimulates CCR2. P2Y2 receptor activation also results in an increase in intracellular Ca2+ through
activation of IP3 receptors (IP3R). Activation of CCR2 has been shown to (4) increase the
expression and trafficking of P2X4 receptors on ATP-rich lysosomes, which maintain P2X4
receptors in an inactive state due to the low luminal pH (<5) of lysosomes. (5) Lysosomal
exocytosis results in the release of ATP which locally activates P2X4 receptors, resulting in an
influx of Ca2+. (6) This increased intracellular Ca2+ stimulates the p38 MAPK/phospholipase A2
(PLA2) pathway, resulting in the cyclooxygenase-mediated conversion of arachidonic acid (AA)
to PGE2. The subsequent release of PGE2 then contributes to chronic pain signalling. Figure
created using BioRender.

per platelet (Baurand et al., 2001) and ~400 P2Y12 binding sites per platelet (Ohlmann et
al., 2013). Platelets from mice are reported to contain ~650 P2Y12 receptor binding sites
per platelet (Ohlmann et al., 2013), suggesting that differences in the expression of
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platelet P2Y receptors between species is not uncommon.
To study P2Y receptor function on canine platelets, the current study established a
low-volume, high-throughput, 384-well plate aggregation assay in line with
recommendations for standardisation of light transmission aggregometry (LTA)
(Cattaneo et al., 2013). This assay offered a suitable alternative for studying platelet
aggregation and aligned with ethical guidelines for replacement, reduction and refinement
of animals and animal tissues in research (Fenwick et al., 2009). Given ethical restrictions
on blood collection volumes from dogs and cats throughout this study (up to 5 mL), this
assay allowed a more detailed pharmacological investigation of platelet P2Y receptors
which would not be possible with traditional LTA methods (Tsoupras et al., 2018).
During the course of this research, a study was published describing a similar 384-well
plate aggregation assay that has demonstrated suitability for high-throughput screening
of anti-platelet therapeutic compounds (Martins Lima et al., 2018).
In line with current demand for high-throughput screening methods, the use of multi-well
plate-based aggregometry methods have been more frequently reported in recent years
(Chan, Armstrong, et al., 2018; Lordkipanidze et al., 2014; Vinholt et al., 2017).
However, it has been demonstrated that ADP-induced aggregation of human platelets
differs significantly with increasing mixing speeds up to 1200 rpm in plate-based assays
(Chan, Leadbeater, et al., 2018). Furthermore, the use of an external vortex mixer with
fixed-point readings gave different results to that observed using a kinetic plate reader
(Chan & Warner, 2012), emphasising the role of the mechanical environment in platelet
aggregation. Despite the benefits of plate-based methods, these studies highlight potential
limitations compared to traditional cuvette-based LTA and as such, future studies would
benefit from a more standardised approach to plate-based LTA.

236

Data from this thesis demonstrated that ADP and 2MeSADP induced aggregation of dog
platelets ex vivo and that this was inhibited by P2Y1 and P2Y12 antagonists, MRS2179
and ticagrelor, respectively (Chapter 7). This data is consistent with reports of platelet
function in canine models of arterial thrombosis (Thomason et al., 2016). Dog platelets
demonstrated similar pharmacological profiles to cat and human platelets, however
canine platelet aggregation induced by ADP appeared to be more sensitive to inhibition
by MRS2179 when compared to cat and human platelets. This data is consistent with a
recent study which demonstrated that MRS2179 could inhibit 2MeSADP-induced
aggregation of dog platelets (Chaudhary & Kim, 2019), supporting a role for the P2Y1
receptor in the activation of dog platelets.
Notably, it was observed throughout Chapter 7 that aggregation of dog platelets in
absence of P2Y receptor agonists revealed high amounts of spontaneous aggregation of
these platelets. This data is consistent with a report of spontaneous aggregation of dog
platelets under similar conditions to that used in this thesis (Marschner et al., 2012), while
high biological variability with dog platelet aggregation has also been reported (Blois et
al., 2015). Although the reason for this remains unknown, spontaneous aggregation was
not typically observed with human platelets, nor for cat platelets which were collected
and transported from the same veterinary hospital and processed in the exact same manner
as dog platelets. Given the similar expression profiles of P2Y1 and P2Y12 receptors
between dog and cat platelets, it seems unlikely that differences in P2Y receptor
expression would be solely responsible for spontaneous aggregation of dog platelets.
Furthermore, neither MRS2179 or ticagrelor inhibited spontaneous aggregation and as
such, the data presented in this thesis does not support a functional role for canine P2Y1
or P2Y12 receptors in spontaneous aggregation of dog platelets. Notably, it has been
shown that stimulation of A2 adenosine receptors inhibited platelet activation in human,
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but not dog models of thrombosis (Linden et al., 2008). This may suggest that canine
platelets lack functional adenosine receptors and as such, future studies should investigate
the expression and function of adenosine receptors, as well as ectonucleotidases involved
in the breakdown of nucleotides to adenosine (CD39/CD73), on dog platelets. This may
lead to identifying novel functions of platelet receptors in dogs, or even novel receptor
isoforms involved in dog platelet physiology. However, if true, this highlights a potential
issue for the use of canine models of thrombosis for studying the effect of anti-platelet
drugs designed for use in humans.
Similar to P2X4, P2X7 and P2Y2 receptors, the platelet P2Y receptors also have
demonstrated roles in chronic pain signalling (Gu et al., 2016; Kobayashi et al., 2008;
Tozaki-Saitoh et al., 2008). A recently published study has reported that the P2Y12
receptor antagonist, clopidogrel, can prevent severe post-operative pain (Tsuchida et al.,
2020). This is consistent with an earlier study in rats which demonstrated that clopidogrel,
as well as a second P2Y12 receptor antagonist (cangrelor), can alleviate allodynia in rats
following nerve injury (Tozaki-Saitoh et al., 2008). However, none of the dogs studied in
Chapter 7 were reported to be on anti-platelet drugs, and as such, no conclusions can be
made regarding the effect of P2Y12 antagonists on canine nociception. Despite this, a
recent consensus statement of the American College of Veterinary Internal Medicine has
suggested clopidogrel for the treatment of immune-mediated haemolytic anaemia in dogs
(Swann et al., 2019), suggesting it is safe for use in dogs at the recommended dosages.
Additionally, the effectiveness and safety of clopidogrel in the treatment of canine arterial
thrombosis has been recognised (Brainard et al., 2010; Thomason et al., 2020). Thus, in
addition to potential benefits of anti-platelet drugs in dogs for treatment of thrombosis, it
may be of interest to veterinary practices to study the effect of P2Y12 receptor antagonists
on nociception in natural models of canine chronic pain. Studies such as this would
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greatly benefit from a cell model of pain signalling, such as the proposed DH82 canine
macrophage model (Chapter 6).
Additionally, reversible P2Y12 antagonists such as ticagrelor and cangrelor have been
demonstrated to alter lysosomal pH in retinal epithelial cells (Lu et al., 2018). Given the
expression of canine P2X4 receptors in lysosomal compartments (Chapter 5), it could be
suggested that activation of the canine P2X4 receptor, like the rat P2X4 receptor (Huang
et al., 2014), is tightly controlled by lyosomal pH. Future studies may look to study the
expression of P2X4 and P2Y12 receptors on canine macrophages and microglia and
determine the effect that P2Y12 antagonists have on lysosomal pH and the activation of
P2X4 receptors in these cells. This may provide further detail on macrophage/microglia
nociceptive signalling pathways involving canine P2Y2, P2X4, P2X7 and P2Y12 receptors

8.5.

Conclusions

In summary, this thesis describes the genetics of two canine P2X receptors, the P2X4 and
P2X7 receptors, with the former being unequivocally more conserved compared to the
latter. At least four previously reported missense variants were observed in the canine
P2RX7 gene, one with association to canine brachycephaly, one associated with Cocker
Spaniels and one associated with Labrador Retrievers. Moreover, this study has
demonstrated for the first time, the direct functional expression of a number of canine P2
receptors, including the P2X4 and P2Y12 receptors. To further support these findings,
future studies could analyse P2 receptor expression using a panel of cells and tissues
known to express P2 receptors in humans and rodents. This should be validated using
multiple methods, such as PCR, flow cytometry and western blotting, given the variability
in antibody detection methods. This would also aid in expanding the knowledge of P2
receptor expression in dogs and allow further probing of their role in canine physiology
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and pathophysiology. This data could also aid in targeting large-scale genomic screens
for novel P2 receptor genetic variants that may be associated with canine
pathophysiology.
The function of the canine P2X4 receptor was reported through pharmacological
activation, potentiation and inhibition in a heterologous expression system. Activation of
the canine P2X4 receptor by ATP and potentiation of these responses by ivermectin was
similar to that of the human P2X4 receptor. In contrast, the canine P2X4 receptor
demonstrated decreased sensitivity to activation and inhibition by BzATP and BX430,
respectively. Furthermore, canine P2X4 receptor expression and function has now also
been described in a canine cell model of purinergic signalling; DH82 canine
macrophages, which also express functional P2Y2 receptors. To expand on these findings
it would be of interest to firstly determine the agonist/antagonist profile of DH82 cells
following cytokine-stimulation and polarisation, as described in Chapter 6. Secondly, the
physiological role of canine P2 receptors, such as P2X4 and P2Y2 receptors, could be
assessed in resting and polarised DH82 cells through investigation of their trafficking and
sub-cellular localisation. This may further expand our understanding of the indirect
mechanisms by which these receptors interact and their roles in signalling of pain and
inflammation. Thirdly, this data should be confirmed in native canine cells, such as in
canine monocyte-derived macrophages and microglia, to further expand on the suggested
roles of these receptors in canine physiology and pathophysiology.
Finally, the function of platelet P2Y1 and P2Y12 receptors was investigated on dog
platelets in comparison to cat and human platelets using a 384-well plate LTA assay
modified for low sample volume. Species-similarities were observed in the efficacy and
potency of ADP and 2MeSADP, as well as with ticagrelor. In contrast, dog platelets
activated by ADP appeared more sensitive to inhibition of P2Y1 by MRS2179. Notably,
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platelets from dogs commonly exhibited unanticipated levels of spontaneous aggregation
that were not observed in platelets from cats or humans, potentially highlighting an
unknown difference between canine and human platelet physiology. Future studies
should validate these species differences using a range of other methods for assessing
platelet function, such as impedance aggregometry, high-shear adherence (PFA-200) and
flow cytometry-based methods. This would also aid in the implementation of highthroughput assays as standardised methods of assessing platelet function disorders.
Standardisation of high-throughput platelet function assays, combined with large-scale
genetic screening, would allow researchers to easily identify novel genetic variants that
may be associated with increased risk of thrombotic events. This would further benefit
point-of-care treatment and allow for greater confidence in the prescription of targeted
therapies. Future studies should also focus on collaborative efforts to recruit greater
sample sizes, spanning a wide range of dog breeds. This would allow increased
confidence in the analysis of breed-specific platelet function disorders, such as that
observed in the Greater Swiss Mountain Dog.
Collectively, this thesis reveals that dogs express functional purinergic receptors and that
purinergic signalling pathways may play important roles in physiology and
pathophysiology as observed in humans and rodents.
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Appendices

Appendix Figure A5.1. Secondary antibody control for anti-LAMP1 antibody. 1321N1
human astrocytoma cells, transfected with canine or human P2X4-EmGFP or pEmGFP alone,
were fixed, permeabilised and stained with PE-conjugated anti-mouse secondary antibody. Cells
were imaged by confocal microscopy and co-localisation analysed by ImageJ. Images are
representative results of three independent experiments. Scale bar = 20 µm.
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Appendix Figure A6.1. Decay kinetics of ATP-induced Ca2+ responses in 1321N1 transfected
with canine P2X4-EmGFP and DH82 cells. 1321N1 cells transfected with canine P2X4EmGFP or DH82 cells in extracellular Ca2+ solution were loaded with Fura-2 and activated with
10 or 100 µM ATP. ATP concentrations of 10 µM and 100 µM are maximal (max) for
heterologously expressed P2X4 (Figure 5.9) and DH82 responses (Figure 6.2), respectively. Ca2+
traces (ΔF340/380) were measured and one-phase decay (τ) was calculated from the peak of each
Ca2+ trace. Data shown are mean ± SEM from nine (1321N1) or six (DH82) independent
experiments. *P < 0.05,

***

P < 0.001 and not significant (ns) compared to indicated treatment

using a one-way ANOVA with Bonferroni post hoc test.
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Appendix Figure A6.2. Thapsigargin-induced Ca2+ mobilisation in DH82 cells in the absence
of extracellular Ca2+. (A, B) DH82 cells in Ca2+ free solution were loaded with Fura-2, incubated
in absence (control) or presence of 1 µM thapsigargin and Fura-2 fluorescence was recorded. (A)
Ca2+ traces (F340/380) were measured and (B) net Ca2+ movement calculated. Data shown are
mean ± SEM from four independent experiments. ***P < 0.001 compared to control using a
parametric Student’s t-test.
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Appendix Figure A6.3. Cell surface expression of P2Y2 receptors on DH82 cells. DH82 cells
were fixed and stained with anti-P2Y2 receptor primary antibody, followed by Alexa Fluor594conjugated anti-rabbit secondary antibody. Cells were imaged by confocal microscopy. Images
are representative results of three separate experiments. Scale bar = 20 µm.
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Appendix Figure A6.4. Secondary antibody controls for anti-P2X4 receptor and anti-P2Y2
receptor antibodies in DH82 cells. DH82 cells were fixed, permeabilised and stained with AlexFluor594-conjugated anti-goat or anti-rabbit secondary antibodies. Cells were imaged by confocal
microscopy. Images are representative results of three separate experiments. Scale bar = 20 µm.

